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ABSTRACT 
 
Hepatitis C Virus (HCV) infects hepatocytes, a liver cell type with complex polarity. Virus 
entry is a multi-step process that is dependent on a number of host proteins including CD81, 
scavenger receptor BI, and the tight junction proteins claudin-1 and occludin. CD81 is an 
attachment receptor for the virus, however, internalization is dependent upon CD81 
association with claudin-1 to form a coreceptor complex.  
 The presentation and diffusion kinetics of CD81 shows variable conformation between 
diverse cell types. Using live imaging I show that CD81 diffusion is regulated by cellular 
localisation and polarity. Whilst the addition of growth factors and cytokines can modulate 
infection these effects are not consistently reflected by changes in CD81 diffusion, 
suggesting that CD81 diffusion kinetics alone does not define HCV entry.  I demonstrate that 
the diffusion of the claudin-1 co-receptor also plays a role in defining infection. In addition, I 
demonstrate a complex interplay between the coreceptors and EGFR signalling that may 
involve the rearrangement of membrane domains to promote virus entry.  
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FREQUENTLY USED ABBREVIATIONS 
 
AcGFP   Aequorea coerulescens Green Fluorescent Protein 
BC   Bile Canaliculus 
CD81   Cluster of Differentiation 81 
CLDN-1  Claudin-1 
CMFDA  5-chloromethylfluorescein diacetate 
EGF   Epidermal Growth Factor 
EGFR   Epidermal Growth Factor Receptor 
ERM   Ezrin, radixin, moesin 
EWI   Glu-Trp-Ile motif 
FRAP   Fluorescence Recovery After Photobleaching 
FRET   Förster Resonance Energy Transfer 
Grb2   Growth factor receptor-bound protein 2 
HCV   Hepatitis C Virus 
HCVpp   Hepatitis C Virus pseudoparticle 
IFN   Interferon 
ITGβ1   Integrin β1 
LDL   Low Density Lipoprotein 
LEL   Large Extracellular Loop 
MAPK   Mitogen-Activated Protein Kinase 
MFI   Median Fluorescence Intensity 
MRP2   Multidrug Resistance-associated Protein 2 
PHH   Primary Human Hepatocytes 
PM   Plasma Membrane 
RFC   Relative Fold Change 
RLU   Relative Light Units 
RTK   Receptor Tyrosine Kinase 
v 
 
SEL   Small Extracellular Loop 
SH2   Src Homology 2 
Shc1   (Src homology 2 domain containing) transforming protein 1 
SR-B1   Scavenger Receptor class B member 1 
SPT   Single Particle Tracking 
SPR   Surface Plasmon Resonance 
TEM   Tetraspanin Enriched Microdomains 
TJ   Tight Junction 
TM   Transmembrane 
TNF-α   Tumour Necrosis Factor alpha 
WT   Wild Type
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1. INTRODUCTION 
1.1 BRIEF HISTORY OF NON-A, NON-B POST TRANSFUSION HEPATITIS 
 
The Second World War holds a significant place in history. It heralded the beginning of a new 
era with the rise of the USA and USSR as new superpowers, and the falling of the Iron 
Curtain between the East and West.  In the aftermath, whilst the world recovered, the field 
of medicine was consolidating the huge advances it had made during the conflict. These 
included the industrialisation of penicillin production and pioneering skin graft technologies.  
A field which saw considerable improvement in the 6 years between 1939 and 1945 was that 
of blood transfusions. Before the war, the organisation of this had been primitive, but by its 
conclusion ran like a well-oiled machine, and as a result the National Blood Transfusion 
Service was formed in 1946.  
There is no doubt that blood transfusions saved countless lives during the most deadly 
conflict in history. However, it also served medical advancement as due to the sheer number 
of blood transfusions performed, the potential dangers of the practice were noticed far 
more quickly than may otherwise have been possible. One of these was post transfusion 
hepatitis (PTH).  
During the war, numerous transmission and epidemiology studies led to the identification of 
two distinct possible viral causes of PTH. These were named hepatitis A and hepatitis B and 
were distinguished by their routes of transmission: hepatitis A was transmitted via the 
faecal-oral route, whereas hepatitis B was transmitted via blood and blood products (Havens 
1944, MacCallum 1944, Neefe, Stokes et al. 1944, MacCallum 1972, Krugman 1976, Reuben 
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2002).  Due to the faecal/oral route of transmission, hepatitis A was thought unlikely to be 
the cause of PTH.  
In 1965 an investigation into the immune reactivity of plasma proteins identified a unique 
protein in the serum of Australian aborigines –  the ‘Australia antigen’ (Blumberg, Alter et al. 
1965). This was shown to have a strong association with acute hepatitis, and was later 
identified as the surface antigen of the hepatitis B virus (HBsAg) (HBV). (Prince 1968, London, 
Sutnick et al. 1969, Dane, Cameron et al. 1970). With the detection of HBV possible (Bayer, 
Blumberg et al. 1968, Feinstone, Kapikian et al. 1973), compulsory screening of blood 
transfusions was introduced in US federal regulation in 1972 (Alter, Holland et al. 1972), and 
PTH rates subsequently fell by 97%.  
Despite this, 10% of transfusion patients continued to develop hepatitis despite being given 
blood that had tested negative for HBsAg during screening. Furthermore, the symptoms 
observed in these patients indicated a shorter incubation period than observed with HBV 
suggesting that this form of PTH was caused by a different agent. This hypothesis was 
further supported by the observation that these patients could be subject to recurrent 
hepatitis episodes post-transfusion, an occurrence not seen in either hepatitis A or B (Alter, 
Holland et al. 1975, Alter, Holland et al. 1975, Feinstone, Kapikian et al. 1975). Therefore, it 
became known as non-A non-B hepatitis (NANBH) (Feinstone, Kapikian et al. 1975). 
Despite significant research, the agent responsible for NANBH was not identified due to the 
lack of available cell culture or animal models. In 1978 the NANBH agent was successfully 
transmitted into chimpanzees (Tabor, Gerety et al. 1978). In subsequent work, Houghton 
and colleagues at Chiron and Daniel Bradley at the Centre for Disease Control carried out a 
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non-biased genetic screen and successfully identified the agent responsible (Choo, Kaya et 
al. 1989).  
The team extracted and reverse transcribed nucleic acid from the plasma of chimps that had 
been infected with NANBH agent. They used the resulting cDNA fragments to design a 
recombinant expression library in E.Coli and screened the expressed proteins against the 
serum of a chronically infected NANBH patient. The resulting clone was isolated and 
sequenced to give a single immunoreactive clone (Choo, Kuo et al. 1989, Choo, Weiner et al. 
1990).  
Further analysis showed that the nucleotide sequence of the NANBH agent comprised a 
9,600 nucleotide positive-strand RNA genome and it was designated the hepatitis C Virus 
(HCV). It was classified within a separate Hepacivirus genus of the Flaviviridae family 
alongside arthropod-borne human pathogens including yellow fever virus (YFV), West Nile 
virus (WNV) and Dengue virus (DNV) (Kuo, Choo et al. 1989, Houghton 2009). Today, the 
Hepacivirus genus includes not only HCV, but also GB virus B (GBV-B) and a number of non-
primate, rodent and bat hepaciviruses (Kapoor, Simmonds et al. 2011, Drexler, Corman et al. 
2013, Kapoor, Simmonds et al. 2013, Quan, Firth et al. 2013).  
Following the discovery of HCV, diagnostic assays were developed that could detect HCV in 
blood, and due to the introduction of screening in the 1990s the risk of transmission via 
blood products is now low. Whereas the primary routes of transmission of HCV had 
previously been blood transfusion or organ transplantation (Balogun, Ramsay et al. 2002), 
today the predominant route of transmission is sharing contaminated hypodermic needles. 
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However, vertical and sexual transmission do contribute moderately to the global 
prevalence of HCV (Busch 2001, Shepard, Finelli et al. 2005).   
1.1.1 Epidemiology of HCV 
 
Current studies estimate that there are around 115 million post-viraemic HCV infections 
worldwide, with up to 4 million people newly infected every year (Gower, Estes et al. 2014). 
This number accounts for 1.6% of the global population, and in the vast majority of cases 
(104 million) refers to adults (Westbrook and Dusheiko 2014). The most recent World Health 
Organisation (WHO) epidemiological record taken in 2009 reports that there are around 10 
million cases in Africa, 6-12 million cases in Asia, 5-10 million cases in Europe, 3-5 million 
cases in India and 2-4 million cases in North America (WHO Epidemiological Record 2009). 
To date seven genotypes of HCV have been identified, and these have about 30% divergence 
(Simmonds, Holmes et al. 1993, Simmonds, McOmish et al. 1993, Simmonds 2004). While 
these strains have a broadly similar mode of infection and progression, they show 
differences in geographical prevalence.  
Genotype 1 is the most common genotype globally, as well as in Australasia, Europe, Latin 
America and North America, accounting for 62-71% of total cases in these countries. In 
contrast, genotype 3 accounts for 40% of infections in Asia. Genotype 4 is the most common 
genotype in North Africa and the Middle East, but when Egypt is excluded genotype 1 is the 
most common. Worldwide, genotype 3 represents 22% of cases, with genotypes 2 and 4 
contributing to 13% of cases each (Gower, Estes et al. 2014). However, more than half the 
countries in the world do not have reports of the HCV infected population and so these 
estimates are likely to be an underrepresentation. 
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1.1.2 Outcome and treatment of HCV 
 
It has been reported that more than 60% of HCV infections will progress to chronic liver 
disease, with 20% of infected patients developing cirrhosis of the liver and 5-7% developing 
end-stage liver disease (Seeff 2002, Chen and Morgan 2006, Seeff 2009).  However, between 
15-40% of those infected with HCV will spontaneously clear the virus. This is a process that is 
still poorly understood (Rustgi 2007, Grebely, Page et al. 2014). 
Multiple lines of epidemiological evidence have shown that persistent infection with HCV is a 
major risk for the development of hepatocellular carcinoma (HCC), (de Oliveria Andrade, 
D'Oliveira et al. 2009) and the outcome of infection with HCV seems to be at least partly 
associated with the genotype of the virus. In general, individuals infected with genotype 1 
appear to be more likely to develop a chronic infection and liver carcinoma (Mazzeo, Azzaroli 
et al. 2003, Resti, Jara et al. 2003). In contrast, individuals carrying a genotype 3 virus are 
more susceptible to steatosis, an abnormal retention of lipids (Farci, Shimoda et al. 2000).  
Many HCV infections are asymptomatic, especially in the acute and early stages. This often 
results in a delay in detection and as such HCV infection may not be diagnosed until there is 
severe liver injury (Alter 1997, Shepard, Finelli et al. 2005). However, once detected chronic 
HCV can be treated and a ‘cure’ is deemed to be the achievement of a sustained virologic 
response (SVR), in which the level of viral RNA in the patient blood remains undetectable for 
24 weeks following cessation of antiviral therapy. 
At the time of writing, the standard of care (SOC) for chronic HCV infection in the UK is a 
combination treatment of pegylated interferon (PEG-IFN) and ribavirin (RBV). Whilst 
providing a relatively effective treatment in patients infected with genotype 2 or 3 viruses 
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(76%-86% SVR rates), the percentage of genotype 1 patients achieving SVR using this 
therapy is much lower (40%-64%) (Di Bisceglie and Hoofnagle 2002, Fried, Shiffman et al. 
2002, Davis, Wong et al. 2003, McHutchison, Lawitz et al. 2009, Lawitz, Lalezari et al. 2013).  
In recent years the landscape of HCV treatment has changed dramatically, and attention has 
moved towards drugs targeting multiple steps in the viral lifecycle (Gao, Nettles et al. 2010, 
Jacobson, McHutchison et al. 2011, Poordad, McCone et al. 2011). In 2011 the first 
generation of direct acting antivirals (DAAs) telaprevir and boceprevir were licensed for use 
(Lin, Kwong et al. 2006, Berman and Kwo 2009), and these raised genotype 1 patient SVR 
rates to 60.8% - 74.7% and 54.2% - 74.8% respectively. These drugs were developed to be 
particularly effective against the dominant NS3 protease in genotype 1, and have limited 
efficacy against other genotypes.   
These numbers represent a significant improvement on the SVR rates obtained by use of IFN 
and RBV alone. However, levels of HCV RNA do not correlate directly with disease severity 
(Rustgi 2007), and the SVR for triple therapy with the first generation DAAs have remained 
relatively low due to a number of host, virus and treatment-related factors.  
Host factors are numerous, and include age, male gender, cirrhosis, diabetes, alcohol 
consumption, coinfection with HIV or HBV, and the IL28B gene (Seeff 2002, Asselah, 
Estrabaud et al. 2010).  Viral factors include genotype and high viral load, alongside the 
development of resistance: the HCV polymerase is highly error prone, leading to significant 
virus diversity and the potential for a rapid development of resistance. Indeed, both 
treatment-naive and treatment-experienced patients have been reported to carry HCV 
sequences that are predicted to be resistant to boceprevir and telaprevir (Kuntzen, Timm et 
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al. 2008, Lemm, O'Boyle et al. 2010, Susser, Vermehren et al. 2011, Palanisamy, Danielsson 
et al. 2013). Finally, treatment factors have provided significant obstacles to achieving SVR, 
particularly with regimens involving PEG-IFN. This regime can lead to anaemia, fatigue, 
headache and neutropenia, all of which can cause patients to discontinue their treatment 
(Manns, McHutchison et al. 2001, Torriani, Rodriguez-Torres et al. 2004). In addition to this, 
there can be compatibility issues between HCV drugs and other therapies, leading to a 
narrow range of possible treatments for some coninfected patients.  
In late 2013 sofosbuvir and simeprevir were approved for use, and since have been used in 
combination with PEG-IFN and either with or without RBV. These have been demonstrated 
to be easier to use and result in higher efficiency rates and better tolerability alongside 
better patient reported outcomes (PRO) (Manns and Cornberg 2013, Younossi and Henry 
2014).  
Despite the significant advances made in HCV treatment in recent years, the long 
asymptomatic period of HCV infection means that chronic infection can still cause significant 
liver damage even if patients later achieve SVR.  
1.2 VIROLOGY 
1.2.1 The structure and genome of HCV 
 
Despite significant breakthroughs in our understanding of HCV since its discovery, the 
structure of the virion is still poorly understood. Our current understanding is that it has a 
diameter of 50-80 nm, and is encompassed by a lipid bilayer in which the E1E2 glycoproteins 
are anchored (Gastaminza, Dryden et al. 2010, Catanese, Uryu et al. 2013). This bilayer 
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surrounds a nulceocapsid composed of the core protein which contains a positive sense 
single stranded RNA genome of 9600 base pairs (Gastaminza, Dryden et al. 2010, 
Bassendine, Sheridan et al. 2011) (Figure 1.1).  
The HCV virion is known to associate with low density and very low density lipoproteins (LDL 
and vLDL) in the host (Andre, Komurian-Pradel et al. 2002, Merz, Long et al. 2011) and 
therefore has a lower buoyant density than many other viruses. Furthermore, due to this 
association with lipoproteins the virus is also able to associate with apolipoproteins such as 
apoE, apoB, apoA1, apoC1, C2 and C3 (Itzhaki, Irving et al. 2003, Chang, Jiang et al. 2007, 
Hishiki, Shimizu et al. 2010). This variation in associated proteins means that HCV virions 
have a range of buoyant densities (Lindenbach, Meuleman et al. 2006).  
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Figure 1.1: HCV viral particle. The viral RNA genome is stabilised and surrounded by the 
capsid, which is icosahedral and composed of the viral core protein. The nucleocapsid is 
surrounded by a host cell-derived lipid envelope into which the viral glycoproteins E1 and E2 
are inserted. These glycoproteins form a heterodimer which stabilises the viral particle and 
interacts with host receptors. Diagram from http://viralzone.expasy.org.  
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1.2.2 Entry and uncoating 
 
HCV entry is a complex, multistage process involving the interaction of HCV glycoproteins E1 
and E2 with a number of cellular receptors. As with many viruses, entry is initiated by the 
formation of low affinity interactions between the virus and the host cell, and this facilitates 
subsequent high affinity interactions with a number of receptors. For HCV, the initial low 
affinity interactions occur with heparan sulphate proteoglycans, glycosaminoglycans (GAGs), 
lectins, and low density lipoprotein receptor (LDLR) 2 (Barth, Schnober et al. 2006, 
Koutsoudakis, Kaul et al. 2006).  
HCV entry has been shown to be dependent on the expression of four entry receptors; 
scavenger receptor B1 (SR-B1) (Scarselli, Ansuini et al. 2002), the tetraspanin CD81 (Pileri, 
Uematsu et al. 1998), claudin-1 (Evans, von Hahn et al. 2007), and occludin (Ploss, Evans et 
al. 2009) (Figure 1.2).  
In recent years, a number of further proteins with roles in HCV entry have been identified. 
Niemann-Pick C1-like 1 (NCP1L1) cholesterol absorption receptor appears to be involved at a 
very late stage of viral entry by interacting with virus-associated cholesterol (Ray 2012, Sainz, 
Barretto et al. 2012). Additionally, epidermal growth factor receptor (EGFR) and EphA2 have 
been identified as HCV entry cofactors which are able to boost levels of HCV entry both in 
vitro and in vivo (Lupberger, Zeisel et al. 2011, Diao, Pantua et al. 2012, Zona, Lupberger et 
al. 2013). Interestingly, CD63 has been shown to interact with E2 and to restrict HCV entry 
when knocked down, and it has been speculated that it may be involved in the entry process 
(Park, Park et al. 2013). Finally, it has been demonstrated that silencing transferrin receptor  
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Figure 1.2: Host receptors in the HCV entry process. Following initial binding steps involving 
LDL-R and GAGs, HCV entry has been demonstrated to be dependent upon in the expression 
of SR-B1, CD81, claudin-1, and occludin along with the endocytosis of the viral particle  
(Popescu and Dubuisson 2010).  
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1 (TfR1) or adding antibodies to the protein either before or after viral inoculation inhibits 
HCV infection, suggesting that it acts at a post-binding step (Martin and Uprichard 2013). 
The following section will discuss in detail the known roles and characteristics of the major 
HCV receptors. 
1.2.2.1 SR-BI  
 
SR-BI is a scavenger protein and is expressed mainly on steroidogenic tissues, macrophages, 
and in the liver (Krieger, Lohmann et al. 2001). It is involved in the selective uptake of 
cholesterol from ligands such as high density lipoproteins (HDLs) and their particle 
endocytosis or selective transfer to the membrane (reviewed in (Fidge 1999). In normal liver, 
it is predominantly expressed at the basolateral membrane of hepatocytes (Reynolds, Harris 
et al. 2008) (Figure 1.3).  
SR-BI was identified as an HCV receptor by virtue of its specific interaction with HCV-E2 
(Bartosch, Vitelli et al. 2003), likely facilitated by the hypervariable region 1 (HVR-1) domain 
of E2 (Scarselli, Ansuini et al. 2002, Bartosch, Dubuisson et al. 2003, Bartosch, Vitelli et al. 
2003, Callens, Ciczora et al. 2005, Voisset, Op de Beeck et al. 2006). The importance of SR-B1 
in HCV entry has since been verified using gene silencing and addition of anti – SRB1 
antibodies (Lavillette, Tarr et al. 2005, von Hahn, Lindenbach et al. 2006, Grove, Huby et al. 
2007, Dreux and Cosset 2009). Furthermore, HDLs have been shown to promote HCV 
infection in an SR-BI dependent manner (Bartosch, Verney et al. 2005, Meunier, Engle et al. 
2005, Voisset, Callens et al. 2005). 
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Deleting the HVR1 domain has been shown to decrease the dependency of virus entry on SR-
B1, but to increase the affinity of the E2-CD81 interaction (Bankwitz, Steinmann et al. 2010, 
McCaffrey, Gouklani et al. 2011, Prentoe, Serre et al. 2014). Therefore, HVR1 may interact 
directly or indirectly with SR-B1 to cause a conformational change in E2 exposing the CD81 
binding site (Bankwitz, Steinmann et al. 2010). 
1.2.2.2 CD81  
 
CD81 was first described in 1990 (Oren, Takahashi et al. 1990), and was initially identified as 
an HCV receptor due to its interaction with HCV-E2 (Pileri, Uematsu et al. 1998). Its role was 
later confirmed by the discovery that its expression in a CD81-deficient cell line confers 
infectivity (Bartosch, Vitelli et al. 2003, Hsu, Zhang et al. 2003, Cormier, Tsamis et al. 2004, 
Zhang, Randall et al. 2004, Lavillette, Tarr et al. 2005, Lindenbach, Evans et al. 2005), and 
that the level of HCV infection is closely related to cellular CD81 expression levels (Akazawa, 
Date et al. 2007, Koutsoudakis, Herrmann et al. 2007, Rocha-Perugini, Lavie et al. 2009). In 
support of this, downregulating CD81 levels using siRNA in hepatoma cells has been shown 
to abolish infection (Zhang, Randall et al. 2004, Akazawa, Date et al. 2007, Koutsoudakis, 
Herrmann et al. 2007, Molina, Castet et al. 2008). 
CD81 is expressed on all cells of the body with the exception of red blood cells, neutrophils 
and platelets, and in the liver is expressed on the sinusoidal epithelium and hepatocytes. In 
normal liver, CD81 is expressed predominantly at the basolateral surface of hepatocytes, 
with minimal expression at the apical membrane (Reynolds, Harris et al. 2008) (Figure 1.3).  
Due to the direct nature of the interaction between CD81 and HCV-E2, there has been 
extensive research into therapeutically targeting CD81 to prevent HCV entry and this has 
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robustly demonstrated the essential role of CD81 in the process. Neutralising antibodies 
against the CD81-LEL have been shown to inhibit entry of HCV pseudoparticles (HCVpp) and 
HCV in cell culture (HCVcc) infection as well as serum-derived HCV (Scarselli, Ansuini et al. 
2002, Bartosch, Vitelli et al. 2003, Hsu, Zhang et al. 2003, Cormier, Tsamis et al. 2004, Zhang, 
Randall et al. 2004, Lavillette, Tarr et al. 2005, Wakita, Pietschmann et al. 2005, Zhong, 
Gastaminza et al. 2005, Koutsoudakis, Kaul et al. 2006, Kapadia, Barth et al. 2007) along with 
protecting against HCV infection in vivo (Meuleman, Hesselgesser et al. 2008). Furthermore, 
antibodies specific to CD81 can neutralise infection post entry (Farquhar, Hu et al. 2012). 
1.2.2.3 Claudin-1  
 
In 2007, Evans et al., (Evans, von Hahn et al. 2007) created a complimentary DNA (cDNA) 
library from the permissive hepatocarcinoma cell line Huh-7.5 and used an iterative 
expression cloning approach to express the relevant proteins in the non-permissive 293T cell 
line. Infection of these cells led to claudin-1 subsequently being identified as a potential HCV 
receptor (Evans et al. 2007). Both claudin-6 and -9 are to compensate as receptors if claudin-
1 is absent (Meertens, Bertaux et al. 2008), however these are expressed at a very low level 
in the liver (Zheng, Yuan et al. 2007) and cannot be used by all genotypes: genotype 2a and 
2b viruses cannot use claudin-6 for infection, whereas viruses with broad viral tropism can 
use claudin-6 for escape from antibodies specific for claudin-1 (Haid, Grethe et al. 2013). 
Claudin-1 is expressed at its highest concentrations in the liver, but is also present in many 
other tissues (Furuse, Fujita et al. 1998). In healthy liver tissue, it is expressed at both the 
canalicular and basolateral membranes of hepatocytes (Reynolds, Harris et al. 2008) (Figure 
1.3). It is a 25 kDa integral transmembrane protein with a structure that is similar to that of 
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CD81, with four transmembrane domains, two extracellular loops and one intracellular 
region (Furuse, Hata et al. 2002). The residues in claudin-1 which are necessary for HCV 
infection are in the first extracellular loop in the highly conserved W30-GLW51-C54-C64 domain 
(Cukierman, Meertens et al. 2009).  
Claudin-1 plays a key role in the formation of tight junctions (Krause, Winkler et al. 2008), 
and members of the claudin-1 family are able to form dimers between proteins both on the 
same cell and on adjacent cells (Piontek, Winkler et al. 2008).  The latter interaction has 
been implicated in HCV entry (Liu, Yang et al. 2009). Claudins are also able to form 
heterodimers with SR-B1, occludin and CD81, (Farquhar, Harris et al. 2008, Piontek, Winkler 
et al. 2008, Reynolds, Harris et al. 2008, Harris, Davis et al. 2010, Zona, Lupberger et al. 
2013). The formation of the CD81- claudin-1 interaction is essential for HCV entry (Yang, Qiu 
et al. 2008; Cukierman et al. 2009; Harris et al. 2010; Krieger et al. 2010) and appears to be 
necessary for clathrin-mediated endocytosis of the receptor complex and for fusion with 
Rab5a endosomes (Farquhar, Hu et al. 2012). Recent evidence also suggests that claudin-1 
may potentiate the interaction between CD81 and HCV-E2 (Krieger, Zeisel et al. 2010). 
However, there is no evidence for a direct interaction between claudin-1 and infectious viral 
particles, although recent work has shown that E1E2 complexes can interact with claudin-1 
(Douam, Dao Thi et al. 2014) and the authors suggest that the lack of binding is due to host-
derived lipoproteins masking the viral envelope.  
1.2.2.4 Occludin  
 
cDNA screening identified the tight junction protein occludin as necessary to confer HCVpp 
entry into the non-permissive murine  fibroblast cell line NIH3T3 expressing CD81, claudin-1 
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and SRB1 (Ploss, Evans et al. 2009).  In the same year, occludin was independently identified 
as an HCV receptor by siRNA silencing of proteins known to associate with claudin-1 in Huh-
7.5 cells (Liu, Yang et al. 2009). Whilst occludin has been reported to interact with the E2 
glycoprotein, it is unknown whether this is direct or indirect via CD81- claudin-1 (Meredith, 
Wilson et al. 2012). Occludin is a tight junction protein, and internalises with claudin-1 in 
caveolae and clathrin-dependent processes (Stamatovic, Keep et al. 2009). In healthy liver, 
occludin is expressed solely at the apical surface of hepatocytes (Figure 1.3). 
1.2.2.5 Other factors which affect HCV entry 
 
There are a number of additional factors which have been demonstrated to affect HCV 
entry. For example, enrichment of ceramide at the plasma membrane induces the 
internalisation of CD81, and thus inhibits infection (Tribouillard-Tanvier, Beringue et al. 
2008). Additionally, the depletion of cholesterol inhibits HCV infection, possibly as a result of 
interactions with CD81 (Charrin, Manie et al. 2003, Kapadia, Barth et al. 2007).  
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Figure 1.3: Localisation of HCV receptors in normal liver tissue. The expression of CD81, SR-
B1, claudin-1 and occludin in hepatocytes in a healthy liver (Reynolds, Harris et al. 2008). 
  
CD81 Claudin-1 Occludin SR-BI 
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1.2.3 Internalisation of the virus 
 
Internalisation of HCV has been shown to occur by dynamin-dependent clathrin-mediated 
endocytosis into Rab5 positive endosomes (Blanchard, Belouzard et al. 2006, Meertens, 
Bertaux et al. 2006, Coller, Berger et al. 2009) in a Rho dependent manner (Farquhar, Hu et 
al. 2012).  Studies using both HCVpp (Hsu, Zhang et al. 2003) and HCVcc (Tscherne, Jones et 
al. 2006) have demonstrated that this occurs in a pH dependent manner. In other enveloped 
viruses, a drop in pH causes a conformational change in the envelope glycoproteins to 
expose fusion peptides. These are responsible for triggering a fusion with the endosomal 
membrane and their exposure therefore leads to the release of the viral genome into the 
cytosol (Thorley, McKeating et al. 2010).  
Three classical fusion loop motifs have been reported in the HCV E1 and E2 glycoproteins, 
and their importance confirmed using site-directed mutagenesis (Lavillette, Pecheur et al. 
2007), suggesting that the HCV genome is released by a similar fusion to process to that 
described above. However, in contrast to the initial structure of the E2 ectodomain (Krey, 
d'Alayer et al. 2010) the recently published crystal structures did not identify any classical 
fusion peptides, and this model does not demonstrate any significant changes in 
conformation when exposed to a low pH (Kong, Giang et al. 2013, Khan, Whidby et al. 2014). 
Therefore, the exact mechanism of HCV genome release is not understood. The diagram 
below illustrates the current model of the HCV lifecycle (Figure 1.4). 
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Figure 1.4: The HCV lifecycle. Following initial interactions with LDLR and GAGs, the virion 
undergoes high affinity interactions with SR-B1, CD81 and claudin-1 in a coreceptor complex, 
and occludin. Following virus internalisation in a clathrin-dependent mechanism, the virus 
fuses with the endosome and the genome is released into the cytoplasm. Here, it associates 
with ER-derived membranous webs where the viral replication processes take place. The 
resulting assembly process is highly associated with the apolipoprotein synthesis. Diagram 
from (Zeisel, Fofana et al. 2011). 
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1.3 THE HCV VIRAL GENOME 
 
The HCV genome comprises a 9600 base uncapped positive sense single RNA strand, whose 
5’ and 3’ untranslated regions act as control elements for translation and replication. The 
area between these regions is a single uninterrupted open reading frame (ORF), which when 
translated results in a single polyprotein of around 3011 amino acids (aa). This polyprotein is 
modified by host and viral proteases to give 3 structural proteins – core, E1 and E2 - and 7 
non-structural proteins – p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (for review see 
(Lindenbach, Evans et al. 2005, Zeisel, Koutsoudakis et al. 2007, Ashfaq, Javed et al. 2011) 
(Figure 1.5). The host proteins involved in this process are signalase and signal peptide 
peptidase, and the viral proteases involved are NS2-NS3 and NS3-NS4A (Kuo, Choo et al. 
1989).  
  
21 
 
 
 
  
Fi
g
u
re
 1
.5
: D
ia
g
ra
m
 o
f 
th
e 
H
C
V
 g
en
o
m
e.
 M
o
d
if
ie
d
 f
ro
m
 (
M
o
ra
d
p
o
u
r,
 P
en
in
 e
t 
a
l. 
2
0
0
7
).
 
 
22 
 
1.3.1 Translation of the viral genome and polyprotein maturation 
 
Following internalisation the viral capsid is uncoated, and translation of the HCV genome has 
been demonstrated to occur in the rough endoplasmic reticulum (ER). It is at this stage of 
the replication cycle that the majority of changes to the HCV glycoproteins E1 and E2 are 
made. The C terminal and transmembrane domains of the glycoproteins form hairpin 
structures which cross the ER membrane twice. When they are separated the C-terminal 
domains translocate to the cytoplasm, where the type 1 membrane topology of the mature 
glycoproteins is formed whilst the proteins remain facing the ER (Akazawa, Date et al. 2007). 
These proteins later undergo the final maturation steps of glycosylation and disulphide 
rearrangement in the Golgi apparatus.  
At this point, NS2 and the highly hydrophobic NS3 are cleaved by zinc-dependent cysteine 
protease activity at the C-terminal of NS2 and the N –terminal of NS3 (Akazawa, Date et al. 
2007, Moradpour, Penin et al. 2007, Lango Allen, Estrada et al. 2010). The remaining 
polyprotein is cleaved by the serine protease activity of the N terminal of NS3 in association 
with NS4.  
In addition to its role as a serine protease, NS3 also has RNA helicase/NTPase activity. This is 
necessary for separating dsRNA replication intermediates, removing nucleic acid binding 
proteins from the genome and for eliminating RNA secondary structures. Therefore, it is 
thought that NS3 plays a role in RNA unwinding. NS4A also has RNA helicase/NTPase activity, 
and in addition to acting as the NS3 cofactor has a role in locating NS3 to the ER membrane 
(Dubuisson 2007; Moradpour, Penin et al. 2007; Suzuki, Ishii et al. 2007; Joyce and Tyrrell 
2010; Kim and Chang). Alongside its role in the virus lifecycle, the HCV protease NS3 also 
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disrupts the IFN and TLR3 pathways which are activated in response to the recognition of 
pathogens by the host cell.  Specifically, NS3 cleaves a number of host proteins including the 
caspase recruitment domain of MAVS (Li, Foy et al. 2005, Meylan, Curran et al. 2005) and 
TRIF (Li, Foy et al. 2005).  
1.3.2 Viral replication 
 
Following translation, the viral replicase protein NS4B in association with NS5A initiates a 
complex membrane remodelling process to form a membranous web composed of double 
and multi-membrane vesicles (DMV and MMV), and this is the site of replication of the HCV 
virus (Egger, Wolk et al. 2002, Moradpour, Penin et al. 2007, Romero-Brey, Merz et al. 2012). 
In addition to initiating the formation of these essential structures, NS4B may be necessary 
for recruiting the non-structural proteins to this site, including the RNA dependent RNA 
polymerase (RdRp) NS5B (Elazar, Liu et al. 2004).  
NS5B is responsible for synthesising the complementary negative strand RNA from the 
original positive strand genome which is then used to make a positive genome for viral 
assembly (Gu and Rice 2013; Kim and Chang 2013; Moradpour 2007; Suzuki 2007).  NS5B 
does this in a primer-dependent manner, with 3’ UTR structures creating a cis-acting ‘copy 
back’ strand, and secondary structures priming the complimentary strand for replication. 
The phosphorylation state of NS5B regulates the balance between RNA replication and 
downstream processes (Neddermann, Quintavalle et al. 2004) and acts as an RdRp (Behrens, 
Tomei et al. 1996). 
 NS5B exhibits a significant lack of proofreading and error correction mechanism and as a 
result, HCV replication is highly error prone and generates a high degree of genetic diversity 
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(Cruz-Rivera, Carpio-Pedroza et al. 2013) (Honegger, Kim et al. 2013). This means that HCV is 
able to rapidly adapt to pressures such as the immune response and antiviral therapy (von 
Hahn, Yoon et al. 2007, Ralston, Jacobson et al. 2011, Honegger, Kim et al. 2013).  
NS5A has been demonstrated to interact with a number of host and viral partners including 
core (Masaki 2008), cyclophillin A (Lim and Hwang et al., 2011) and PI4KIIIα (Foster 2011). It 
also binds to positive and negative strands before replication (Huang 2005) in a manner 
dependent upon its phosphorylation status (Shulla and Randall 2012). 
1.3.3 Assembly and release of HCV virions 
 
Following replication, signal peptidase and signal peptide peptidase cleave the polyprotein 
to form a mature protein on the ER-derived membranous web. The protein then relocates to 
cytoplasmic lipid droplets (McLauchlan, Lemberg et al. 2002, Boulant, Montserret et al. 
2006) in a process assisted by diacylglycerol diacyltransferase-1 (DGAT1) (Herker, Harris et 
al. 2010). 
This stage of the HCV lifecycle is not completely understood. In the current model, newly 
synthesised RNA and structural proteins are assembled on ER-derived lipid droplets in 
association with the membranous web.  
The core protein is concentrated on these lipid droplets, and there are surrounded by 
membranous structures containing the non-structural viral proteins (Miyanari 2007). NS5A 
associates with host apolipoproteins including ApoE, which are incorporated into the viral 
envelope (Benga 2010). The core protein also plays an essential role in this process, and if it 
is not present studies have shown a reduction in infectious particle release (Miyanari 2007).  
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During viral packing, NS2 is believed to interact with p7, and this stabilises the structure of 
NS2 alongside promoting the association of NS2 and NS3/4A (Lindenbach 2013; Lindenbach 
and Rice 2013; Stapleford and Lindenbach 2011). The latter interaction leads to the 
trafficking of core from the lipid droplets to the assembly site (Coller 2012). In addition to 
core, NS2 also recruits E1E2 to the assembly site (Stapleford and Lindenbach 2011), and the 
interaction between core and NS5A at this point on lipid droplets is thought to play a central 
role in genome packaging and the formation of the icosahedral capsid (Miyanari 2007).   
The final assembly stages of the virus are thought to occur by budding into the ER, where the 
last stages of viral maturation is closely linked with the vLDL secretion pathway (Gastaminza 
2008).  A study using HCVcc has demonstrated that it is translocated to the Golgi, where the 
final maturation steps are thought to occur (Gastaminza 2008) and E2 is glycosylated by 
Golgi glycosidases and glycosyltransferases (Vieyres 2010).  Following this, the virions are 
sorted into endosomal compartments and released at the PM (Coller 2012). The non-
structural p7 protein plays an essential role at this point by forming ion channels in artificial 
bilayers, thus preventing acidification of endolysosomal compartments during the secretion 
(Wozniak 2010).  
1.4 VIRAL TRANSMISSION 
 
HCV can be transmitted between cells via two routes – by extracellular virus particles or cell-
cell transmission (Marsh and Helenius 2006, Timpe, Stamataki et al. 2008). The cell-cell route 
was initially described following the identification of foci of positive cells in infected human 
livers (Chang, Williams et al. 2003, Wieland, Makowska et al. 2014), suggesting a preferential 
transference of infection between contacting cells. Whilst all four receptors play a role in 
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HCV entry (Grove, Huby et al. 2007, Grove, Nielsen et al. 2008, Brimacombe, Grove et al. 
2011, Syder, Lee et al. 2011), cell-cell transmission is relatively more dependent on SR-B1 
expression (Meredith, Harris et al. 2013). 
It has been demonstrated recently that tetraspanin-rich exosomes from cells infected with 
HCV can infect naive human hepatoma cells even in the presence of neutralising antibodies 
(Ramakrishnaiah, Thumann et al. 2013, Bukong, Momen-Heravi et al. 2014), and are also 
able to transfer the HCV viral RNA to both uninfected human hepatoma cells and 
plasmacytoid dendritic cells (pDCs).  In the latter, transference of  viral RNA has been 
demonstrated to induce the production of type 1 interferon (IFN) in a TLR-7-dependent 
manner (Dreux, Garaigorta et al. 2012).  These exosomes have been observed both in the 
serum of HCV-infected patients and in the supernatant of HCV-infected cells (Pietschmann, 
Lohmann et al. 2002, Masciopinto, Giovani et al. 2004, Gastaminza, Dryden et al. 2010, 
Bukong, Momen-Heravi et al. 2014). Exosomes have been reported to be involved in the 
mediation of infection by a number of agents including viruses and bacteria (Bhatnagar, 
Shinagawa et al. 2007, Silverman and Reiner 2011).   
1.5  HEPATIC POLARITY AND HEPATOCYTES AS A TARGET 
1.5.1 Liver physiology  
 
The liver is a large and complex organ consisting of numerous specialised cell types which 
allow it to carry out a range of essential functions. Hepatocytes are the parenchymal cells of 
the liver and make up 80% of liver mass, with the other 20% comprising non-parenchymal 
cell types such as liver sinusoidal endothelial cells (LSECs) and liver myofibroblasts. The blood 
supply to the liver enters via the sinusoids, and leaves via the portal vein (Figure 1.6).  
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Structurally, the hepatocytes are separated from the sinusoidal blood vessels by the Space of 
Disse, and are arranged into plates giving a large area for nutrient absorption (Branch, Stump 
et al. 2005). One of the many functions of the liver is to produce bile, and this is secreted by 
the hepatocytes into the extensive network of bile canaliculi (BC), which merge to form 
ductules and eventually the common hepatic duct (Figure 1.6). Hepatocytes are also 
responsible for carrying out a range of metabolic and detoxification functions which are 
unique to the liver (Kim and Rajagopalan 2010), such as detoxification (Decaens, Durand et 
al. 2008). 
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Figure 1.6: Schematic diagram of liver physiology. Hepatic blood vessels are shown bounded 
by LSECs, Kupffer cells and hepatic stellate cells (HSC) and separated from the hepatocytes by 
the Space of Disse. The bile canaliculus is shown bounded by a single layer of hepatocytes 
and separated from the hepatic blood vessels by at least one layer of hepatocytes. Adapted 
from (Wilson, Tennant et al. 2014).  
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1.5.2 Hepatic Polarity 
 
Many tissues in the body contain polarised cells, and their polarity contributes not only to 
their function but also to the formation of a barrier, for example in the gut or airways. The 
majority of epithelial cells exhibit a simple, columnar polarity with only one apical and one 
basal surface (Cereijido, Valdes et al. 1998, Shin, Fogg et al. 2006). These surfaces appose 
each other, with the lateral surfaces in contact with neighbouring cells forming interactions 
such as tight junctions (TJ) and adherens junctions (AJ) (Figure 1.7a).  These junctions contain 
characteristic sets of proteins, with claudin, occludin and junctional adhesion molecule (JAM) 
in tight junctions and cadherin and nectin in adherens junctions (Figure 1.7b).                       
In contrast to this, hepatocytes exhibit a more complex polarity, and instead are polygonal 
and multipolar, with several apical membranes bounded by tight junctions. The apical 
membranes of adjacent cells form the walls of BC lumen (Feldmann 1989, Selden, Khalil et 
al. 1999, Decaens, Durand et al. 2008, Mee, Harris et al. 2009, Perrault and Pecheur 2009), 
with at least two basolateral membranes facing the sinusoids (Figure 1.7c). Therefore, the 
polarised nature of the hepatocyte is essential to maintaining the separation between blood 
and bile (Figure 1.6).   
The apical and basal poles of the cell contain specific proteins which allow the hepatocyte to 
carry out essential functions. The apical surface carries out secretory functions via the 
actions of proteins such as multidrug resistance protein 2 (MRP2) and bile salt export pump 
(BSEP) (Trauner and Boyer 2003, Decaens, Durand et al. 2008). In contrast, the hepatic basal 
membrane expresses characteristic proteins such as Na+/Taurocholate cotransporting 
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Figure 1.7: Organisation of epithelial polarity.  In polarised epithelial cells a single apical 
and basal membrane appose each other and are separated by tight junctions (TJ) and 
adherens junctions (AJ), with the apical surface facing the lumen and the basal surface facing 
the tissue (a). The junctional complex is shown in more detail, with typical proteins of the TJ 
and AJ annotated alongside their linkage to the cytoskeleton (b). Polarised hepatocytes have 
several apical membranes which form the walls of the bile canaliculus, and these are 
separated by TJs and AJs from the basal membranes which face the sinusoids (c). 
 
  
(a) (b) (c) 
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polypeptide (NTCP) and organic anion transporting polypeptide proteins which allow the 
uptake of biliary salts from the circulation. The tight junctions in hepatocytes are composed 
of transmembrane proteins with associated cytoplasmic proteins. Such proteins include 
members of the zona occludins (ZO) and claudin families. The HCV receptors also localise 
distinctly in a polarised cell, with CD81 at the apical and basolateral surfaces, claudin-1 at the 
apical surface with minimal basolateral expression, and SR-B1 at the basolateral surface 
(Reynolds, Harris et al. 2008) (Figure 1.3). 
 
The establishment of hepatic polarity also necessitates the coordination of the cytoskeleton 
and the Golgi apparatus, along with the organisation of tight junctions and specialised 
membrane domains. 
The major components of the cytoskeleton have both direct and indirect associations to the 
plasma membrane, especially at the tight junctions of polarised cells. In hepatocytes, the BC 
is surrounded by two circumferential belts of actin and actin binding proteins. The first belt 
contains myosin II, is in association with the adherens junctions, and is involved in the 
contractility of the BC. The second regulates transport near the plasma membrane (Tsukada 
and Phillips 1993). Microtubules are also very highly concentrated around the BC, and are 
central to the development of cellular polarity (Novikoff, Cammer et al. 1996). They are 
organised in a polar fashion with the minus ends facing the apical membrane allowing the 
trafficking of not only apical membrane proteins (Bacallao, Antony et al. 1989, Cohen, 
Brennwald et al. 2004), but also the arrangement of the Golgi between the nucleus and 
apical membrane (Musat, Sattler et al. 1993). Indeed, the Golgi apparatus exhibits changes 
in structure and function along this axis (Baumann and Walz 2001). Along with the high 
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concentration of microtubules around the BC, these structures are also stabilised by 
intermediate filaments.  
1.6  VIRUS INFECTION OF POLARISED CELLS 
 
The establishment of cellular polarity is refractory to the entry stages of a number of viruses, 
as many utilise junctional receptors in their entry pathways.  A number of viruses have 
therefore evolved mechanisms to overcome these barrier sites and disseminate viral particles, 
and some of the most notable examples are discussed briefly below.  
The rotavirus expresses two viral proteins which allow it to manipulate cellular polarity. The 
non-structural protein NSP4 and capsid spike protein VP4 have both been demonstrated to 
induce changes in the actin cytoskeleton (Gardet, Breton et al. 2006, Berkova, Crawford et al. 
2007), and the expression of NSP4 alone causes epithelial leakage, tight junction disruption 
and membrane destabilisation (Tafazoli, Zeng et al. 2001). This has the effect of making the 
intracellular actin network more accessible for virus entry and trafficking.  
Similarly, the adenovirus has established a complex mechanism to utilise receptors from the 
basolateral domains – Coxsackievirus adenovirus receptor (CAR) and αvβ3-5- to infect from the 
apical surface. Adenovirus-infected macrophages secrete IL-8, which cause CAR and αvβ3-5 to 
relocate to the apical membrane in a Src-dependent manner (Lutschg, Boucke et al. 2011). 
These receptors are then available for the virus to utilise in entry. In a similar manner, the 
coxsackie virus B (CVB) initially interacts with decay accelerating factor (DAF) at the apical 
surface (Bergelson, Modlin et al. 1997, Shieh and Bergelson 2002, Coyne and Bergelson 2006). 
Cross-linking of apically-located DAF can induce it to form larger lipid rafts containing other 
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proteins, and as a result Abl is activated. Abl is a tyrosine kinase, and its activation results in a 
Rac-dependent actin reorganisation which relocates the CVB-DAF dimer to the TJ in an actin-
dependent process (Coyne and Bergelson 2006). This then allows the complex to interact with 
CAR, whose involvement is necessary for the initiation of CVB uncoating.   
These examples demonstrate the ability of viruses to utilise the association of actin with the 
cell membrane, actin signalling and regulatory components and TJ proteins to facilitate viral 
entry despite the polarised nature of their target cells. 
1.7 TOOLS TO STUDY HCV  
 
Attempting to recreate complex hepatic polarity in vitro has proved problematic. Whilst it is 
possible to use primary human hepatocytes (PHH) for research into the viral lifecycle, over 
time in cell culture PHH and primary non-parenchymal cells dedifferentiate and undergo a 
number of physiological and metabolic changes. These include the dissolution of the nucleus 
(karyolysis) and cytoskeletal rearrangement, and this leads to a fibroblast-like appearance 
and cells ultimately detach and die (Berthiaume, Moghe et al. 1996, Wang and Boyer 2004).  
Additionally, PHH are generally hard to use and maintain and the methods of doing so vary 
considerably between labs. Specifically in terms of HCV, primary hepatocyte cultures support 
low levels of HCV infection, and preparations of hepatocytes from different donors exhibit 
heterogeneous viral populations (Bartenschlager and Lohmann 2001, Gondeau, Pichard-
Garcia et al. 2009).  
The expense and difficulty of obtaining and using model systems necessitates the use of cell 
culture systems across the field of biology. However, finding such a system which accurately 
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replicates the specialised and complex nature of the liver has been a major challenge in the 
progression of HCV research. 
1.7.1 In vitro systems 
 
In addition to being essential for the correct functioning of the liver, hepatic polarity has also 
been demonstrated restrict HCV entry (Mee, Grove et al. 2008, Mee, Harris et al. 2009, 
Harris, Clerte et al. 2013). As a result, identifying a cell type which polarizes and supports 
HCV replication has been a key area for research.  
The HepG2 cell line is a perpetual cell line isolated from the well-differentiated 
hepatocellular carcinoma of a 15 year old Caucasian male (ATCC). It is able to polarise and to 
generate apical cysts equivalent to bile canaliculi (BCs) which can span several cells 
(Herrema, Czajkowska et al. 2006), are functional as BCs and are easily visible (Mee, Harris et 
al. 2009) (Figure 1.8). These cysts contain integral TJs, and cultures of HepG2s have been 
demonstrated to achieve up to 40% of cells polarised over time in culture (Theard, Steiner et 
al. 2007, Decaens, Durand et al. 2008, Mee, Harris et al. 2009). Whilst HepG2 cells also 
display the correct localisation of apical membrane markers, claudin (Zegers and Hoekstra 
1997, Kubitz, Sutfels et al. 2004, Reynolds, Harris et al. 2008) and cytoskeletal components 
(Sormunen, Eskelinen et al. 1993), they do not naturally express CD81, and therefore this 
must be done exogenously. Additionally, they do not express miR-122, a liver-specific miRNA 
which is required for HCV replication (Jopling, Yi et al. 2005), and (Jopling, Yi et al. 2005), and 
therefore HepG2s only weakly support HCV replication and viral assembly, around 850-fold 
lower than Huh-7.5 (Lindenbach, Evans et al. 2005, Flint, von Hahn et al. 2006, Narbus, 
Israelow et al. 2011).   
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In terms of infectivity studies then, a different cell type is necessary and for this the Huh- 7 
cell line and its derivatives are widely used (Lohmann, Korner et al. 1999). This immortal cell 
line was derived from the well-differentiated hepatocellular carcinoma of a 57 year old 
Japanese male. Although these polarise very poorly, they naturally express the four essential 
HCV receptors and are capable of supporting a robust level of infection (Lohmann, Korner et 
al. 1999). The latter characteristic is attributed to a defective retinoic acid inducible gene-I 
(RIG-I) pathway (Preiss, Thompson et al. 2008).  
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Figure 1.8: Phase contrast image of two polarised HepG2 cells forming a bile canaliculus 
(black arrow). Thanks to Sven van Ijzendoorn. 
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1.7.2 Animal models 
 
The use of chimpanzee animal models has been central to the breakthroughs in our 
understanding of HCV to date, and is the only animal model of HCV able to support infection 
by all HCV genotypes (Bukh 2012).  Most notably, chimpanzees were used to isolate the virus 
itself (Choo, Kuo et al. 1989), but the similarity of their innate and adaptive immune 
responses to that of infected humans (Bukh 2004, Bukh, Meuleman et al. 2010) means that 
they have been essential to furthering our understanding of HCV disease processes since 
(Houghton 2009). In terms of understanding the host response to HCV infection, chimpanzee 
models have been used to investigate the immune response and intrahepatic response to 
primary and secondary infections (Bukh 2004, Bowen and Walker 2005, Rehermann 2009). 
They have also been heavily  involved in the development of other model systems, as their 
use in demonstrating the infectivity of HCV clones (Kolykhalov, Agapov et al. 1997, Yanagi, 
Purcell et al. 1997, Yanagi, Purcell et al. 1999, Sakai, Takikawa et al. 2007, Gottwein, Scheel 
et al. 2010) led to the development of HCV culture systems (Lohmann, Korner et al. 1999, 
Wakita, Pietschmann et al. 2005, Lindenbach, Meuleman et al. 2006) and that of small, 
genetically humanized animal models that can be challenged with modified forms of HCV 
(Dorner, Horwitz et al. 2011, Bukh 2012).  This is the only alternative in vivo model available, 
as mouse livers are otherwise unable to support HCV infection and no other primate model 
has yet been identified. 
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1.7.3 Virus models 
1.7.3.1 Cell culture virus systems 
 
 Early attempts to study the virus-host interaction and entry stages of the viral lifecycle 
utilised the viral glycoproteins E1E2 expressed in isolation from other the viral proteins. 
However, expressing high levels of these proteins in a cellular background resulted in their 
misfolding and aggregation due their transmembrane domains containing sequences which 
promote ER retention and heterodimerisation (Cocquerel, Wychowski et al. 2000). 
Therefore, chimeric E1E2 proteins were developed which incorporated only sections of the 
TM regions of E1E2 known to be expressed at the plasma membrane, or were truncated 
proteins lacking TM domains entirely (Flint, Maidens et al. 1999, von Hahn and Rice 2008). 
This latter method resulted in a soluble form of E2 (sE2) (Michalak, Wychowski et al. 1997, 
Flint, Maidens et al. 1999). This approach laid the foundation for many studies identifying 
receptors, and was subsequently used to identify both SR-B1 and CD81 as receptors.  
Retroviruses are able to incorporate glycoproteins into their membranes during budding, 
and this characteristic was used to develop the infectious HCV pseudoparticle system 
(HCVpp) (Hsu, Zhang et al. 2003) which is now widely used. HCVpp are generated using 
human embryonic kidney (293T) cells into which the gag-pol gene of murine leaukaemia 
virus (MLV) or HIV is transfected alongside the E1E2 glycoproteins and a GFP or luciferase 
reporter gene (Figure 1.9). Expression of gag-pol leads to the assembly of retroviral particles, 
and these contain the provirus genome encoding the reporter gene. During release, E1E2 is 
incorporated into the envelope resulting in an infectious particle whose entry is mediated 
solely by the expression of E1E2 glycoproteins. Following entry and the delivery of the 
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retroviral nucleocapsid protein into the cytoplasm, the viral genome is reverse transcribed 
and incorporated into the host cell genome, with the reporter gene expressed for a readout 
(Voisset, Op de Beeck et al. 2006, Regeard, Lepere et al. 2007, von Hahn and Rice 2008).  
HCVpp infection can be blocked by neutralising antibodies to the viral glycoproteins E1 and 
E2, providing confirmation that they are essential for HCV entry (Lagging, Meyer et al. 1998, 
Bartosch, Dubuisson et al. 2003, Hsu, Zhang et al. 2003) and this system was central to the 
identification of occludin and claudin-1 as receptors. In the time since, glycoproteins from 
different genotypes have been isolated and used to create HCVpp for studying genotype 
specific events and characteristics (Bartosch, Dubuisson et al. 2003). However, this system 
only models the entry stages of the viral lifecycle, and does not allow the association of the 
virus with lipoproteins.  
Until its development, the lack of HCV cell culture (HCVcc) system was a major obstacle to 
the study of the full HCV lifecycle. However, since 2005 it has been possible to study the full 
viral lifecycle of HCV with complete viral replication processes and infectious particle release, 
following the cloning of a genotype 2a virus from a patient carrying an acute HCV infection 
(Lindenbach, Evans et al. 2005, Wakita, Pietschmann et al. 2005, Zhong, Gastaminza et al. 
2005). The clone is referred to as Japanese Fulminant Hepatitis 1 (JFH-1), and is infectious in 
chimpanzees and mice transplanted with human hepatocytes.  
The development of the HCVcc systems has greatly improved our understanding of the 
complete lifecycle of HCV, confirming many findings made using HCVpp and enabling the 
development of chimeric HCVcc constructs covering diverse genotypes (Gottwein, Scheel et 
al. 2007, Scheel, Gottwein et al. 2008, Gottwein, Scheel et al. 2009).  
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Figure 1.9: Cartoon depicting HCVpp generation (Voisset and Dubuisson 2004). Plasmids 
expressing the HCV glycoprotein dimer E1E2, gag-pol and luciferase under CMV promoters 
are transfected into 293T cell. These are assembled into HCV pseudoparticles which are then 
released, harvested and can be used to infect permissive cells. Level of infection is quantified 
by luciferase read-out. Modified from (Voisset and Dubuisson 2004). 
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1.8 TETRASPANINS 
1.8.1 Tetraspanin interactions  
 
The first members of the tetraspanin family of proteins were discovered when studies 
cloning membrane antigens identified tetraspanin 8 and a number of cluster of 
differentiation (CD) proteins CD63, CD53, CD37, CD81 and CD9 (Maecker, Todd et al. 1997, 
Boucheix and Rubinstein 2001, Yanez-Mo, Barreiro et al. 2009). Members of the tetraspanin 
family have since been identified in all metazoans, and related proteins have been found in 
plants. To date, 33 tetraspanins have been described in mammals, 37 in Drosophila 
melanogaster, and 20 in C. Elegans (Huang, Yuan et al. 2005). In humans, tetraspanins have 
been shown to be expressed at varying levels on all cells except for sperm cells (Boucheix 
and Rubinstein 2001).  
CD81 is a 26kDa tetraspanin containing 236 amino acids, and has a structure typical of the 
tetraspanin family of proteins, described below. However, unlike most tetraspanins, CD81 is 
not glycosylated. CD81 is palmitoylated on 6 juxtamembranous cysteine residues (Charrin, 
Manie et al. 2002, Delandre, Penabaz et al. 2009) and this palmitolyation has been 
demonstrated to negatively affect HCV entry to a moderate degree by mediating the 
associations between CD81 heterodimers and partner proteins, and by cholesterol 
partitioning (Nakajima, Cocquerel et al. 2005).  
Tetraspanins are type IV glycoproteins (Oren, Takahashi et al. 1990), and first appeared 600 
million years ago. They are highly conserved (Huang, Tian et al. 2010), with the sub loop 
structure containing most of the sequence diversity within the family (Kitadokoro, Bordo et 
al. 2001). Tetraspanins are relatively small for transmembrane proteins, containing only 200-
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350 residues (Kitadokoro, Bordo et al. 2001).  They have a specific structure, with four 
transmembrane domains linked by one small extracellular loop, one short intracellular 
domain, and one large extracellular loop (LEL) which in the case of CD81 protrudes 3.5 nm 
from the cell surface (Kitadokoro, Bordo et al. 2001). They contain 4-6 cysteine residues and 
these form critical disulphide bonds with the second large extra cellular loop. 
It is possible to study tetraspanin interactions by co-immunoprecipation, as specific 
detergents can be used which preserve tetraspanin associations. Studies using this 
technique have demonstrated that tetraspanins are able to form cell-type specific, direct 
interactions with tetraspanin partners to form small complexes (Yauch, Berditchevski et al. 
1998, Serru, Le Naour et al. 1999), which then form dynamic secondary interactions to form 
a tetraspanin enriched microdomain (TEM). These structures are linked to form a cell type-
specific tetraspanin web (Boucheix and Rubinstein 2001, Hemler 2003). These domains are 
highly dynamic in terms of the interactions formed within them, with many interactions 
being transient (Barreiro, Zamai et al. 2008, Espenel, Margeat et al. 2008).  
Tetraspanins are known as ‘molecular organisers’, and can form secondary interactions with 
a diverse range of proteins alongside other tetraspanins. It has been demonstrated that 
these interactions involve either the LEL or TM domains of the proteins (Hemler 2003, 
Charrin, le Naour et al. 2009, Yanez-Mo, Barreiro et al. 2009), and typically consist of at least 
three proteins (Claas, Stipp et al. 2001). Such protein partners include: integrins and other 
adhesion receptors; immunoglobulin domain-containing factors; growth factor and cytokine 
receptors; ectoenzyme  receptors; MHC antigens; immunoglobulin family members; and 
signalling molecules (reviewed in (Boucheix and Rubinstein 2001, Yanez-Mo, Barreiro et al. 
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2009). Tetraspanins are able to regulate the function of these binding partners and as a 
result, have roles in a wide variety of processes including cell proliferation, cell-cell adhesion, 
and tumourigenesis (Hemler 2005), alongside signal transduction, cell migration, and 
membrane remodelling (reviewed in (Boucheix and Rubinstein 2001). Therefore, it is 
possible that TEMs represent sites of activity, and studying agonist ligands of tetraspanins 
has shown that alongside the interaction between CD81 and HCV-E2, CD9 has been robustly 
shown to bind the pregnancy specific glycoprotein 17 (PSG17) (Waterhouse, Ha et al. 2002, 
Ellerman, Ha et al. 2003, Ha, Waterhouse et al. 2008, Sulkowski, Warren et al. 2011). The 
latter interaction may play a role in the release of anti-inflammatory cytokines (Ha, 
Waterhouse et al. 2005) . 
The ability of CD151 and CD9 to link their partner proteins to other tetraspanins in primary 
and secondary complexes has been demonstrated (Berditchevski, Odintsova et al. 2002, 
Charrin, Manie et al. 2003, Takeda, Kazarov et al. 2007). The high affinity interactions formed 
by CD151 with integrins in TEMs provides them with varying partner and associated 
proteins. As a result, the responses to binding of laminin substrates can vary from integrin 
ligand binding, trafficking and signalling (Stipp 2010).  
TEMs are highly regulated structures, and the interactions between tetraspanins and their 
partner proteins are regulated by lipids in TEMS and by cholesterol and gangliosides in the 
membrane (Berditchevski, Odintsova et al. 2002, Yang, Claas et al. 2002, Charrin, Manie et 
al. 2003, Odintsova, Butters et al. 2006). They can also be influenced by the physiological 
stage of the cell and palmitoylation (Berditchevski, Odintsova et al. 2002, Yang, Claas et al. 
2002, Kovalenko, Yang et al. 2004).   
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1.9 TETRASPANINS IN DISEASE 
 
Members of the tetraspanin family have been shown to be involved in the infection of 
numerous viruses, bacteria and protozoa (Monk and Partridge 2012). For example, CD151 is 
involved in the endocytosis of HPV (Scheffer, Gawlitza et al. 2013), and CD81 and TSPAN9 
have been identified as cofactors in influenza virus and alphavirus infection (Karlas, Machuy 
et al. 2010, Konig, Stertz et al. 2010, Ooi, Stiles et al. 2013) where it has been suggested that 
CD81 regulates viral fusion in endosomes (He, Sun et al. 2013, Ooi, Stiles et al. 2013).  
CD81 in particular plays a major role in infectious diseases alongside HCV, having been 
implicated in infection by Plasmodium (Charrin, Yalaoui et al. 2009), HIV (Deneka, Pelchen-
Matthews et al. 2007, Krementsov, Weng et al. 2009, Fournier, Peyrou et al. 2010, 
Krementsov, Rassam et al. 2010, Monk and Partridge 2012), influenza (Karlas, Machuy et al. 
2010, Konig, Stertz et al. 2010), HPV 16 (Spoden, Freitag et al. 2008), Listeria monocytogenes 
(Yauch and Hemler 2000, Tham, Gouin et al. 2010), and protozoal infections (Silvie, 
Rubinstein et al. 2003, Silvie, Greco et al. 2006, Yalaoui, Zougbede et al. 2008).  
1.10  CD81 AND HCV  
 
Very few pathogen-tetraspanin interactions have been reported and one of the best 
characterised is that of the CD81-LEL loop with HCV-E2, although there is also considerable 
literature surrounding the interaction between Uropathogenic Escherichia coli and the 
tetraspanin uroplakin 1B. In the context of HCV infection, the direct interaction of the HCV-
E2 glycoprotein with CD81 makes a tempting target for therapeutic intervention, and there 
has been extensive research in this area which will be discussed in chapter 3.  
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HCV has a relatively narrow species tropism, infecting only humans and chimpanzees. It is 
possible that CD81 may play a significant role in this specificity, as sE2 cannot bind to mouse, 
rat or African green monkey CD81 (Flint, Maidens et al. 1999, Higginbottom, Quinn et al. 
2000) However, it cannot be the sole determinant of HCV species tropism as mice expressing 
hCD81 are also not able to support infection (Masciopinto, Freer et al. 2002), and sE2 is 
capable of binding tamarin CD81 despite the observation that HCV does not infect this 
species (Allander, Forns et al. 2000, Meola, Sbardellati et al. 2000).  
Aside from the formation of the essential CD81- claudin-1 coreceptor complex (Harris, Clerte 
et al. 2013), other interactions formed by CD81 have been shown to be central to HCV 
tropism. CD81 is associated with an Ig superfamily protein containing a Glu-Trp-Ile (EWI) 
motif, EWI-2, in a high stoichiometry in most cell lines, along with a cleaved product of EWI 
lacking the N terminus, EWI-2wint, in hepatocytes. The physical association of CD81 and 
EWI-2 has been shown to inhibit the binding of HVC-E2 to CD81 (Rocha-Perugini, Montpellier 
et al. 2008), but the association with EWI-2wint allows infection and it is possible that it is 
this interaction which causes the hepatic specificity of HCV.  
1.11 CD81 STRUCTURE 
 
The CD81-LEL contains five helices which are stabilised by two disulphide bridges to form a 
mushroom-shaped antiparallel dimer composed of two subdomains (Kitadokoro, Bordo et al. 
2001, Kitadokoro, Galli et al. 2001, Olaby, Azzazy et al. 2013). The first subdomain is comprised 
of two antiparallel helices denoted A and E, along with a third helix B which together form the 
stem of a ‘mushroom’ (Figure 1.10). The second subdomain is situated above the first ‘stem’ 
subdomain and is composed of two shorter C and D helices stabilised by two disulphide bonds. 
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This region contains the E2 binding region (Kitadokoro, Bordo et al. 2001, Kong, Giang et al. 
2013) and thus the stabilisation of this structure is central to the CD81-E2 interaction 
(Petracca, Falugi et al. 2000). A nuclear magnetic resonance (NMR) study has identified a 
dynamic motif linking helix C (subdomain 2) and helix E (subdomain 1) which may form the 
basis of the initial hydrophobic interaction with E2. The authors suggest that this interaction 
becomes more substantial following the formation of a helical domain in the D-helix region. 
Therefore, this dynamic region may be involved in a structural change in CD81 during E2 
binding (Rajesh, Sridhar et al. 2012). 
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Figure 1.10: CD81 structure.  The structure of CD81 comprises four transmembrane domains, 
and two extracellular loop known as the small extracellular loop (SEL or EC1) and large 
extracellular loop (LEL or EC2), along with a small intracellular loop and intracellular N and C 
termini. The diagram shows the conserved cysteine residues (red) along with the conserved 
CCG motif in the LEL. This forms disulphide bridges (shown as purple lines) with additional 
cysteine residues. The orange structures in the intracellular and transmembrane domains 
represent palmitoylated cysteine residues. Diagram from (Feneant, Levy et al. 2014). 
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1.12 VISUALISING THE VIRUS-HOST CELL INTERACTION 
 
That the membrane of eukaryotic cells is best viewed as a ‘mosaic’ of diverse membrane 
microdomains is now well accepted (Maxfield 2002), and the lateral segregation of 
eukaryotic plasma membrane into compartments is essential for the function of most 
biological processes. The initial discovery of and subsequent research into microdomains 
used detergents for membrane solubilisation which maintained interactions in these regions. 
These interactions were then studied by fixed cell imaging by conventional fluorescence and 
electron microscopy. However, these approaches were not able to probe the dynamics of 
these structures.  
Membrane microdomains have long been associated with virus infections (first reviewed in 
(Yanez-Mo, Barreiro et al. 2009), and this relationship was  first identified following the 
observation that influenza A viral proteins colocalised with raft markers of apical lipid 
ordered domains in epithelial cells (Guess and Quaranta 2009, Stipp 2010). In addition, HIV 
also been demonstrated to associate with rafts (Boon, den Hollander et al. 2008, Charrin, le 
Naour et al. 2009). Investigating the dynamics of receptor and virus movement prior to entry 
can lead to insights into the early stages of the viral lifecycle, as viruses undergo a series of 
well-defined actions prior to entry. Binding is initiated by low affinity interactions with non-
specific receptors such as LDL receptors, and is followed by high affinity binding to one or a 
number of receptors before trafficking to sites of entry. Live imaging can be used to study 
both receptor associations and locations alongside virus trafficking. 
A notable example of the ability of live imaging to significantly increase in our understanding 
of viral processes is the observation by Walter Mothes (Sherer, Lehmann et al. 2007) that 
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particles containing an MLV GAG-CFP bind to and travel along the filopodia of the kidney cell 
line COS-2 from infected to non-infected cells (Sherer, Lehmann et al. 2007). Similarly, it has 
been demonstrated that HIV moves along T-cell nanotubes between infected and non-
infected cells at the speed of actin flow (Jolly, Kashefi et al. 2004, Jolly, Mitar et al. 2007). As 
many T cells can be connected by these nanotubes, this is believed be an efficient method of 
viral spread. 
Viruses have been observed to undergo three types of diffusion trajectories, and these are 
diffusion, directed drift, and confinement (Reviewed in (Burckhardt, Suomalainen et al. 
2011). These trajectories are very highly conserved between viruses, (Burckhardt and Greber 
2009) suggesting that the processes dictating these movements are inherent to plasma 
membranes rather than distinct to viruses. 
There are currently two major techniques employed in the study of protein dynamics. The 
first, Fluorescence Recovery After Photobleaching (FRAP) involves the bleaching of one area 
of a cell membrane containing a fluorescently tagged protein with a high powered laser, and 
observing the change in fluorescence in that area over time. This will be discussed in more 
detail in the introduction to Chapter 4, but in brief allows the researcher to find the speed of 
diffusion and mobile fraction of a large population of a protein in a relatively short period of 
time (Yang, Xiao et al. 2011). This technique can provide data on the speed of movement 
(diffusion coefficient) and mobile fraction of the population of fluorescently tagged proteins 
within the membrane. 
The second major technique is single particle tracking (SPT), which uses individual molecules 
tagged with fluorescent markers to follow the movement of individual proteins frame by 
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frame (Miyado, Yamada et al. 2000, Karamatic Crew, Burton et al. 2004). The major 
differentiation of this from FRAP is that this technique can be used to determine the 
trajectory of proteins in addition to the diffusion coefficient and mobile fraction.  
SPT studies have identified three types of protein trajectories:  Brownian, confined and 
mixed (Harris, Clerte et al. 2013, Potel, Rassam et al. 2013).  Confined proteins tend to have 
a slow speed of diffusion and travel a very short distance or not at all, whereas diffusing 
proteins have a relatively quicker diffusion speed and cover a larger area. Proteins 
undergoing mixed diffusion display a proportion of both of these. Several studies have 
suggested that directional, diffusive receptor-defined movements allow viruses to scan large 
areas of the membrane quickly and to escape from non-productive confinements (Helmuth 
et al., 2007; Ewers et al., 2005; and Lehmann et al., 2005(Burckhardt, Suomalainen et al. 
2011). 
 A major difference between FRAP and SPT is that FRAP measures a population of proteins 
whereas SPT measures the movement of one protein at the time. As a result, whilst SPT is 
arguably a more informative technique, it is more expensive and time consuming. However, 
studies of viral and protein movements on host cell plasma membranes using SPT have 
identified a number of common traits which will be discussed below. Therefore once it has 
been understood how these changes in trajectory relate to changes in global protein 
diffusion, it is efficient to continue to use a combination of FRAP and SPT to drive forward 
our knowledge of protein dynamics. 
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1.13 PROJECT AIMS 
 
The work presented here provides insights into the role of CD81 in HCV entry mechanisms. 
CD81 is an essential receptor for HCV and forms a direct and well-studied interaction with 
the virus, although the entry mechanism as a whole is complex and is still relatively poorly 
understood. However, it is essential and therefore an attractive target for therapeutic 
intervention and continued research.  
CD81 is almost ubiquitously expressed, but its specific role in the entry cycle of HCV - a virus 
with a narrow organ and species tropism - is unclear. However, it is known to have a limiting 
effect on virus entry in terms of its diffusion and protein associations. This project aims to 
further interrogate the role of CD81 in HCV entry in terms of its expression, protein diffusion 
and impact on cell signalling. We intend to do this largely with the use of the live imaging 
technique, FRAP. Specifically, it will address the following issues: 
1. There are currently no published data examining the availability of CD81 residues 
relevant to HCV infection between cell types expressing the protein. We aim to 
investigate whether antibodies to functionally and pathogenically-important residues 
in CD81 can be used to identify the protein between cell types.  
 
2. The majority of infection studies rely on hepatocellular carcinoma-derived cell lines 
which do not exhibit complex hepatic polarity, despite published data demonstrating 
that hepatic polarity defines HCV infection. Therefore, we aim to characterise 
polarised HepG2s as an in vitro model for CD81 diffusion and to use this model to 
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further our knowledge of the factors governing protein diffusion across the cell 
membrane.  
 
 
3. Recent work in a non-polarised cell line has demonstrated a link between EGFR 
signalling, HCV infection and the CD81-claudin-1 complex. We aim to further 
interrogate this association, looking specifically at the dependence of the EGFR 
signalling pathway and EGF-stimulated CD81 diffusion on the formation of the HCV 
coreceptor complex in a polarised cell type.  
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2  MATERIALS AND METHODS 
2.1 CELL LINES, PRIMARY CELLS AND TISSUE CULTURE 
 
All cells (Table 2.1) were incubated in 20% O2 and 5% CO2 at 37˚C. Hepatoma cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, USA) 
supplemented with 10% foetal bovine serum (FBS), 1% L-glutamine, 1% non-essential amino 
acids and 50 units/mL penicillin/streptavidin (Life Technologies, USA). Jurkat and Raji cell 
lines were maintained in Roswell Park Memorial Institute medium (RPMI) 1640 (Sigma, USA) 
supplemented with 2mM Glutamine + 10% FBS and incubated in the same manner. In all 
cases, in order to enumerate cells they were washed thoroughly with PBS and incubated in 
trypsin (Life Technologies, USA) for 3-6 minutes at 37˚C. The resulting suspension was then 
mixed with an equal amount of DMEM or RPMI and cells counted with a haemocytometer. 
Primary human hepatocytes were a kind gift from Dr Ragai Mitry (Kings College, London) and 
were obtained from unused donor liver tissue rejected for transplantation due to a long 
ischaemic period. Both isolation and preservation were performed in accordance with good 
laboratory practice guidelines using pharmaceutical grade reagents (Mitry 2009). Signed 
ethical consent forms were obtained prior to tissue processing. Hepatocytes were frozen 
and recovered from liquid nitrogen following lab standard procedures. Briefly, cells were 
stored by aliquoting 106 cells into 1 mL of freezing medium (95% FBS, 5%DMSO) and slowly 
cooling to -80°C in an insulated chiller box designed to cool the cells at ~1°C/ min (“Mr 
Frosty” chiller, Thermo Fisher), for longer term storage cells were transferred to liquid 
Nitrogen (-165°C). Cells were recovered by rapid thawing in a 37°C water bath followed by 
immediate transfer into 10 volumes on DMEM/10%FBS.  
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Mononuclear cells were isolated from human peripheral blood following established 
methodology (Aspinall, Curbishley et al. 2010). CD4+ T cells were isolated from peripheral 
blood mononuclear cells (PBMCs) using the CD4 Easysep enrichment kit (Stemcell 
technologies) following the manufacturer’s instructions. The resulting population were 
shown to consist of 99% CD4+ T cells by flow cytometry. This procedure was carried out by 
Dominik Niesen and Sudha Purswani. 
Cell type Tissue type 
Growth 
media 
Source 
HepG2 Human Hepatoblastoma DMEM 
American Type Culture 
Collection 
HepG2.CD81 Human Hepatoblastoma DMEM In House 
Huh-7.5 Human Hepatoma DMEM 
C Rice, Rockefeller University, 
NY, USA 
 
293T Human Embryonic Kidney DMEM 
American Type Culture 
Collection 
Jurkat 
Human leukaemic T cell 
lymphoblast 
RPMI 
American Type Culture 
Collection 
Raji Human B cell lymphoblast RPMI 
American Type Culture 
Collection 
Primary 
hepatocytes 
Human Liver Williams E 
Ragai Mitry, Kings College 
London, UK 
PBMCs 
Peripheral blood 
mononucleocytes 
Used 
immediately 
upon 
isolation 
Zania Stamataki, University of 
Birmingham, UK 
 
Table 2.1: Cell lines used, tissue type, growth media and source 
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2.2 ROUTINE TECHNIQUES 
2.2.1 Flow cytometry 
 
Flow cytometry was used to quantify the expression levels of proteins of interest using live 
cell staining, and also to isolate cells type of interest from heterogeneous primary cell 
populations.  
For experiments looking at binding of CD81 mAbs across cell types, cell lines were grown in 
tissue culture flasks in DMEM or RPMI before being trypsinised for 3-6 minutes at 37˚C and 
resuspended in an equal amount of DMEM or RPMI for quantification. Primary cells were 
obtained as described above and were used immediately upon isolation (primary immune 
cells) or following thawing from storage (PHH).  
Following quantification with a haemocytometer, cells were pelleted at 1500 rpm for 3 
minutes before resuspension in a blocking solution (PBS/1% BSA/ 0.01% sodium azide) at a 
density of 2x106 cells/mL. 100 µl of this solution was seeded per well of a 96 well plate 
(Sigma, UK) in triplicate for each condition tested. Following a 15 minute incubation in 
blocking solution at 37˚C, the cells were spun down and the solution replaced with fresh 
blocking solution containing anti-CD81 primary antibodies of interest or species matched 
IgGs at the required concentration (1 µg/mL)(Table 2.2 and 2.3). Binding of IgGs is shown 
throughout. Cells were incubated with primary antibody for 30 minutes at 37˚C before 
washing 3x in PBS. To detect primary cell-bound antibodies, anti-Ig AlexaFluor secondary 
antibodies were diluted 1:1000 in the antibody buffer and incubated with the cells for 30 
minutes at 37˚C in the dark to prevent photobleaching.  Cells were washed extensively with 
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PBS and fixed with 1% PFA for 20 minutes at 4˚C. The antibodies used, their sources, 
applications and concentrations can be found in tables 2.2 and 2.3. 
For identification of PBMC cell types, live cell staining was carried out as above, with a third 
staining step added before fixing to identify components of the PBMC population. CD3+ T 
cells were identified using a CD3-APC conjugate antibody and B cells using a CD19-Tricolour 
conjugate antibody, both of which were added for 30 minutes at 37˚C in the dark to prevent 
bleaching (Table 2.2 and 2.3). This dual staining approach allowed cell types to be identified 
simultaneously with the quantification of the level of CD81 binding. 
2.2.2 Analysis of and comparisons using CD81 flow cytometry data 
 
Protein expression was measured using a FacsCalibur flow cytometer (Becton Dickinson, 
Europe), and the cell population data analysed using FlowJo software (Tree Star, OR, USA) 
following the identification of intact, live cells by size and density. Where a dual staining 
approach was used, intact live cells were selected and PBMCs isolated according to their 
relative size and density in the context of the populations of live cells within the sample. 
CD3+ and CD19+ cells were then identified by their relative levels of APC and tricolour 
staining.  The levels of CD81 mAb binding could then be determined for each cell type. In all 
cases, CD81-mAb binding levels are expressed relative to the IgG control for each 
experiment in order to normalise results across multiple repetitions of experiments.  
Where the binding capacity is compared to binding affinities to MBP-CD81-FL and MBP-
CD81-LEL, these values were obtained by Michelle Farquhar (manuscript in preparation, see 
appendix table 2).  
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Table 2.3: List of antibodies concentrations used 
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2.2.3 Western Blotting 
 
Western blotting was used to determine levels of total and phosphorylated EGFR in 
HepG2.AcGFP-CD81 cells and HepG2 cells expressing AcGFP-tagged mutant CD81 proteins. 
Cells were seeded at 3x104/well and allowed to polarise for 5 days in DMEM. On the fifth 
day, they were subjected to a serum starvation period of 30 minutes before the addition of 
EGF at 1µg/mL or 30 µg/mL anti-CD81 mAb for defined periods of up to 60 minutes. As these 
time course experiments were carried out in a 6 well plate, the procedure was carried out in 
media supplemented with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer on a heat block at 37˚C. 
Once the treatment period was complete, cells were transferred to ice to prevent any 
further stimulation of signalling. All subsequent steps were carried out on ice with ice-cold 
reagents. Cells were washed with PBS, removed from the wells with a cell scraper and the 
suspension transferred to Universal tubes for pelleting at 1500 rpm (1000 g) at 4˚C for 5 
minutes. Cells were resuspended in lysis buffer (PBS, 1% Brij97, 20mM Tris [pH 7.5], 300 mM 
CaCl2, and 2mM MgCl2) supplemented with protease and phosphate inhibitors (Roche, UK) 
and incubated on ice for 30 minutes. The resulting lysate was centrifuged at 15000 rpm for 
20 minutes at 4˚C to remove nuclei and cell membranes. The supernatant was aspirated 
from the pellet and the protein present quantified with a BCA Protein Assay Kit (Thermo 
Scientific, USA) following the manufacturer’s instructions. Briefly, 100 µl of BSA standard or 
of lysate were mixed with 200 µl of BCA working reagent, in a 96 well plate in triplicate. The 
plates were incubated at 37˚C for 30 minutes and the absorbance read at a wavelength of 
490nm in an ELISA plate reader. The concentration of protein in the samples was found by 
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comparing the average (blank corrected) 490nm measurement for each sample to that 
found for the BSA standards forming the standard curve. 
2.2.4 Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
 
Samples were made up to a 25µl volume by mixing with 3x Laemmeli dye (30% v/v Glycerol, 
6% w/v SDS, 0.02% v/v Bromophenol Blue and 0.2M Tris-HCl; pH 6.8) with or without 2-β-
mercaptoethanol (to create non-reducing conditions). Samples were denatured at 95˚C for 5 
minutes and allowed to cool before gel loading.  
20 µl of samples were separated on 6% SDS gels by gel electrophoresis at a constant 200 
volts for 20-30 minutes using the Mini Protean 3 System (Bio-Rad Laboratories, USA) 
according to the manufacturer’s instructions. 
Following completion of the run, proteins on the gel were transferred to a polyvinylidene 
membrane (Millipore, USA) using a Mini Trans-Blot Electrophoresis Transfer System (Bio-
Rad). The membranes were treated with methanol for 2 minutes and washed with H2O 
before incubation in transfer buffer (25mM Trizma Base, 0.2M Glycine, 200mL/L methanol 
and 10% SDS) for 5 minutes at room temperature. Gels were also equilibrated in the transfer 
buffer to prevent shrinking. Electrophoretic transfer was carried out at room temperature at 
350mA for 90 minutes using the Mini Protean 3 System (Bio-Rad Laboratories, USA). 
2.2.5 Immunoblotting and chemiluminescent detection of proteins 
 
The following protocol was used for the staining and detection of total and phosphorylated 
EGFR and for β-actin, which was used as a control.   
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Following transfer membranes were placed in 50 mL falcon tubes and washed extensively 
with PBS. To prevent non-specific antibody binding membranes were incubated at room 
temperature in blocking buffer for 1 hour in (TBS-T[10mM Trizma base, 0.1M Sodium 
Chloride, 10% v/v Tween-20] with 5%w/v Marvel dry milk powder) before extensive washing 
with PBS. Primary antibody was added at the recommended dilution in antibody buffer (TBS-
T with 5% bovine serum albumin) and incubated overnight at 4˚C before 4 washes for 5 
minutes each with PBS. Membranes were incubated with HRP-conjugated secondary 
antibody at the recommended dilution in antibody buffer for 1 hour at room temperature 
followed again by extensive washing. The antibodies used, their sources, applications and 
concentrations can be found in tables 2.2 and 2.3. 
Detection of the antibodies by chemiluminescence was carried out using an ECL Western 
Blotting Detection System (GE Healthcare, UK). This process involved incubating the 
membranes in detection reagent for 1 minute before detecting luminescence using the PXi 
Multi-application gel imaging system (Syngene, UK). 
2.2.6 Analysis of Western Blotting experiments 
 
Following detection of fluorescence using the PXi Multi-application gel imaging system 
(Syngene, UK), the densities of protein bands quantified using the Gel analysis function of 
ImageJ (NIH, USA). The data were then analysed to find the density of each band of total or 
phosphorylated EGFR in relation to the level of β-actin in each lane. Once these had been 
determined, the level of pEGFR in comparison to total EGFR could be found as a ratio. 
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2.3 TRANSFECTIONS AND VIRUS  
2.3.1 Generation of cell lines expressing proteins of interest 
 
HepG2 cells were transduced to express AcGFP.CD81, AcGFP.claudin-1 and the mutant 
AcGFP.CD81 plasmids using TRIP lentiviruses containing the relevant insert. A list of plasmids 
used and their sources can be found in table 2.4. 
 
To make TRIP virus 6 well tissue culture plates were pre-coated with poly-L-lysine (Sigma) for 
5 minutes. These were washed extensively with PBS and 293-T cells seeded at a density of 
7x105/well in DMEM/10%FBS. The following day cells were incubated in 1 mL of 3% 
antibiotic-free DMEM for 1 hour prior to transfection. For each well, a total of 1.6µg of DNA 
in the ratio 600ng:400ng:600ng of pGag-pol 8.2, VSV and the pTRIP plasmid of interest 
respectively was made up to 10µl with sterile distilled water. 6µl of Fugene (Roche) was 
added to 100µl of serum free media (Optimem) and incubated at room temperature for 5 
minutes and then added to the DNA, mixed gently and incubated at room temperature for 
20 minutes. The entire reaction mixture was then added to the 1mL of 3%, antibiotic-free 
media in each well and incubated at 37˚C for 6 hours. After this time, the media was 
replaced with DMEM/10%FBS and the cells incubated for 72 hours, with harvests at 48 and 
72 hours. The harvested virus containing supernatant was pooled and clarified at 1500 rpm 
for 5 minutes in a centrifuge. 
 
For transduction, target HepG2 cells were seeded at 3.5x104/well in 2mL of media. After 24 h 
the media containing virus was added at a 1:2 dilution with 3% DMEM with antibiotics for 24 
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hours before removal and replacement with normal media. Cells were checked at 48 hours 
post-transfection for a high level of expression before use. For studies using the cell lines 
expressing mutant CD81 proteins, cells were freshly transfected for each experiment.
 
Table 2.4: Cytokines, growth factors and drugs used 
 
2.3.2 HCVpp Genesis and Infection 
 
H77 HCV (HCVpp), vesicular stomatitis virus (VSVpp) and No Env (NEpp) pseudoparticles 
were produced as described (Fafi-Kremer, Fofana et al. 2010). Specifically, 6 well tissue 
culture plates were pre-treated with poly-L-Lysine as previously described and 293-T cells 
seeded at a density of 7x105. The following day cells were incubated with 1 mL of 3% 
antibiotic free DMEM for 1 hour prior to the beginning of the process. 
The cells were co-transfected with a plasmid encoding the Gag-pol gene of HIV, the 
luciferase reporter gene, (NL4.3R-E-Luc) and a plasmid encoding either the HCV strain H77 
E1E2 envelope glycoprotein, an empty vector control (Env-pp) or Vesicular Stomatitis Virus G 
(VSV-G) protein.  
6μl of Fugene was incubated with 100μl Optimem for each well of cells for 5 minutes at 
room temperature. This was then added to a 10μl solution containing 600 ng of NL4.3R-E-
Luc, 600ng of HIV gag-pol and 600ng envelope protein expression plasmid. The mixture was 
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then incubated at room temperature for 20 minutes, added to the cells and incubated for 6 
hours. The media was then replaced with fresh 3% FBS, antibiotic-free DMEM. At 48 and 72 
hours post transfection the media was removed and stored at 4˚C and replaced with fresh 
3%, antibiotic-free media. The virus containing supernatant was either used immediately or 
aliquoted for storage at -80˚C. 
 
2.3.3 Virus infectivity assay 
 
For experiments looking at the effect of polarisation on infection, HepG2 cells were seeded 
in a 96 well plate at 1.5x105/mL for 1, 3 and 5 days to polarise. To examine the effect of EGF 
stimulation on HCVpp infection, HepG2.AcGFP-CD81 cells and HepG2 cells, which had been 
seeded at 1.5x105/mL for 5 days, and Huh-7.5 cells, which had been seeded at 1.5x105/mL, 
were subjected to a serum starvation period of 30 minutes. They were than stimulated with 
EGF for 30 minutes at a concentration of 1 μg/mL prior to the addition of virus. The 
untreated cells in this experiment were also serum starved, but remained unstimulated. 
These experiments studying the effect of TNF-α on infection have now been published by 
Nicola Fletcher (Fletcher, Sutaria et al. 2014). 
Cells were seeded in triplicate for each condition and pseudoparticle type tested. Virus 
pseudoparticles containing H77pp or NEpp were added at a 1:2 dilution whilst MLVpp was 
added at a 1:50 dilution in a 100μl total volume of 3% FBS media.  
After a 72 hours of incubation at 37˚C with the virus, the media was replaced with 40μl cell 
lysis buffer (12.5 mL 1M TrisPO4 solution pH7.8, 5mL CDTA, 50mL Glycerol, 5mL Triton-X-
100, 1mL 1M DTT, made up to 500mL with dH2O) and incubated at 4˚C for 1 hour. The 
infection levels of the sample lysates were assessed using a Luciferase Assay System Kit 
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(E1501, Promega, Madison, USA) by adding 40μl of lysate to a 35μl volume of Luciferase 
Assay Substrate mixed with Luciferase Assay Buffer. Luciferase output was monitored with a 
luminometer (Berthold Technologies, UK).  
The level of infection was determined by subtracting the values obtained for a ‘blank read’ 
of the infection plate with no lysate and the values for infection with a NEpp virus from 
those obtained with H77pp or MLVpp. 
2.4 SPECIFIC ASSAYS 
2.4.1 Quantification of polarity 
 
HepG2.CD81 cells were seeded at least one day prior to the experiment on glass coverslips. 
These were fixed for 30 minutes in 3% EM-grade paraformaldehyde at room temperature 
and stained with anti-MRP2 in 0.1% Triton-X100 (Sigma Aldrich) with 0.5% bovine serum 
albumin (BSA) in phosphate buffered saline (PBS) for 1 hour. AlexaFluor 488-conjugated goat 
anti-mouse was used as a secondary antibody and nuclei were visualised using 4’, 6’-
diamidino-2-phenylindole (DAPI; Invitrogen, UK). The polarity index was determined by 
counting the number of MRP2-positive apical structures per 100 nuclei using a Nikon Eclipse 
TE2000-S fluorescence microscope (Figure 2.1a).  
Where this technique was used to examine the effect of time in culture, cells were seeded at 
3x104 and allowed to polarise for 1, 3 or 5 days before commencement of the experiment. 
Where TNF-α was used, this was added to 5 day polarised cells at 100ng/mL for 1 hr prior to 
beginning the experiment alongside a control at the appropriate dilution. Cytochalasin D and 
latrunculin B were again added to 5 day polarised cells at concentrations of 1µM and 2.5 µM 
respectively for 1 hour before imaging, again alongside an appropriately diluted control. 
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2.4.2 Tight junctional integrity 
 
The trapping of fluorescent molecules within bile canaliculi (BC) is a well-established 
technique to identify these structures and can be used to quantify the amount of 
polarisation of a hepatocyte cell culture. HepG2.CD81 cells were seeded at least one day 
prior to beginning the experiment before washing three times with PBS at 37˚C. Cells were 
incubated with 5µM 5-chloromethylfluorescein diacetate (CMFDA, Invitrogen) at 37°C for 10 
min. After washing extensively with PBS, the cells were incubated for 15 minutes at 37˚C and 
the capacity of BC lumens to retain CMFDA monitored using a fluorescence microscope. The 
percentage of cells retaining CMFDA at their BC was compared to the total number of BCs 
visible by phase microscopy (Figure 2.1 b, c). The protocols for using this technique to study 
the effect of time in culture and addition of TNF-α, cytochalasin D and Latrunculin B are 
detailed in the above section on quantification of polarity. 
2.5 ADDITION OF DRUGS, CYTOKINES AND GROWTH FACTORS 
2.5.1 Cytoskeletal disruption and phalloidin staining 
 
Latrunculin B and cytochalasin D were purchased from Sigma and added to media at 1µM 
and 2.5 µM respectively for 1 hour before imaging. Phalloidin-633 (Alexa-Fluor) was used to 
label actin following the manufacturer’s protocol described below. A list of the cytokines 
used in this study, their working concentrations and sources can be found in table 2.5. 
Glass-bottomed MatTek™ dishes containing cells expressing fluorescent CD81 were washed 
3x with PBS and stained for actin with 633-phalloidin using a simultaneous fixation,   
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Figure 2.1: MRP-2 staining and CMFDA retention in polarised HepG2 cells. 
Immunfluorescent staining of MRP-2 (green) with DAPI nuclear stain (blue) (a). Fluorescence 
images of CMFDA retention (green) in HepG2 bile canaliculi (arrows) (b). Phase contrast 
images of polarised HepG2 cells with bile canaliculi (arrows) (c). Scale bars represent 20µm.  
 
  
(a) MRP2 
(b) Phase contrast 
(b) CMFDA (c) Phase contrast 
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permeabilisation and staining method recommended by the manufacturer (Life 
Technologies, USA). Briefly, a solution of lysopalmitoylphosphatidylcholine, 3.7% 
formaldehyde and fluorescent phalloidin was added to cells and incubated at 4˚C for 20 
minutes. Cells were then washed 3x with PBS and mounted for imaging.   
2.5.2 EGF addition and inhibition with Erlotinib 
 
Erlotinib-HCl (LC Labs) was added at 10µM in SF media for 1 hour after a 30 min period of 
serum starvation. Similarly, EGF (Peprotech, USA) was added at 10ug following a 30 min 
period of serum starvation. In all cases, untreated samples were subjected to a 30 minute 
serum starvation. A list of the cytokines used in this study, their working concentrations and 
sources can be found in table 2.5. 
2.5.3 Addition of TNFα 
 
Following 5 days of polarisation, cells in which protein diffusion, infection and tight 
junctional integrity and function had been tested were treated with TNF-α (10 ng/mL) or a 
control in the normal culture medium for 1h before the beginning of the experiment, and 
the cytokine left on for the remainder of the procedure. 
2.6 LIVE IMAGING STUDIES 
2.6.1 Fluorescence recovery after photobleaching (FRAP) 
 
For all FRAP experiments, cells transduced to express fluorescent proteins were plated onto 
MatTek™ glass-bottomed 35mm dishes at a density of 3x104 cells/well and incubated for 5 
days to allow polarisation. For studies of non-polarised cells, cells were seeded at 1x105 the 
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day before imaging. Prior to imaging cells were washed thoroughly with PBS and the media 
replaced with phenol red-free DMEM supplemented with HEPES buffer along with any 
cytokines, growth factor and drugs (Table 2.5). The protocols for use of TNFα, cytochalasin D, 
latrunculin B, EGF and erlotinib are detailed in separate sub sections above. Where the 
effect of time in culture was studied, cells were seeded at 3x104 and allowed to polarise for 1 
(non-polarised) or 5 days (polarised) before beginning the experiment.  all cases, cells were 
imaged at 37˚C using a 100x Plan Achromat 1.4 NA oil immersion objective on a Zeiss LSM 
780 confocal microscope fitted with a GaAsP spectral detector. 16 bit images were obtained 
with optimal pixel resolution. Fluorescently tagged proteins were excited with an argon laser 
at <2% of full power to capture 4 initial iterative images before bleaching of selected circular 
regions on the base of the cell in contact with the glass for 10 iterations at 100% laser 
power. Following bleaching, recovery was recorded over 300 iterations which allowed the 
recovery curve to reach a plateau. Subsequent analysis of the fluorescence recovery was 
normalised to the natural bleach rate, and the curve fitted with the exponential decay 
formula Y=Span(1-exp (-K*X))+plateau. An unbleached background region of interest (ROI) 
and sampled ROIs were selected using the inbuilt Zeiss Zen software and statistical analysis 
carried out using GraphPad Prism software. 
Regions were selected on polarised HepG2 cells expressing AcGFP-CD81 or AcGFP-claudin-1. 
In all regions, bleached spots were placed randomly, and the diameter of the regions chosen 
so as not to encompass any other membrane structures. The recovery curve was modelled in 
GraphPad Prism using an analysis where the program determined whether the curve best 
fitted a single (equation 1) or double exponential equation, in addition to finding the k value 
(equation 3) and mobile fraction. 
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Where the diffusion parameters of CD81 at different cellular locations was investigated, the 
PM was defined as the regions of the cell membrane in contact with the glass surface and 
ECM, the filopodia were identified as small, motile projections from the cell surface attached 
at only one end, thus distinguishing them from microtubules. The cell contact regions were 
defined as parts of the cell surface in physical contact with the plasma membrane of 
another, and where a BC-like structure was present. In these cases, one cell contact region 
was analysed per two cells. 
 
Table 2.5: Plasmids used 
2.6.2 Analysis of FRAP data 
 
To establish the necessary samples sizes for FRAP data, Montecarlo bootstrap analysis was 
carried out by repeated selection of the stated sample sizes with replacement from the 
population. The mean diffusion coefficient and mobile fraction of these compared to that of 
the population to find the coefficient of variation using GraphPad Prism 6.  
In order to establish the diffusion mode of CD81, the fluorescence intensity of bleached 
regions were plotted against the time post-bleaching to form a recovery curve. The curve 
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was then analysed using GraphPad Prism 6 to confirm the equation of the curve – single or 
double exponential. Additionally, the mean T1/2 was plotted against the size of the bleached 
region from which it was calculated to establish to direction of diffusion.  
2.7 CONFOCAL MICROSCOPY 
 
In all cases, cells were seeded in glass bottomed MatTek™ dishes or plates five days before 
the experiment. Cells were imaged using a 100x Plan Achromat 1.4 NA oil immersion 
objective on a Zeiss LSM 780 confocal microscope with a GaAsP spectral detector. 16 bit 
images were attained with optimal pixel resolution. Fluorescently tagged proteins were 
excited with 488 nm or 633 nm lasers which had been adjusted to prevent bleed-through. 
2.7.1  Effect of CD81 mutant proteins on CD81 and EGF localisation 
 
To examine the effect of the mutant CD81 proteins on CD81 and EGFR localisation, cells 
expressing AcGFP-tagged versions of the proteins were seeded at 3x104 on the glass 
bottomed MatTek™ dishes and were allowed to polarise for 5 days. Cells were subjected to a 
serum starvation of 30 minutes prior to fixation for 15 minutes at room temperature with 
3.6% formaldehyde diluted in the serum free medium. Cells were washed 3x with PBS and 
incubated with the blocking buffer (1X PBS / 5% normal serum / 0.3% Triton™ X-100) for 60 
minutes at room temperature. The primary antibody (EGFR, Cell Signalling Technology, USA) 
was then added at a dilution of 1:50 in antibody dilution buffer (1X PBS / 1% BSA / 0.3% 
Triton X-100) at 4˚C overnight. Following a further thorough wash with PBS, dishes were 
incubated with anti-rabbit IgG-633 at 1:1000 for 1 hour at room temperature in the dark. 
Cells were again washed 3x with PBS and nuclei visualised with DAPI (Invitrogen, UK) prior to 
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a final wash and mounting with Prolong Gold Antifade reagent (Cell Signalling Technology, 
USA). The staining was then visualised as described above. 
2.8 BACTERIAL WORK 
2.8.1 Transformation 
 
Competent cells (One Shot ®TOP10 Chemical Competent E.coli, Invitrogen) were thawed on 
ice. For each transformation, 20 µl of competent cells was added to 1 µl of plasmid and the 
mixture agitated carefully before incubating for 30 minutes on ice to allow uptake of the 
DNA. The reaction mixture was then subjected to a heatshock of 42˚C for 45 seconds in a 
water bath before a further 5 min incubation on ice. 100 µl of culture broth (S.O.C. medium, 
Invitrogen) was added to the reaction mixture and incubated for 30 minutes to allow 
recovery. The entire reaction mixture was then spread on plates containing 2% Luria Broth 
(LB, Invitrogen) + 1% agarose (Bioline) supplemented with ampicillin (100ng/mL) (Sigma-
Aldrich). This was incubated at 37˚C overnight to allow colonies to grow. 
2.8.2 Preparation and multiplication of plasmid DNA 
 
Two colonies were picked from each transformation reaction. These were incubated in 5 mL 
of 2% LB broth with ampicillin (100ng/mL) at 300 rpm at 32˚C overnight. The suspension was 
centrifuged at 4000 rpm for 10 minutes and the resulting pellet used to isolate the plasmid 
using a Qiaprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s instructions. 
Briefly, pellets were resuspended in 250 µl Suspension Buffer P1 (containing LyseBlue pH 
indicator) followed by the addition of 250 µl ice cold Lysis Buffer P2. The tube containing this 
suspension was then inverted gently until the solution turned blue. This lysis product was 
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then mixed with Neutralising Buffer N3 and the tube inverted again until the blue colour had 
disappeared. The lysates were transferred to sterile 1.5mL eppendorf tubes and centrifuged 
at 13000 rpm for 10 minutes to remove the bacterial precipitate. The supernatant was 
transferred to a spin column and centrifuged for 30-60 seconds to capture the DNA. The 
column filter was washed by centrifugation with Buffer PB and then Buffer PE, and then by a 
further centrifugation to remove any remaining buffer. Finally, the dry filter was incubated 
with Buffer EB for 1 minute followed by a 1 minute centrifugation to elute the DNA. The 
concentration and purity of the resulting purified plasmid was measured by spectrometry 
and stored at -20˚C. Typical yields were 10 – 25 µg of plasmid with purity of 1.8 – 1.85 
(260/280nm ratio). 
2.9 STATISTICAL ANALYSIS 
 
All statistical tests and analyses were carried out using Prism 6.0 software (GraphPad, CA). In 
order to avoid testing the assumptions of a particular data distribution, all tests were 
performed using non-parametric methods. Statistics used in FRAP experiments were Mann-
Whitney U tests for non-parametric distributions, and a probability value (P) <0.05 was 
considered statistically significant. All tests and significance values are quoted in the figure 
legends. Where necessary corrections for multiple comparisons were made (Bonferroni 
method). 
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3.  A COMPARATIVE ANALYSIS OF CD81 PRESENTATION BETWEEN 
CELL TYPES 
3.1 INTRODUCTION 
 
The development of HCV model systems has enabled the entry stages of the viral lifecycle to 
be studied extensively, and early work showed the direct interaction of HCV-E2 with residues 
in the CD81 large extracellular loop (CD81-LEL) to be essential for HCV entry (Pileri, Uematsu 
et al. 1998, Flint, Maidens et al. 1999, Higginbottom, Quinn et al. 2000, Zhang, Randall et al. 
2004, Flint, von Hahn et al. 2006). Numerous studies have since identified key amino acid 
residues in the CD81-LEL that define protein dimerization (K124, V146, F150, C157, T166, 
C190), claudin-1 association (K148, T149, E152, T153) and CD81 association  with HCV-E2 
(L162, I182, N184, F186) (Higginbottom, Quinn et al. 2000, Kitadokoro, Galli et al. 2001, 
Drummer, Wilson et al. 2002, Drummer, Wilson et al. 2005) (Figure 3.1). Regions in the small 
extracellular loop and the transmembrane (TM) domains TM3 and TM4 of CD81 have also 
been reported to contribute to HCV entry by mediating CD81 cell surface expression and its 
interaction with partner proteins (Masciopinto, Campagnoli et al. 2001, Montpellier, Tews et 
al. 2011).  
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Figure 3.1: Ribbon diagrams and surface representations of the epitopes studied.  K124 in 
the A helix and H191 in the E helix (a); T161, T163, L165, Q132 and D128 surrounding the 
L162 in the 3-10 helix (b); F150, T167 and L162 in the B, C and 3-10 helices (c); and T149, 
E152 and T153 alongside V146, F150 and V123 (d). V146, T149, F150 and V123 form a 
binding pocket. (Farquhar et al., in preparation). 
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The initial attachment steps of the viral lifecycle are essential and highly conserved, and 
therefore represent an attractive target for antiviral therapies. Indeed, host-generated 
antibodies to HCV glycoproteins appear to contribute to disease outcome (Chapel, Christie et 
al. 2001, Pestka, Zeisel et al. 2007). Some degree of prophylactic protection has been 
demonstrated in animal models using anti-HCV antibodies (Chapel, Christie et al. 2001, Pestka, 
Zeisel et al. 2007, Keck, Machida et al. 2008), however this success has not been replicated in 
human clinical trials. Whilst a number of anti-E2 antibody therapies have been tested, none 
have demonstrated a significant effect on viral load, and in one study escape mutations were 
seen in all patients (Gordon, Lynch et al. 2011, Vercauteren 2012). This failure may to some 
degree be attributed to the extreme plasticity in the HVR1 of the HCV glycoprotein E2, to 
which many of these antibodies are targeted. An alternative target for antibody therapy 
therefore is the host factors themselves, as they are completely conserved and cannot 
develop escape mutations. Inhibiting the virus-receptor interaction by blocking either the 
virus or host proteins may occur through direct blocking of binding sites or by antibody 
coating. 
 
To date, a number of antibodies to CD81 have been described and the most widely used are 
JS-81 and 1.3.3.22, both of which bind a conformational epitope within the CD81-LEL and are 
capable of recognising CD81 on a variety of cell types (Bertaux and Dragic 2006, Meuleman, 
Hesselgesser et al. 2008). Both antibodies have been shown to inhibit HCVpp and HCVcc 
infection, (Bertaux and Dragic 2006, Meuleman, Hesselgesser et al. 2008, Farquhar, Hu et al. 
2012) and with JS-81 neutralisation has been demonstrated across genotypes 1-6. The binding 
site of 1.3.3.22 overlaps with the L162 residue (Drummer, Wilson et al. 2002), providing a 
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mechanism for at least some aspects of its neutralizing activity. JS-81 has also been shown to 
act at additional stages of the viral lifecycle during the formation of receptor complexes and 
at post-internalisation steps (Bertaux and Dragic 2006, Schwarz, Grove et al. 2009, Farquhar, 
Hu et al. 2012). The use of these antibodies demonstrates their therapeutic potential, and this 
is supported by a study in 2008 in which prophylactic protection from genotype 1a and 4a 
infections in human liver uPA-SCID mice was observed using anti-CD81 antibodies (Meuleman, 
Hesselgesser et al. 2008).  
 
It should be noted that antibodies can block infection via a number of mechanisms throughout 
the virus entry process (reviewed in (Klasse and Sattentau 2002, Marasco and Sui 2007). 
Alongside simply blocking interactions, antibodies may also induce the aggregation of the virus 
or promote the endocytosis of receptors, as has been reported for a number of CD81 mAbs 
(Farquhar, Hu et al. 2012). Furthermore, they may inhibit the fusion of the virus with the target 
cell by inhibiting the conformational changes necessary for fusion.  
 
The well-characterised interaction between CD81 and HCV-E2 has made it a preferred target 
for intervention. However, CD81 is expressed almost ubiquitously, and therefore it is probable 
that widespread CD81 ligation with antibody would cause off-target effects in vivo. As the 
CD81 protein has an important role in the immune response, its engagement on immune cells 
has been investigated and shown to cause: the activation of T cells via Lck (Wack, Soldaini et 
al. 2001, Crotta, Ronconi et al. 2006); the activation and induction of B-cell proliferation 
(Cocquerel, Kuo et al. 2003, Rosa, Saletti et al. 2005, Coffey, Rajapaksa et al. 2009); the 
promotion of T and B cell collaboration (VanCompernolle, Levy et al. 2001); and the inhibition 
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of NK cell activation, proliferation and cytokine production (Crotta, Stilla et al. 2002, Tseng 
and Klimpel 2002, Maecker 2003).   Within the cell antibody ligation of CD81 has been shown 
to activate the MAPK-ERK and Rho-family GTPase signalling pathways (Carloni, Mazzocca et 
al. 2004, Zhao, Wang et al. 2005, Brazzoli, Bianchi et al. 2008) in addition to promoting 
hepatoma spread in an actin-dependent manner (Brimacombe, Wilson et al. 2014) and 
stimulating clathrin-dependent internalisation of CD81 (Farquhar, Hu et al. 2012). A study in 
uPA-SCID mice showed that administration of antibodies to CD81 caused an elevation of 
transaminase levels and syncytia formation in the human portion of the liver (Pilot-Matias T. 
2010).  Given this list of potential side effects, antibodies which cannot distinguish between 
CD81 expressed in hepatic and non-hepatic backgrounds are likely to be of limited therapeutic 
use in preventing HCV infection. 
Previous reports have shown that the conformations of CD151 and of CD63 are altered by 
epitope masking in the presence cell type-specific binding partners, and that these resulting 
changes in conformation alter antibody binding affinities (Rubinstein, Le Naour et al. 1996, 
Serru, Le Naour et al. 1999, Sincock, Fitter et al. 1999). Similarly, CD81 structure is altered by 
the interaction with E2 (Rajesh, Sridhar et al. 2012), and with other tetraspanins (Silvie, Charrin 
et al. 2006). Indeed, this latter study has demonstrated that murine CD81 in the presence of 
other tetraspanins can be specifically identified with the antibody MT81w (Silvie, Charrin et 
al. 2006).  
As cell-specific interactions are formed by the protein, distinguishing CD81 in a hepatic 
background from CD81 in other cell types may be theoretically possible due to the formation 
of cell-type specific interactions.  Perhaps the most relevant of these interactions is the 
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hepatocyte-specific interaction between CD81 and the cleavage product of EWI-2, EWI-2wint, 
which has been suggested to contribute to the liver tropism of HCV (Rocha-Perugini, 
Montpellier et al. 2008, Montpellier, Tews et al. 2011). CD81 has additionally been reported 
to form T cell-specific interactions with CD4 (Fournier et al., 2010) and CD8 (Todd et al., 1996), 
and B cell-specific interactions with CD63, very late antigen (VLA) integrins and human 
leukocyte antigen – DR (HLA-DR antigens) (Rubinstein, Le Naour et al. 1996).  
Given these known interactions it is possible that a hepatocyte-specific conformation of 
human CD81 may exist. If this were identified, an antibody could be designed which 
preferentially bound hepatocyte CD81 with limited recognition of CD81 on other cell types, 
thus causing limited off-target effects. 
The McKeating group has produced a panel of antibodies targeting human CD81 expressed in 
Pichia Pastoris (Jamshad, Rajesh et al. 2008) (Figure 3.1). These antibodies were identified by 
their reactivity with recombinant forms of full length (FL) and truncated CD81-LEL in an ELISA 
assay. These screening assays identified 17 LEL-specific monoclonal antibodies (mAbs) which 
were tested for reactivity with a panel of CD81 proteins with mutations in regions necessary 
for HCV-E2 binding and CD81 dimerisation (Farquhar et al., in preparation) (Higginbottom, 
Quinn et al. 2000, Drummer, Wilson et al. 2005) (Table 3.1, Figure 3.1). They were also shown 
to be able to inhibit HCV infection in a manner strongly correlated with their binding affinity 
to CD81.  
This panel of mAbs was used to probe the availability of CD81-LEL epitopes on different cell 
types with the goal of identifying antibodies that preferentially recognise hepatocellular CD81. 
It should be noted that in the experiments described below members of the antibody panel 
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were used at identical concentrations across all cell lines studied. As a result, in the absence 
of proper optimisation the data presented here should be treated as a starting point for more 
thorough investigation. The caveats of the methodology used will be elaborated upon in the 
discussion. 
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3.2 RESULTS 
3.2.1. Anti-CD81 mAbs show variable binding to Huh-7.5 hepatoma cells. 
 
Previous work has examined the ability of the antibody panel to bind to recombinant MBP-
CD81-FL and -LEL, and the antibodies demonstrate varying binding efficiencies to both 
proteins (Farquhar et al., in preparation, appendix table 1). To characterise the ability of the 
panel to bind to full length CD81 expressed in the background of a hepatic membrane, the 
antibodies were used at a saturating concentration and examined for their ability to bind Huh-
7.5 hepatoma cells (optimisation work carried out by Michelle Farquhar). This cell line was 
chosen since it supports robust HCV replication and naturally expresses CD81. Representative 
FACS profiles are shown for each antibody (Figure 3.2 a-n). Whereas the majority of antibodies 
bound with high median fluorescent intensities (MFI), mAbs 2s24, 2s131, 1s73 and 2s141 
(Figure 3.2f, e, n, and l respectively) exhibited somewhat lower binding capacities.  
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Figure 3.2: Representative FACS curves of anti- CD81 monoclonal antibody panel on Huh-
7.5. A representative curve (black line) of three duplicate repeats is shown against isotype 
matched control (grey shaded). (a) 2s20, (b) 2s48, (c) 2s63, (d) 2s66, (e) 2s131, (f) 2s24, (g) 
2s139, (h) 1s201, (i) 1s337, (j) 1s262, (k) 1s135, (l) 2s141, (m) 2s155, (n) 1s73. Antibodies 
were used at 1 µg/ml. 
(a) (b) (c) 
(d) (e) (f) 
(g) (h) (i) 
(j) (k) (l) 
(m) (n) 
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In order to establish whether some of these epitopes are less accessible on the Huh-7.5 cell 
surface in comparison to others, mAb binding was expressed relative to an irrelevant IgG 
control and defined as relative fold change (RFC) to normalise binding levels over multiple 
experiments. The antibodies were organised into groups of high, medium, or low binding 
intensity (Figure 3.3a). 2s24, 2s131, 1s73, 2s141 and 2s139 are placed in the lowest group, 
with an RFC range of 6.69 to 24.36; 1s262 and 2s66 were assigned to the medium group, with 
RFCs of 36 and 53.1 respectively; and 2s63, 1s135, 2s48, 2s20, 1s201, 1s169, 2s155 and 1s337 
constituted the highest binding group with RFCs ranging from 67.53 to 93.72. This wide range 
of RFC values may demonstrate the varied availability of the epitopes studied in this cellular 
background if confirmed following proper optimisation of antibody usage.   
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Figure 3.3: Epitope recognition of anti- CD81 monoclonal antibody panel on Huh-7.5 
hepatoma cells. Fold change in MFI from IgG for each antibody on CD81 expressed on Huh-
7.5 cells (n=3) organised by binding level (a) and epitope group (b). Staining was carried out 
live before fixing and analysis using flow cytometry. All data shown are representative of 3 
repeats. 
(a) 
(b) 
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In previous work Farquhar et al., classified the mAbs into 6 groups according to their binding 
to a panel of recombinant CD81 proteins containing mutations at specific LEL residues 
involved in E2 binding and dimerisation (Table 3.1). In order to establish whether the variation 
in epitope availability on Huh-7.5 cells could be linked to these epitope groupings, the RFC 
values for each antibody were compared between the groups (Figure 3.3b).  This analysis 
revealed no apparent relationship between the parameters.  RFC values in group I range from 
6.6 -74.3 RFC. MAbs 2s20, 2s48 and 2s63 in group I have similar values, but the presence of 
the much lower 2s24 and 2s131 in group I, along with that of 1s135 in group V negates the 
low level of binding as being specific to group I. Groups V and VI are also variable, displaying 
values of 12.2 - 68.7 RFC and 14.8 - 89.4 RFC respectively. The antibodies in group II and III 
have similar binding levels, with 1s201 and 1s337 displaying values of 81.7 RFC and 93.7 RFC. 
The single antibody in group IV has an intermediate binding value of 36.2 RFC. These data 
demonstrate no direct relationship between the epitope grouping of an antibody and its 
ability to bind to Huh-7.5 cells. These epitope groups are based on binding in a membrane-
free system, and one possible interpretation of the discrepancy observed with the data 
presented here is that the differences in epitope binding patterns are due to the presence of 
a membrane in a cell background.  
3.2.3 Comparative binding of anti-CD81 on hepatocytes and immune cells 
 
CD81 is expressed on T and B cells in addition to hepatocytes, and forms cell-type specific 
interactions in these cells. To begin to investigate whether CD81 epitope availability can be 
affected by the type of cell membrane in which it is expressed, the ability of the antibody panel 
to bind CD81 expressed on hepatocytes and immune cells was examined by live cell staining 
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and FACS analysis. In addition to PBMC-derived primary T and B cells, antibody binding to the 
T cell line Jurkat and the B cell line Raji was assessed. Four separate donor isolations were 
used for the primary immune cells, whilst two separate isolations were used for PHH. 
Representative FACS profiles are shown for antibodies from each Huh-7.5-defined binding 
group for all cell types (Figure 3.4). As before, the antibodies were used at an identical 
concentration across all cell types studied. Therefore, this work would need to be repeated 
following optimisation on each cell type before any valid conclusions could be derived.  
Initially, binding capacity was measured for primary human hepatocytes (PHH) (Figure 3.4a-
c), as these are most representative of the hepatocytes in the liver. Whilst the antibodies were 
capable of binding to this cell type, they did so to a much lower degree than observed with 
Huh-7.5 cells and displayed less variation in binding across the groups. For example, 2s141 
(Figure 3.4a) in the low binding group has an intensity of 6.8 MFI whereas 1s290 in the high 
binding group has an intensity of 29.9 MFI (Figure 3.5c), for both mAbs irrelevant IgGs bound 
with an MFI of 3.4.   
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Figure 3.4: Representative FACS curves of anti-CD81 monoclonal antibody panel on primary 
and immune cell types. A representative curve (black line) of three duplicate repeats is 
shown against isotype matched control (grey shaded) for one antibody from each of the Huh-
7.5-defined binding groups. (a) 2s141, (b) 2s66, (c) 2s20, (d) 2s141, (e) 2s66, (f) 1s337, (g) 
2s141, (h) 1s262, (i) 1s135, (j) 2s141, (k) 2s66, (l) 1s337, (m) 2s131, (n) 1s262 (o) 1s201. 
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Using the current methodology, the relative binding of the antibody panel to the Jurkat cell 
line shows broad similarities to that observed with Huh-7.5, with the representative 
antibodies showing an increase in binding capacity between the low, medium and high groups. 
2s141 in the low group binds with 180 MFI (Figure 3.4d), and 1s337 in the high binding group 
displays a value of 1056 MFI (Figure 3.4f), the irrelevant IgG bound with 3.2 MFI. The Raji cell 
line exhibits a similar range, from 329.5 MFI (2s141, Figure 3.4g) to 1467.5 MFI (1s135, Figure 
3.4i). The binding of all antibodies to both immune cell lines was around ten times higher than 
Huh-7.5 cells, which may reflect their higher CD81 expression if confirmed following 
optimisation.  
With primary T and B cells, the levels of binding are lower than are observed on the immune 
cell lines. On primary T cells, antibodies in all binding groups displayed very similar MFI values, 
with 2s141 (Figure 3.4j), 2s66 (Figure 3.4k) and 1s337 (Figure 3.4l) displaying values of 50.5 
MFI, 61.3 MFI and 77.2 MFI respectively.  In contrast, on primary B cells binding capacities 
were more varied between the high binding group and other groups. MAbs 2s131 (Figure 
3.4m) and 1s262 (Figure 3.4n) in the low and medium binding groups bound with an MFI of 
3.5 and 3.8 respectively, whereas 1s201 (Figure 3.4o) in the high binding group had an MFI of 
6.7.  
These data suggest considerable variation in antibody binding capacities across the cell lines 
tested. As a result, all members of the antibody panel were carried forward for continued 
screening across all cell types to attempt to identify epitopes which are particularly accessible 
in a hepatic background. 
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3.2.4 The expression of CD81 in a membrane background has considerable effects on 
availability of epitopes in the LEL 
 
To investigate cell-type specific patterns of epitope availability, the binding capacities of the 
antibody panel were compared to their binding efficiencies to purified full length recombinant 
CD81 (MBP-CD81-FL). To do this, the binding capacity was plotted against the MBP-CD81-FL 
binding affinity and the 95% confidence interval (CI) of the data found. Any antibodies which 
fell outside of this interval could then be described as binding either to a higher or lower 
degree in the membrane than would be predicted by their binding to MBP-CD81-FL. As 
previously discussed, without the proper optimisation of antibody staining on all cell types 
tested, the conclusions taken from this data can remain only speculation. This is reviewed 
further in the discussion.  
3.2.4.1 Hepatocyte-specific alterations in epitope availability 
 
The comparison of MBP-CD81-FL binding efficiency with Huh-7.5 affinity showed a positive 
correlation between the two parameters, with those antibodies which displayed a higher 
binding efficiency to MBP-CD81-FL in general also displaying a high binding capacity to Huh-
7.5 (Figure 3.5a). However, when the 95% CI of this association was plotted, there were a 
number of antibodies which fell outside of the boundaries. Notably mAbs 1s337, 2s20, 1s135 
and 2s63 were above the CI, suggesting that the epitopes recognised by these antibodies are 
more accessible on Huh-7.5 than on the recombinant protein. By the same reasoning, the 
epitopes bound by the antibodies 2s141, 2s131 and 2s24 are relatively less accessible in the 
Huh-7.5 background. These data suggest that CD81 in a Huh-7.5 membrane has considerable 
differences in the availability of epitopes compared to the purified CD81 protein in isolation. 
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When this analysis was repeated for primary human hepatocytes, the data again show a 
positive correlation (Figure 3.5b). However, we found fewer antibodies falling outside of the 
CI than were observed in the Huh-7.5 background (Figure 3.5a). In this case, only 2s20 and 
2s139 bind to a higher degree on PHH than on MBP-CD81-FL, whereas 2s24 and 2s131 
binding capacities were higher on the MBP-CD81-FL protein. Therefore, in the PHH 
membrane CD81 shows further changes in the availability of the epitopes. 
These data suggest a positive correlation between the binding of the antibodies to MBP-
CD81-FL and to CD81 in hepatic backgrounds. However, there are individual differences in 
the availability of a number of epitopes between these backgrounds, which may reflect 
considerable changes in the conformation of the LEL region. The relatively higher number of 
antibodies deviating from the CI in Huh-7.5 cells compared to PHH suggests that CD81 in the 
membrane of the hepatic cell line presents its epitopes in a different way from CD81 in 
primary cells.  
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Figure 3.5: Comparison of antibody binding on recombinant CD81 to hepatic cells. Fold 
change in MFI from IgG for each antibody on CD81 expressed on Huh-7.5 cells (binding 
capacity, n=3) (a) and PHH (binding capacity, n=2) (b) was plotted against the observed 
binding affinity to MBP-CD81-FL. Each black spot represents one antibody, and the full black 
line the regression line. Dotted curves above and below represent 95% confidence interval. 
  
(a) (b) 
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3.2.4.2 T cell-specific alterations in epitope availability 
 
As the availability of CD81 epitopes is affected not only by the presence of a membrane, but 
also in a cell-specific manner, we were interested to investigate the impact of an immune 
cell membrane on epitope availability.  
The binding capacity of the antibodies to the Jurkat T cell line demonstrated a positive 
correlation with their binding efficiency to MBP-CD81-FL (Figure 3.6a). However, there were 
many outliers from the 95% CI. MAbs 1s201, 2s155, 2s139, 1s337, 2s20 and 1s135 were 
located above the CI, suggesting that the epitopes recognised by these antibodies are more 
exposed on Jurkat cells than on the recombinant protein. In contrast, 2s131, 2s141 and 2s24 
were found below the CI, suggesting that these epitopes are more accessible in MBP-CD81-
FL.  
Repeating this analysis with primary T cells demonstrates that there are considerable 
differences between the binding of the antibody panel to these cells and to MBP-CD81-FL 
(Figure 3.6b). The epitopes recognised by the antibodies 2s63, 2s139 and 2s20 are more 
available on primary T cells, whilst those targeted by 2s66, 2s131 and 2s24 are more 
accessible on MBP-CD81-FL.  
These data again suggest considerable differences between the availability of the mAb 
epitopes in the background of a cell membrane and in a recombinant, full length protein. 
However, there are many more differences between Jurkat cells and MBP-CD81-FL than 
between primary T cell CD81 and the recombinant protein. 
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Figure 3.6: Comparison of antibody binding on recombinant CD81 to T cells. Fold change in 
MFI from IgG for each antibody on CD81 expressed on Jurkats (binding capacity, n=3) (b) and 
primary T cells (binding capacity, n=4) (b) was plotted against the observed binding affinity to 
MBP-CD81-FL. Each black spot represents one antibody, and the full black line the regression 
line. Dotted curves above and below represent 95% confidence interval. 
   
(a) (b) 
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3.2.4.3 B cell-specific alterations in epitope availability 
 
CD81 is expressed not only on T cells, but also on B cells. In order to interrogate the effect of 
B cell membranes on the conformation of CD81, the binding capacity of the antibodies to 
Raji cells and primary B cells were compared to MBP-CD81-FL binding efficiency. As in all the 
other studies, we found a positive correlation between the observed binding affinities and 
binding efficiencies in both the Raji B cell line and primary B cells.  
Again, there are a number of antibodies which display a considerable divergence from the 
overall trend. The epitopes recognised by 1s201, 1s135, 1s337, 2s139 and 2s20 are relatively 
more accessible on CD81 expressed in the Raji cell line than on MBP-CD81-FL (Figure 3.7a), 
whereas those recognised by 2s63, 2s141, 2s131 and 2s24 are more accessible in MBP-
CD81-FL. These data show that there are epitopes in the LEL of CD81 whose availability is 
considerably altered in the Raji cell membrane. 
Similarly, for primary B cells, the antibodies 2s155, 2s139 and 2s20 bind to a higher degree 
on primary B cells than MBP-CD81-FL, whereas 2s131, 2s141 and 2s24 bound preferentially 
to MBP-CD81-FL (Figure 3.7b).  
These data suggest that there are considerable changes in the availability of the epitopes 
recognised by these antibodies when in the background of either a Raji B cell line or primary 
B cells. Interestingly, there are fewer differences between MBP-CD81-FL and the primary 
cells than between MBP-CD81-FL and the Raji B cell line. This trend has been seen in all cell 
types studied, with both PHH and primary T cells having fewer outliers from the 95% 
confidence interval than their corresponding cell lines. 
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Figure 3.7: Comparison of antibody binding on recombinant CD81 to B cells. Fold change in 
MFI from IgG for each antibody on CD81 expressed on Rajis (binding capacity, n=3) (b) and 
primary B cells (binding capacity, n=4) (b) was plotted against the observed binding affinity 
to MBP-CD81-FL. Each black spot represents one antibody, and the full black line the 
regression line. Dotted curves above and below represent 95% confidence interval. 
   
(a) (b) 
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3.2.5 Cell-type specific alterations in epitope availability in comparison to the LEL in 
isolation 
 
 The binding efficiencies of the antibody panel to a recombinant protein containing just the 
CD81-LEL in isolation from the full length molecule, MBP-CD81-LEL, have also been 
determined. Given the considerable variation in epitope availability observed in the 
background of a cell membrane compared to MBP-CD81-FL, we were interested to 
understand whether such differences were conserved when the binding capacities were 
compared to the binding efficiencies of the panel to MBP-CD81-LEL. In this protein, the LEL is 
expressed in isolation without the other constituents of the CD81 molecule, the SEL, TM 
regions 3 and 4 and the carboxy terminus. 
When compared to MBP-CD81-LEL, all cell types exhibited very similar patterns of outliers to 
those identified in the comparison with MBP-CD81-FL (Figure 3.8, Table 3.3). The greatest 
difference in binding patterns was observed with the hepatic cell types. Whilst the epitopes 
recognised by 1s337, 2s20 and 1135 were all more accessible on Huh-7.5 cells than on both 
MBP-CD81-LEL and MBP-CD81-FL, those recognised by 2s155 and 1s201 were additionally 
more accessible when compared to MBP-CD81-LEL (Figure 3.8a). In addition, whilst 2s139 
2s141 and 2s131 were again bound more strongly to the recombinant protein, 2s24 did not 
fall outside of the confidence interval when compared to MBP-CD81-LEL binding efficiencies.  
The comparisons of PHH and MBP-CD81-LEL were the most divergent from those observed 
with MBP-CD81-FL (Figure 3.8b). In this data set mAbs 2s20, 2s24 and 2s141 no longer fell 
outside of the 95% confidence interval, whereas 2s155 displayed higher RFC values on PHH 
than the LEL recombinant protein, and the epitopes recognised by 2s141 were more 
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accessible on the recombinant protein. These data suggest that availability of epitopes 
differs between CD81 in a PHH and MBP-CD81-LEL in a manner which is distinct from MBP-
CD81-FL.   
In contrast to hepatocytes, the outliers observed when comparing Jurkat cells to MBP-CD81-
LEL are identical to those that were identified following comparison to MBP-CD81-FL, with 
only exception being mAb 2s63, that replaces 2s24 in falling below the CI (Figure 3.8c). This 
once again suggests that epitope availability in CD81 expressed in the background of a Jurkat 
cell differs greatly from CD81 LEL in isolation, but Jurkat cells differ from both CD81-MBP-FL 
and CD81-MBP-LEL in a very similar way. 
When the binding efficiencies of the antibodies to MBP-CD81-LEL were compared to binding 
capacities on the remaining immune cells and cell lines they displayed almost identical 
outliers to those previously identified in the comparison to MBP-CD81-FL (Figure 3.6 and 
3.7). Although in the case of primary T cells, mAbs 2s20 and 2s24 were no longer outliers 
from the CI (Figure 3.8d), and in Raji cells mAb 2s155 was an additional outlier above the CI 
with 2s24 no longer falling below the CI (Figure 3.8e). MAb 2s24 also no longer fell below the 
CI in primary B cells (Figure 3.8f).  
If these findings were confirmed with properly optimised antibody concentrations, these 
data would confirm that the availability of CD81 –LEL epitopes differs in a membrane-
specific manner from CD81 in a cell membrane, as with full length CD81.  
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Figure 3.8: Comparison of antibody binding on MBP-CD81-LEL to CD81 in a membrane 
background. Fold change in MFI relative to an isotype matched IgG control for each antibody 
(binding capacity, n=3) for CD81 expressed on Huh-7.5 (a), PHH (b), on Jurkat (c) on CD3+ T 
cell (d), on Raji (e) and on CD19+ B cells (f) was plotted against the binding affinity to MBP-
CD81-LEL. Each black circle represents one antibody. The solid line the regression best fit. 
Dotted curves above and below depict the 95% confidence interval. 
(c) (d) 
(e) (f) 
  
(b) (a) 
(d) (c) 
(f) (e) 
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3.2.6 Anti-CD81 antibodies show cell-type specific binding.  
 
Having observed multiple differences between cell-expressed CD81 and recombinant CD81, 
we were interested to interrogate any differences or similarities in epitope availabilities 
between these cell types and hepatocellular CD81. To do this, the RFC for each antibody on 
each cell type was compared to its ability to bind CD81 expressed on Huh-7.5 (shown in figure 
3.3a) (Figure 3.9).  
The RFCs for antibody recognition of PHHs (Figure 3.9a) was much lower than that observed 
with Huh-7.5 (Figure 3.3), and was associated with a higher error, a characteristic which is 
likely a reflection of the smaller amounts of mAb bound and variability between the two donor 
isolations. However, the overall binding pattern of the antibodies to PHH largely reflected that 
for Huh-7.5, with the majority remaining in the previously defined low, medium and high 
binding categories. The only exception to this is 2s139, which was placed in the low group on 
the basis of Huh-7.5 binding but bound well to PHH. This implies a significant change in the 
epitopes recognised by 2s139 which causes it to be more strongly recognised on the primary 
cell type than on Huh-7.5. However, for all of the other antibodies the binding patterns are 
very similar, suggesting that the overall conformation of CD81 is very similar in PHH and Huh-
7.5.  
The pattern of antibody binding to the CD81 transduced cell line Jurkat-CD81 is also similar to 
that observed with Huh-7.5, with the majority of antibodies being placed in the same groups 
as the Huh-7.5 ranking (Figure 3.9b). However, there are a number of anomalies. Both 2s63 
and 1s73 are placed higher in the Huh-7.5 ranking than their RFC values would suggest, 
implying that the epitopes recognised by these antibodies are less accessible on Jurkats than 
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on Huh-7.5. In contrast, the epitope recognised by 2s139 is better recognised on Jurkats than 
Huh-7.5.  
The pattern of antibody binding observed on Jurkat-CD81 is repeated almost exactly for Raji-
CD81, with very similar RFC values and trends (Figure 3.9d). 2s139 is recognised more strongly 
on Raji cells than on Huh-7.5 cells, whereas 1s73 and 2s63 are recognised to a lesser degree.   
In contrast to the consistency observed between PHH and Huh-7.5 recognition, the 
relationship between the binding capacities of antibodies on the primary immune cells and on 
immune cell lines is not so consistent. As with PHH, the RFC values are much lower on the 
primary cells than the cell lines, with primary B cells having a particularly low level of binding.  
The majority of antibodies which bind Huh-7.5 to a high level also bind very strongly to primary 
T cells (Figure 3.9c), with the exception of mAbs 1s135 and 2s48, both of which bind to a lower 
degree in this cell type (Figure 3.9d). Conversely, mAbs 2s63, 2s141 and 2s139 bind more 
strongly on primary T cells than on Huh-7.5.  
The overall antibody binding levels in primary B cells are around a third of that seen in primary 
T cells, and are much lower and less varied than in the Raji cell line (Figure 3.9e). Whilst 2s24, 
1s73 and 2s155 are all appropriately placed following the Huh-7.5 ranking, 2s139 a member 
of the low binding group for Huh-7.5, would fit more appropriately into the high binding group 
on Raji. These findings suggest that CD81 has either low expression or an inaccessible 
conformation on B primary B cells, but that there are some regions around the epitopes 
recognised by 2s139 and 2s155 which are particularly accessible.  
In the absence of the proper optimisation of antibody binding on each cell type used, it is not 
possible to form any valid conclusions from the data presented here in terms of the availability 
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of the epitopes studied. The caveats of the methodology used are discussed below, but the 
results presented here provide a basis for further work examining the conformation of CD81 
between relevant cell types.  
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Figure 3.9: Epitope recognition of anti-CD81 monoclonal antibody panel on the surface of 
primary and immune cell types. Fold change in MFI from IgG for each antibody on CD81 
expressed on PHH (n=3) (a), Jurkat cells (n=3), (b) primary T cells (n=4), (c), Raji cells (n=3) (d) 
and primary B cells (n=4) (e). In all cases, staining was carried out live before fixing and 
analysis using flow cytometry. 
  
(a) 
(b) (c) 
(d) (e) 
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3.3  DISCUSSION 
The data presented here attempt to utilise a characterised panel of CD81 mAbs to elucidate 
differences in CD81-LEL epitope availability between cell types.  
Initial experiments looked at antibody binding patterns to the Huh-7.5 cell line in comparison 
to their binding to purified MBP-CD81-FL (Farquhar et al., in preparation, appendix). When the 
antibodies were incubated with Huh-7.5 cells, they displayed a wide range of binding 
capacities, However, this variation did not clearly map to the current epitope groupings of the 
mAbs (Farquhar et al., in preparation, table 3.1), as antibodies in groups I, V and VI exhibited 
no consistent pattern of binding capacities.  
One possible explanation for the variation in binding levels observed on Huh-7.5 cells is that 
there are differences in CD81-LEL epitope availability in this background which can be 
detected by the antibody panel. If so, the discrepancy observed between the antibody binding 
patterns on the MBP-CD81-FL and Huh-7.5 may be related to the effect of the membrane on 
protein conformation, as the binding studies carried out by Farquhar et al., to determine 
epitope groupings used a membrane-free system. In this case, these antibodies would 
represent a useful resource for determining the exposure of CD81-LEL epitopes in a cell 
membrane.  
However, to confirm this and to further explore these results, it would be necessary to carry 
out further optimisation and repeat the experiment. Of paramount importance would be to 
define the optimal concentration of the antibodies in an Huh-7.5 cell to enable a thorough and 
valid comparison of differences in binding between the two backgrounds studied. With the 
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current methodology it is not possible to rule out that the differences in binding levels seen 
are due to sub-optimal antibody concentrations. 
In brief, a full optimisation of antibody usage necessitates carrying out an antibody titration 
in relevant staining conditions. This involves a serial dilution of the antibody and the 
subsequent identification of the lowest concentration at which the maximal fluorescence 
intensity is achieved. Determining the optimal antibody concentration is necessary as too high 
a concentration of antibody can lead to non-specific binding which masks the true amount of 
target antigen in the target cell, whilst too low a concentration leads to the insufficient 
labelling of cells. Only once optimum staining conditions have been determined can any 
significant changes in binding then be attributed to alterations to the antibody binding site.  
 
To begin to understand how cell membrane background may influence the availability of 
CD81-LEL epitopes, live staining of the antibody panel was carried out on a variety of cell 
types in which CD81 is known to form cell type-specific interactions and which exhibit 
responses to CD81 engagement.  This was achieved using flow cytometry with the antibodies 
being used at identical concentrations. As previously discussed, it would be necessary to 
optimise staining conditions on all cell types in order to form any valid conclusions regarding 
the differences in antibody presentation of the CD81 LEL between the cell types tested.  
 
PHH, which are considered the ‘gold standard’ model for hepatocytes, were compared 
alongside the Huh-7.5 cell line. As a primary cell line which exhibits hepatic polarity and 
morphology (Lindenbach, Evans et al. 2005, Flint, von Hahn et al. 2006, Narbus, Israelow et 
al. 2011) the structure and constituents of the membrane of PHH are likely to be 
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considerably different to that of Huh-7.5. In a similar manner, primary immune cells and 
immune cell lines were tested, with primary T cell and B cells being compared alongside the 
cell lines Jurkat and Raji respectively.  All antibodies exhibited positive binding to the cell 
types tested. 
To attempt to model how CD81 expressed in a cell background differs from MBP-CD81-FL in 
a membrane-free system, the abilities of mAbs to bind to these cell types were compared to 
the previously reported binding affinities for the recombinant full length protein (Farquhar 
et al., in preparation. Appendix table 1). A summary of the outliers can be found in table 3.3.  
When this analysis was applied to Huh-7.5 cells the antibodies 1s337, 1s135 and 2s141 
which bind similar epitopes were found on both sides of the line of best fit, as were 2s20, 
2s63, 2s131 and 2s24, which also bind identical epitopes. The residues recognised by 2s139, 
which showed an unusually low RFC on Huh-7.5 cells, are very similar to those of other 
group I antibodies, but it additionally recognises K124 in the A helix. However, this pattern is 
similar to that recognised by the antibody 2s48, which showed no unusual binding.  With 
PHH, outliers from main the relationship trend demonstrated no obvious epitope specificity: 
the outliers 2s20, 2s24 and 2s131, which all belong to epitope group I, recognise an identical 
group of epitopes in the BC loop and C and E helices.  
As previously observed with the hepatic cells, there is no striking epitope specificity between 
the antibodies which bind either above or below the line of association between antibody 
binding capacity to Jurkat cells and binding efficiency to MBP-CD81-FL. Antibodies with 
identical recognition patterns were found on both sides of the confidence interval, with the 
only exception being 2s139. This antibody fell above the CI and additionally recognises the 
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residue K124 in the A helix. The antibody 2s48 has an identical recognition pattern to 2s139, 
and does not fall outside of the Cl. The trends observed with primary T cells were similar to 
those observed with PHH, as all outlying antibodies were in group I, and recognise identical 
epitopes C157, T166 and C190 in the BC loop, A, C and E helices.  
When the binding affinities of the antibodies to the Raji cell line were compared to their 
binding efficiency to MBP-CD81-FL, there was again no apparent relationship between the 
epitopes recognised by the antibodies with unusual recognition profiles, and in these cells 
2s139 binds above the line of best fit. The results seen with primary B cells were identical to 
those described for the Raji cell line, as the outliers recognise the same epitopes.  
These analyses may suggest a significant variation between the availability of the epitopes 
between the full-length CD81 protein in isolation and various membranes. If so, the 
locations of the epitopes discussed above suggest that the changes occur predominantly in 
the BC loop and A, C and E helices.  However, in the absence of proper optimisation the 
causes of this difference cannot be with any certainty attributed to the presentation of the 
target epitopes. Instead, it is possible that the differences in binding intensities seen are due 
to the use of sub-optimal concentrations of the antibodies on the cell types studied.   
To investigate whether these binding patterns could be affected by the dimerisation and TM 
domains of the protein, the same analysis was carried out in comparison to a second purified 
protein, MBP-CD81-LEL which does not contain these regions. 
In general, there are very few differences in the outliers identified by comparison to MBP-
CD81-LEL instead of MBP-CD81-FL. This trend is particularly clear for the immune cell lines 
and primary immune cells, where only one antibody differed in our comparisons of MBP-
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CD81-FL and MBP-CD81-LEL. In these cases, these antibodies have identical recognition 
patterns to those identified in the previous analysis (Table 3.3).  
This recapitulation seen for immune cells was not as complete for PHH and MBP-CD81-LEL. 
For MBP-CD81-FL, 2s20 was an outlier above the line of best fit with 2s24 and 2s131 outliers 
below (Figure 6b), however for MBP-CD81-LEL, 2s155 was the only outlier above the line, 
whilst 2s131 and 2s141 fell below the line.  
The epitopes recognised by 2s155 differ from those targeted by 2s20 by additionally 
recognising V123, L162 and F150 in the A, 3-10 and B helices. However, these residues are 
also recognised by 2s141, which falls below the line. Similarly, the outlier 2s131 binds 
identical epitopes to a number of other antibodies which did not exhibit exceptional binding.  
Interestingly, the only epitope group which routinely binds inside the CI is epitope group IV, 
whose sole member is antibody 1s262. This antibody recognises residues V123, T149, L162, 
T167, V146, F150, C157, T166 and C190. The consistent binding of this antibody may reflect 
the wide range of residues recognised, whereby unavailability of a few residues may be 
compensated for by the presence of others.   
These data may demonstrate that the availability of epitopes in the CD81 –LEL differ from 
one another and from recombinant CD81 proteins in a very similar manner to the variations 
seen with CD81-FL. However, these changes cannot be elucidated using this current 
methodology. Optimisation of antibody binding on all cell types studied here would be 
necessary in order to carry out a valid comparison of antibody binding between the cell 
types.    
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 As these data may suggest considerable differences in epitope availability between cell 
types, we were interested to understand whether CD81 in different membrane backgrounds 
could be discriminated by the antibody panel. To examine this, the RFC of each antibody on 
each cell type was plotted and the antibodies organised into the low, medium, and high 
binding groups established using Huh-7.5 to identify outliers from the trend.  
Comparison of antibody RFCs on Huh-7.5 and PHH revealed a strong similarity between 
binding levels on the two cell types, although the levels of CD81 expression are much lower 
and more varied on PHH, demonstrating what has been previously observed in human liver 
sections (Brimacombe et al., 2014), and it would be interesting to confirm this with western 
blot. The only anomaly is 2s139, which has a comparatively higher RFC on PHH than on Huh-
7.5.  
Both Raji and Jurkat cells display around a 15-fold higher level of CD81 expression than Huh-
7.5 and there are number of differences in binding patterns: 2s63 and 1s73 have lower than 
expected RFC on the immune cell lines, whereas 2s139 exhibits a higher RFC. Aside from 
C157, T166 and C190, 2s63 and 1s73 do not display any similarities in residue binding 
patterns, and all antibodies recognise these epitopes.  2s139 binds to K124 in the A helix in 
addition to C157, T166 and C190. However, this binding pattern is similar to that of 2s48, 
which did not exhibit the same tendencies. 
Examination of antibody binding on primary immune cells demonstrated that both 2s141 
and 2s63 exhibit a higher RFC on T cells and 2s139 and 2s48 show very high binding to both 
primary T and B cells. 2s139 and 2s48 bind identical epitopes and they both bind C157, T166 
and C190 in common with 2s63 and 2s141. 
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If these findings were confirmed following proper optimisation of antibody staining, it would 
be possible to hypothesise that some CD81-LEL epitopes are more available in certain 
backgrounds than others. However, due to the often vast differences in binding affinities 
between antibodies with identical recognition patterns it would not be possible to be more 
specific about what these may be. The data would therefore suggest a significant role for 
other epitopes or factors in determining their binding, and would be an interesting area for 
further characterisation of these antibodies. 
One factor which may cause differences in epitope availability between cell types is the 
formation of distinct associations by CD81 which lead to changes in protein conformation or 
epitope masking. To confirm this, it would be interesting to look at the direct interactions 
formed by CD81 in these cell types using co-immunoprecipation and FRET. As the CD81-LEL 
sequence has been demonstrated to be well conserved (Houldsworth, Metzner et al. 2014) 
any changes are unlikely to be related to changes in protein sequence between the cell 
types.  
The data presented here form a basis for further and more thorough investigation into the 
possibility that the conformation of CD81 is dependent on cell type, as has been shown for 
other tetraspanins (Sincock, Fitter et al. 1999; Geary, Cambareri et al. 2001). However, 
without proper optimisation of antibody staining protocols, it is not possible to rule out that 
any trends highlighted in this work are caused or influenced by inappropriate antibody 
dilutions and procedure. The importance of choosing an optimal antibody concentration has 
already been described, and for future reference, further caveats of the methodology used 
here are briefly discussed below. 
111 
 
This study used flow cytometry to measure antibody binding, a technique which gives an 
estimate of binding on a large number of cells at a point in time. However, the binding of 
antibodies to ligands is a dynamic process, and therefore using this method of assessing 
antibody binding may not be the most informative. Instead, a more appropriate method may 
be to look at the on/off rate of association with the ligand under flow, for example by using 
surface plasmon resonance (SPR). By looking at the rates of antibody association and 
disassociation of the antibodies with target cells under flow conditions, a more accurate 
understanding of the interaction between the antibodies and the cells used could be gained.  
The data presented here used live cell staining in an attempt to preserve the conformation 
of CD81 proteins and avoid the protein cross-linking which can occur during fixed cell 
staining. Aside from the effects of cross-linking, fixation of cells can remove lipids from the 
membrane. As lipids are a vital membrane component and are could integral to membrane 
domains, their removal may significantly alter the interactions within or stoichiometry of 
areas of the membrane in which CD81 is anchored.  
However, live cell staining also carries a specific set of caveats and it could be argued that it 
would be more accurate to carry out the staining at a lower temperature than at the 37˚C 
described here, or following fixation. Both approaches would prevent activation of cellular 
signalling pathways during the live staining process which may affect the interactions formed 
by CD81, and therefore its presentation. However, it has been shown that the stability of the 
antibody-paratope interaction varies with the temperature at which they are incubated 
(Hughes-Jones 1975). Therefore, in order to examine the usefulness of these antibodies in 
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vivo, staining at 37˚C may be most useful. However, a combination of both staining 
techniques would likely be most informative.  
Similarly, it is possible that using bivalent antibodies such as those described here would 
cause the clustering of CD81 molecules on the surface of the cell during live cell staining. 
This could have a number of effects. Firstly, the ligation of CD81 using antibodies has been 
shown to have multiple effects (VanCompernolle, Levy et al. 2001, Tseng and Klimpel 2002, 
Crotta, Ronconi et al. 2006, Brazzoli, Bianchi et al. 2008, Coffey, Rajapaksa et al. 2009, Lin, 
Rossi et al. 2011), and secondly and most importantly for this study, the clustering of CD81 
molecules may cause the protein to form unusual or physiologically unlikely interactions. 
This could result in changes in the CD81-LEL conformation or steric interference, both of 
which would affect the ability of antibodies to bind to their target epitopes.  This aspect of 
the antibody action would also be a significant concern were these antibodies to be used 
therapeutically.  
To conclude, using the methods and antibodies described in this chapter it is not possible to 
elucidate any differences in CD81 conformation between cell types due to the wide range of 
distinct factors which can affect antibody binding. To remedy this, it would be necessary to 
carry out antibody titrations to determine the correct amount of antibody to use and to give 
serious consideration to the use of live or fixed cell staining. In addition to then repeating 
these experiments, it would be useful to additionally look at antibody binding under flow to 
determine antibody binding efficiencies to these cell types.  
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Table 3.3: Trends in epitope binding of antibodies which lie outside of the CI.  Target 
epitopes epitope groupings of antibodies which lie above or below the confidence interval of 
the association of binding capacity and binding affinities to MBP-CD81-FL and MBP-CD81 –
LEL.   
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4 EFFECT OF HEPATIC POLARITY ON CD81 DIFFUSION 
4.1 INTRODUCTION 
 
Cells which exhibit simple epithelial polarity are found at barrier sites throughout the body, 
for example in the gut and airways. In such cells, the apical surface is located above the tight 
junctions and facing a lumen or outer surface. The remaining membrane is basolateral 
surface and is in contact with other cells or the basal lamina (Figure 4.1a). Hepatic polarity is 
distinct from this simple polarity in a number of ways (Figure 4.1b). Hepatocytes are 
multipolar and may have several apical and basolateral membranes that are separated by 
tight junctions. The apical membranes of adjacent hepatic cells form the walls of a lumen, 
the bile canaliculus (BC) which forms a continuous branched network into which bile is 
secreted and transported through the liver. The development of this complex polarity is 
essential for the correct functionality of the hepatocyte, and requires the formation of 
specific membrane domains, cytoskeletal and ER networks to allow for the polar trafficking 
of proteins, drugs and biliary salts (reviewed in (Decaens, Durand et al. 2008).  
The in vitro cell culture model which most accurately recapitulates in vivo hepatic polarity is 
the HepG2 hepatoma cell line, which can polarise over time in culture and forms pseudo BC-
like structures (van, Zegers et al. 1997, van and Hoekstra 2000, Mee, Grove et al. 2008, 
Ohgaki, Matsushita et al. 2010). Furthermore, the HCV receptors show comparable patterns 
of localization in polarised HepG2s with that seen in healthy liver tissue (Mee, Farquhar et al. 
2010). Specifically, both CD81 and SR-BI are located at apical and basolateral membranes, 
claudin-1 predominantly at the TJ with low intensity staining at the basolateral surface, and 
occludin exclusively at the TJ. Studies using this cell line have shown that polarisation  
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Figure 4.1: A comparison of epithelial and hepatic polarity. In polarised epithelial cells a 
single apical and basal membrane appose each other and are separated by tight junctions 
(TJ) and adherens junctions (AJ), with the apical surface facing the lumen and the basal 
surface facing the tissue (a). Polarised hepatocytes have several apical membranes which 
form the walls of the bile canaliculus, and these are separated by TJs and AJs from the basal 
membranes which face the sinusoids (b). 
  
(a) (b) 
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restricts HCV entry (Mee, Harris et al. 2009, Mee, Farquhar et al. 2010), highlighting the 
importance of studying receptor trafficking in a polarised cell type. 
CD81 diffusion has been relatively well studied, and a number of factors affecting this have 
been elucidated. Using single particle tracking, it has been shown that CD81 confinement in 
polarised HepG2s overlaps with TEMs, (Harris, Clerte et al. 2013, Potel, Rassam et al. 2013), 
demonstrating that in this cell type the immobile fraction of the protein is correlated with 
CD81 localisation to these areas. 
 
 Recent work has found that the TEM-specific interactions between CD81 and interacting 
proteins play a central role in HCV infection (Zona, Lupberger et al. 2013). Furthermore, 
CD81 and its partner proteins can interact with the actin cytoskeleton (Sala-Valdes, Ursa et 
al. 2006, Coffey, Rajapaksa et al. 2009, Treanor, Depoil et al. 2011, Mattila, Feest et al. 2013) 
and this association has been shown to confine CD81 diffusion (Harris, Clerte et al. 2013) as 
reported for other membrane proteins such as CD9 (Kusumi, Sako et al. 1993, Sako, 
Nagafuchi et al. 1998, Treanor, Depoil et al. 2011). Additionally, recent work has shown that 
the formation of associations between CD81 and partner proteins claudin-1 and EWI-2wint 
affects lateral protein diffusion speed (Harris, Davis et al. 2010, Potel, Rassam et al. 2013), 
consistent with previous data demonstrating that the diffusion coefficient of a protein is 
dependent on molecular weight (Saffman and Delbruck 1975, Gambin, Lopez-Esparza et al. 
2006). 
 
FRAP is a powerful live imaging technique used to study the diffusion dynamics of 
fluorescent tagged proteins within the cell membrane. Briefly, one or more regions are 
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selected on the surface of a cell expressing a fluorescently tagged protein (Figure 4.2a) and 
are bleached using an appropriate laser until the fluorescence intensity is reduced to around 
40% (Figure 4.2b). Bleaching to this level prevents phototoxicity of the cell. The fluorescence 
intensity of the region is monitored as photobleached proteins move out of the bleached 
regions and are replaced by non-bleached proteins (Figure 4.2c).   
 
Figure 4.2: FRAP methodology: To carry out FRAP, an area of the membrane is selected (a) 
and bleached (b), and the fluorescence intensity of the selected region monitored over time 
whilst recovery is taking place (c).  
 
  
 
Select Bleach Recovery (a) (b) (c) 
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Figure 4.3: Interpreting the FRAP curve. Following bleaching, the fluorescence intensity 
recovers over time (red line) and can be used to interpret the mobile and immobile fraction of 
the protein under study along with the T1/2. 
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The fluorescence intensity of the region can be plotted over time (Figure 4.3). A typical graph 
involves an ‘initial’ pre-bleach recording of the fluorescence intensity of the region, and this 
is normalised to become the 100% fluorescence intensity. The region is then bleached and 
the fluorescence intensity recorded until it stabilizes. The mobile fraction can then be found 
by subtracting the initial fluorescence intensity from the end point value (Figure 4.3).  
Analysis of the recovery curve is essential to correctly interpreting the diffusion patterns of 
the protein under study. A single exponential curve (equation 1) shows that the protein is 
diffusing by one mode only, whereas a double exponential curve suggests multiple modes of 
diffusion. Additionally, from the equation of the curve the rate of protein diffusion (diffusion 
coefficient, equation 3) and the time taken for half the fluorescence intensity to recover (T½, 
equation 2) can be calculated by solving the appropriate single or double exponential 
formula for K.  
𝑌 = 𝑌𝑚𝑎𝑥(1 − 𝑒
𝐾𝑥) 
Equation 1: Simple exponential 
𝑇1
2⁄
=
0.69
𝑘
 
Equation 2 
0.224𝑟2
𝑇1
2⁄
 
Equation 3: Diffusion Coefficient 
The T½ value is essential for determining the mode of protein diffusion. Proteins can diffuse 
into a bleached region by one or both of two methods: lateral diffusion or exchange. In 
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lateral diffusion, proteins diffuse into the bleached region from within the plane of the 
membrane, and in this case the T½ of a small and large bleached region are not equal (Figure 
4.4a). In contrast, exchange diffusion occurs by proteins trafficking to the membrane from 
within the cell, in which case the T½ of small and large regions are the same (Figure 4.4b). 
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Figure 4.4: Modes of protein diffusion. Lateral diffusion occurs from only within the 
plane of the membrane, where the T1/2 differs between small and large bleach spots 
(grey circles) (a). In exchange, the protein diffuses from intracellular compartments 
and the T1/2 is the same for small and large bleached regions (b). 
  
Lateral  
T1/2 small≠T1/2 large 
(a) 
Exchange 
T1/2 small≠T1/2 large 
(b) 
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As with many diseases, HCV exists in an inflamed setting with activated immune cells and 
the associated release of cytokines (Zampino, Marrone et al. 2013). Inflammation has been 
implicated in the initiation or development of a number of diseases associated with barrier 
dysfunction, including irritable bowel disorder (IBD) and infection by other viruses such as 
West Nile Virus (WNV). In IBD, which encompasses ulcerative colitis and Crohn’s disease, the 
release of TNF-α causes a redistribution of tight and adherens junction proteins to the 
basolateral surface of intestinal epithelial cells, and also causes the shedding of these cells 
via p53 and caspase-3 mediated apoptosis (Marchiando, Shen et al. 2011, Goretsky, Dirisina 
et al. 2012). The loss of barrier function is compounded by an increase in myosin light chain 
kinase (MLCK) leading to a contraction of the perijunctional actin and myosin ring 
(Cunningham and Turner 2012). In the case of WNV infection, the detection of the dsRNA 
WNV intermediate by peripheral lymphoid cells leads to the release of TNF-α. This activates 
the canonical NF-κB signalling pathway in polarised cells, followed by MLCK activation 
leading to a reorganisation of the perijunctional F – actin and TJ proteins (Shen L 2006, Lim, 
Koraka et al. 2011). As a result, the target blood brain barrier cells are depolarised and the 
virus is able to cross the barrier without infecting the barrier cells (Wang, Town et al. 2004).  
The inflammatory environment present during chronic HCV infection includes interleukin  
(IL)-1β, IL-6 and tumour necrosis factor α (TNFα) (Liaskou, Wilson et al. 2012). These 
cytokines promote entry of HCV into polarised hepatoma cells, and TNF-α is the central 
cytokine involved in this process (Fletcher, Sutaria et al. 2014) and has been shown to 
reduce tight junction integrity (Mashukova, Wald et al. 2011).   
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It is well established that hepatocyte polarity limits HCV entry, with polarised cells 
supporting lower levels of entry and infection, and that this occurs concomitant with slower 
receptor diffusion (Mee, Grove et al. 2008, Mee, Harris et al. 2009, Mee, Farquhar et al. 
2010, Harris, Clerte et al. 2013). Therefore, in order to establish whether receptor diffusion 
defines HCV entry rate, the effect of polarisation and the processes that regulate it in the 
liver on CD81 diffusion were studied in a relevant, polarised model. 
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4.2 RESULTS 
 
4.2.1 Validation of FRAP methodology 
 
Inherent in studying the diffusion of proteins over a large area of membrane is a variance in 
the data, and thus it is necessary to define the sample size required to accurately represent 
the population. To find the optimal sample size for measuring CD81 diffusion in HepG2 cells 
we employed MonteCarlo bootstrap analysis. Bootstrapping is a method of estimating the 
precision of statistics, in this case the mean CD81 diffusion coefficient or mobile fraction, of 
a sample by repeatedly selecting with replacement from a set of data points.  Sample sizes 
from 4 to 60 cells were analysed to measure mean CD81 diffusion coefficient and mobile 
fraction (Figure 4.5 a,b), and the means of each analysis compared to that of the total 
sample size (60 cells). 10 spots were bleached per cell as this is the highest number possible 
to bleach in one experiment without compromising the speed of data collection. This 
analysis showed 10 cells to be sufficient to model the mean of 60 cells for both diffusion 
coefficient and mobile fraction (Figure 4.5a, b).  
Once the necessary number of cells had been established, the same technique was applied 
to define the total number of bleach spots needed in a triplicate sample size of 10 cells. 
Analysis showed that a minimum of 55 bleached regions across triplicate experiments 
studying 10 cells each was necessary to accurately represent the population in terms of both 
diffusion coefficient and mobile fraction (Figure 4.5 c, d).  
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Figure 4.5: Coefficient of variation analysis of fluorescently tagged proteins in polarised 
HepG2.HepG2 cells expressing AcGFP.CD81 were allowed to polarise for 5 days. 10 bleached 
spots per cell were subjected to FRAP analysis to determine the diffusion coefficient and 
mobile fraction of CD81. MonteCarlo bootstrap analysis was carried out on the specified 
number of variables to determine the number of cells (a and b) and bleached spots (c and d) 
necessary to accurately represent the population in terms of both diffusion coefficient (a and 
c) and mobile fraction (b and d).  Cells were imaged using a 100x Plan Achromat 1.4 NA oil 
immersion objective on a Zeiss LSM 780 confocal microscope with a GaAsP spectral detector, 
and GraphPad prism used to carry out analysis.  
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The recovery of fluorescence intensity relies on fluorescent proteins moving into bleached 
regions via lateral or exchange diffusion (Figure 4.4), and it is important to determine which 
is occurring to ensure that results are properly interpreted. The first step is to identify the 
shape of the FRAP recovery curve. A single exponential recovery curve represents a single 
mode of diffusion, whereas a double exponential represents multiple modes of diffusion. 
The protocol used for FRAP analysis includes a requirement of the software to establish 
whether the data best fits a single or double exponential curve for every bleached region. In 
all cases the best fit was a single exponential and a representative curve is shown (Figure 
4.6a). To establish which mode of diffusion a protein is undergoing, the T½ is plotted against 
the area of the corresponding bleached region. In HepG2 cells the T½ increases with the area 
of the bleached region (Figure 4.6b), and thus CD81 is diffusing laterally within the plane of 
the membrane with minimal contribution from exchange diffusion. Therefore, all 
interpretations relating to changes in protein diffusion will explore factors affecting this 
mode of diffusion only. 
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Figure 4.6: Determination of protein diffusion mode.  HepG2 cells expressing Ac-GFP.CD81 
were used to carry out FRAP. Representative AcGFP-CD81recovery curve displaying line of 
best fit (a). Plotting the T½ against area of the corresponding bleached region was used to 
assess the mode of protein diffusion (b).  
 
 
(b) 
(a)
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4.2.2 CD81 diffusion is defined by cellular location 
 
Data collected during my Masters project showed that the diffusion coefficient and mobile 
fraction of HCV receptors SR-B1, claudin-1 and occludin varied depending upon their 
location within the membrane. Diffusion was studied specifically at the basolateral plasma 
membrane (PM) in contact with the growth substrate, filopodia in contact with the growth 
media and cell-cell contacts.  These regions were chosen because they represent areas of 
the membrane with important roles in the infection and transmission of HCV. The 
basolateral membrane and filopodia regions represent the hepatocellular membrane in 
contact with Space of Disse, the first likely point of contact with HCV. Additionally, cell-cell 
contacts represent the junctions between hepatocytes that have been hypothesized to 
support HCV transmission (Timpe, Stamataki et al. 2008, Brimacombe, Grove et al. 2011).  
In all cases, filopodia were defined as motile protrusions on the plasma membrane of a few 
microns in length that adhered to the glass surface and attached to the cell at one end only. 
As they are visible by confocal microscopy they are distinct from microvilli, but are smaller in 
length then nanotubes, which can extend to over 100 μm (Davis and Sowinski 2008, 
Sowinski, Jolly et al. 2008). Additionally, nanotubes form a connection between two cells, 
further differentiating them from filopodia.  
In order to establish whether CD81 diffusion is affected by membrane structure, the 
diffusion coefficient and mobile fraction of CD81 at the basolateral plasma membrane (PM), 
filopodia and cell junctions in polarized HepG2 cells was studied.  The diffusion coefficients 
of CD81 at these locations all differed significantly from each other, with CD81 diffusing at a 
rate of 0.058 µm2/s at the plasma membrane, 0.009 µm2/s at the filopodia, and 0.003 µm2/s 
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at areas of cell-cell contact (Figure 4.7a, Table 4.1). Similarly, the mobile fraction varied 
between locations, but was similar between regions in the PM and filopodia (56% and 58% 
respectively) whilst it was more confined at cell-cell junctions (33%) (Figure 4.7b, Table 4.1). 
Therefore, CD81 diffuses more slowly at structures such as the filopodia and cell-cell 
contacts than at the basolateral plasma membrane, with an increased confinement at cell 
contacts. 
To date there has been no evidence for filopodia playing a role in HCV entry. Therefore, 
given the significant differences in diffusion parameters between the structures examined, it 
was decided to only study plasma membrane-located CD81 as it best represents the 
basolateral membrane of cells which HCV will first encounter on entering the liver.  
Cellular 
location 
Diffusion  
Coefficient 
(μm2/s) 
IQ range 
(μm2/s) 
Mobile 
Fraction 
(%) 
IQ range 
(pp) 
Sample 
size 
PM 0.058 0.113 56 40 55 
Filopodia 0.009 0.044 59 41 55 
Cell contact 0.003 0.032 33 34 55 
 
Table 4.1: Quantification of figure 4.7. The diffusion coefficient and mobile fraction with 
interquartile (IQ) range and sample size are shown for each cellular location. The IQ range of 
the mobile fraction is given in percentage points (PP).  
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Figure 4.7: Effect of cellular location on CD81 diffusion. HepG2 cells expressing AcGFP-CD81 
were allowed to polarise for 5 days and the diffusion coefficient (a) and mobile fraction (b) 
found at the specific cellular structures stated. Cells were imaged using a 100x Plan 
Achromat 1.4 NA oil immersion objective on a Zeiss LSM 780 confocal microscope with a 
GaAsP spectral detector, and groups were compared by Mann-Whitney U test (GraphPad 
Prism 6.0). Each spot represents one bleached region. *P<0.05, **P<0.001, ***P<0.0001.  
  
(a) (b) 
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4.2.3 Effect of polarisation on CD81 diffusion 
 
Development of hepatic polarity is a key characteristic of hepatocytes in vivo and we were 
keen to understand the extent to which this can be replicated in vitro. Cell polarity can be 
quantified by estimating the number of BCs per hundred nuclei expressing the apical marker 
MRP2 (polarity index). HepG2 cells were plated for 1, 3, or 5 days (Figure 4.8a) and their 
polarity index measured. Tight junction integrity is independent of cellular polarity (Mee, 
Harris et al. 2009) and can be measured by following BC retention of the fluorescent dye 5-
chloromethylfluorescein diacetate (CMFDA). Briefly, CMFDA is added to live HepG2 cells for 
15 minutes to allow trafficking to the apical membrane. At this point the function of the TJs 
is calculated by enumerating the percentage of BC structures visible by phase microscopy 
that retain CMFDA. HepG2 polarity increased from 12% on day 1 to 33% on day 3 and 53% 
by day 5 (Figure 4.8a). This was supported by the CMFDA assay showing that 42% of BC-
expressing cells retained CMFDA on day 1, increasing to 78% by day 3 and 81% by day 5 
(Figure 4.8b). 
It has previously been shown that hepatoma polarity decreases the permissivity of cells to 
HCV infection (Mee, Grove et al. 2008, Mee, Harris et al. 2009), and to confirm this HepG2  
cells at 1 and 5 days post plating were challenged with HCVpp and incubated for 72 hrs. 
Quantification of the infection showed that while cells that had been plated for one day 
showed infection levels of 5x105, cells which had been plated for 5 days prior to infection 
showed a much lower infection level of 1.1x105 (Figure 4.8c). These data show that 5 days of 
polarisation are necessary for the majority of cells within a sample to polarise and form 
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integral tight junctions. Additionally, these data confirm hepatic polarity reduces the 
susceptibility of HepG2 cells to HCV infection.  
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Figure 4.8: Effect of polarisation on tight junctions and HCVpp infection. HepG2.CD81 cells 
were plated and allowed to polarise for 1, 3, and 5 days. HepG2 polarity was assessed by 
measuring the percentage of bile canaliculi staining for MRP2 (a). Tight junction integrity 
was assessed by quantifying the number of bile canaliculi per 100 cells which retain CMFDA 
(b). HepG2.CD81 cells at either 1 or 5 days post plating were challenged with HCVpp strain 
H77 and infection read at 72 hrs (c). Groups were compared by T-test (GraphPad Prism 
6.0)*P<0.05, **P<0.001. 
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Previous work using live imaging has demonstrated that an increased protein diffusion or 
mobility is linked to a higher level of HCV entry (Harris, Davis et al. 2010, Fletcher, Sutaria et 
al. 2014). Therefore, the diffusion coefficients (Figure 4.9 a, c) and mobile fractions (Figure 
4.9 b, d) of AcGFP-CD81 and AcGFP-claudin-1 on polarised (5 days post plating) and non-
polarised (1 day post plating) HepG2 cells were studied. In the case of CD81, there was no 
change in mobile fraction with polarisation, with 68% of CD81 mobile in polarised cells 
compared to 67% in non-polarised cells (Figure 4. 9b, Table 4.2). In contrast, the mobile 
fraction of claudin-1 decreased from 68% to 61% following polarisation. The diffusion 
coefficient of both proteins was higher in non-polarised cells compared to polarised cells. 
AcGFP-CD81 diffusion coefficient was 0.057 μm2/s in polarised cells compared to 0.094 
μm2/s in non-polarised cells (Figure 4.9a), and in those expressing AcGFP-claudin-1 the 
diffusion speed increased from 0.075 μm2/s in polarised cells to 0.117 μm2/s in non-
polarised cells (Figure 4.9c, Table 4.2). Therefore, the diffusion speeds of both CD81 and 
claudin-1 are lower in polarised cells than in non-polarised cells. 
  
135 
 
 
Protein Polarity 
Diffusion 
Coefficient  
(μm2/s) 
IQ range 
(μm2/s) 
Mobile 
Fraction 
(%) 
IQ range 
(pp) 
Sample 
size 
CD81 
Pol 0.057 0.075 68 23 73 
Non-Pol 0.094 0.109 68 14 73 
CLDN-1 
Pol 0.075 0.201 61 26 73 
Non-Pol 0.117 0.271 68 22 73 
 
Table 4.2: Quantification of figure 4.8. The diffusion coefficient and mobile fraction with 
interquartile (IQ) range and sample size are shown for each cell type. The IQ range of the 
mobile fraction is given in percentage points (PP). 
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Figure 4.9: Effect of hepatoma polarity on protein diffusion. HepG2 cells expressing either 
AcGFP-CD81 (a and b) or ACGP-claudin-1 (c and d) were allowed to polarise for either 5 days 
(Pol, polarised) or 1 day (Non-Pol, non-polarised) and the diffusion coefficient (a and c) and 
mobile fraction (b and d) found for each. Cells were imaged using a 100x Plan Achromat 1.4 
NA oil immersion objective on a Zeiss LSM 780 confocal microscope with a GaAsP spectral 
detector, groups were compared by Mann-Whitney U test (GraphPad Prism 6.0). Each spot 
represents one bleached region. *P<0.05, **P<0.001, ***P<0.0001.  
  
(a) (b) 
(c) (d) 
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4.2.4 CD81 diffusion is affected by TNF-α 
 
During chronic HCV infection the liver becomes inflamed, with an infiltration of immune cells 
associated with a release of inflammatory cytokines (Zampino, Marrone et al. 2013) 
including TNF-α (Fletcher, Sutaria et al. 2014). Work from the McKeating group has shown 
that TNFα causes the relocation of occludin from apical junctions to the basolateral 
membrane and increased permissivity to support HCV entry (Figure 4.10a, carried out by 
Nicola Fletcher). To ascertain whether the increased HCV entry could be linked to a loss of 
polarity, the effect of TNFα treatment on hepatic polarity was investigated. Following 
treatment of polarised HepG2.AcGFP-CD81 cells with TNF- α, the polarity index decreased 
from 50% to 19% (Figure 4.10b).  In addition, TNFα reduced the percentage of CMFDA 
positive bile canaliculi to around half the pre-treated number from 79% to 41% (Figure 
4.10c). As it has previously been shown that HepG2 polarisation reduces CD81 diffusion 
(Figure 4.9), we studied the effect of TNFα on CD81 diffusion. Polarized HepG2.AcGFP-CD81 
were treated with TNFα for one hour and CD81 diffusion monitored by FRAP. An increase in 
the diffusion coefficient of CD81 was observed from 0.135 µm2/s in the untreated sample to 
0.198 µm2/s following TNFα treatment (Figure 4.11a, table 4.3), and the mobile fraction 
increased from 81% to 85% following treatment (Figure 4.11b, table 4.3).  These results 
show that TNFα depolarizes HepG2 cells and increases CD81 diffusion. In addition, TNF-α has 
the additive effect of increasing CD81 mobile fraction, suggestive of a relocation of the 
protein from areas of confinement. 
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Figure 4.10: Effect of cytokine treatment on tight junction function and HCVpp infection.  
HepG2.CD81 cells were plated and allowed to polarise for 5 days. HepG2.CD81 cells were left 
untreated or pre-treated with 10 ng/mL TNF- α for 1 hour before challenge with H77-HCVpp 
and the infection read at 72 hrs (a). Polarity was assessed by staining for MRP2 in HepG2 
cells treated with TNF-α (10ng/mL) for 1 hour. Tight junction functionality was assessed by 
quantifying the frequency of bile canaliculi retaining CMFDA (4=, 6=-diamidino-2-
phenylindole) (c). Groups were compared by Mann-Whitney U test (GraphPad Prism 
6.0)*P<0.05, **P<0.001, ***P<0.0001. 
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Figure 4.11: Effect of TNFa cytokine on protein diffusion. HepG2 cells expressing AcGFP-
CD81 were allowed to polarise for 5 days and treated with TNF-α (100ng/mL) or a control for 
1hr before imaging and the diffusion coefficient (a) and mobile fraction (b) found. Cells were 
imaged using a 100x Plan Achromat 1.4 NA oil immersion objective on a Zeiss LSM 780 
confocal microscope with a GaAsP spectral detector, and groups were compared by Mann-
Whitney U test (GraphPad Prism 6.0). Each spot represents one bleached region. *P<0.05.  
  
(a) (b) 
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Treatment 
Diffusion 
Coefficient  
(μm2/s) 
IQ range 
(μm2/s) 
Mobile 
Fraction 
(%) 
IQ range 
(pp) 
Sample size 
Untreated 0.135 0.233 81 9 58 
TNFα 0.198 0.385 85 15 58 
 
Table 4.3: Quantification of figure 4.9. The diffusion coefficient and mobile fraction with 
interquartile (IQ) range and sample size are shown for each treatment type. The IQ range of 
the mobile fraction is given in percentage points (PP). 
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4.2.5 Effect of actin organisation on CD81 diffusion 
 
The actin cytoskeleton is a key determinant of hepatocyte polarity (Tsukada and Phillips 
1993) and links to CD81 via ERM proteins (Sala-Valdes, Ursa et al. 2006). To determine 
whether CD81 lateral diffusion is regulated mediated by its linkage to the actin cytoskeleton, 
an inhibitor of actin polymerisation (cytochalasin D, Cyt D) and an inhibitor of actin assembly 
(latrunculin B, Lat B) were added to polarised HepG2 cells expressing AcGFP-CD81. Phalloidin 
staining of the actin cytoskeleton shows the effect of these agents on the cells (Figure 4.12). 
In the untreated cells, a BC – like structure is evident with strong cortical actin filaments, and 
CD81 localisation at the basolateral and apical cell membrane as previously described (Mee, 
Grove et al. 2008). Additionally, actin-dense filopodia are seen at the membrane. Following 
addition of cytochalasin D (Cyt D), the bile canaliculus is misshapen and appears to lack a 
strong actin structure. Furthermore, there appears to be some membrane deformation and 
fewer filopodia, although CD81 localisation is not noticeably different from untreated cells. 
In contrast, following addition of latrunculin B there is no obvious ordered actin structure at 
all, with the actin forming an intracellular ‘cloud’. There is no evidence of a bile canaliculus 
or filopodia, and CD81 shows relocation to a more diffuse staining pattern.  
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Figure 4.12: The level of actin organisation affects CD81 distribution.  Confocal images of 
polarised (day 5) HepG2. AcGFP-CD81 cells treated with cytochalasin D (2.5μM) and 
latrunculin B (1 μM) for 1 hr and stained with 633-phalloidin (red). 16 bit images were taken 
with optimal pixel resolution using a 100x Plan Achromat 1.4 NA oil immersion objective on a 
Zeiss 780 confocal microscope. Representative maximum projections were constructed from 
Z sections.  
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The observed changes in tight junction morphology are supported by polarity and tight 
junction assays. Both compounds reduced the polarity index, with cytochalasin D having only 
a subtle effect and latrunculin B reducing the polarity index from 50% to 25% (Figure 4.13a). 
In contrast, cytochalasin D reduced the tight junction integrity from 82% to 62% but 
latrunculin B had the largest effect, reducing the integrity to 35% (Figure 4.13b). Having 
observed the effect of cytoskeletal disruption on HepG2 polarity and CD81 location, we 
investigated the dependency of CD81 diffusion on actin cytoskeleton integrity.  
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Figure 4.13: Effect of actin inhibitors on tight junction function. HepG2 polarity was 
assessed by staining for MRP2 in cells which were untreated or treated with cytochalasin D 
(Cyt D, 2.5 μM) or latrunculin B (Lat B, 1 μM) for 1 hour (a). Tight junction functionality was 
assessed by quantifying the frequency of bile canaliculi per 100 able to retain CMFDA (b). 
Groups were compared by T-test (GraphPad Prism 6.0)*P<0.05, **P<0.001, ***P<0.0001. 
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Polarised HepG2 cells expressing AcGFP-CD81 were treated with cytochalasin D or 
latrunculin B for 1 hour and the cells imaged over a 1 hour period. CD81 diffusion was 
reduced from 0.072 µm2/s to 0.038 µm2/s in cells treated with cytochalasin D and 
Latrunculin B (Figure 4.14a, table 4.4). In addition, both treatments increased the fraction of 
mobile CD81 from 57% in untreated cells to 58% and 61% in those treated with cytochalasin 
D and latrunculin B respectively (Figure 4.14b, table 4.4). These data highlight the 
importance of the linkage of CD81 to actin cytoskeleton in defining CD81 diffusion.  
 
Treatment 
Diffusion 
Coefficient  
(μm2/s) 
IQ range 
(μm2/s) 
Mobile 
Fraction 
(%) 
IQ range 
(pp) 
Sample size 
Untreated 0.072 0.160 57 31 80 
Cytochalasin 
D 
0.038 0.177 58 24 80 
Latrunculin B 0.040 0.138 61 11 80 
 
Table 4.4: Quantification of figure 4.14. The diffusion coefficient and mobile fraction with 
interquartile (IQ) range and sample size are shown for each treatment. The IQ range of the 
mobile fraction is given in percentage points (PP). 
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Figure 4.14: Effect of actin inhibitors on CD81 diffusion. HepG2 cells expressing AcGFP-CD81 
were allowed to polarise for 5 days before FRAP was carried out and the diffusion coefficient 
(a) and mobile fraction (b) found. Cells were untreated or treated with cytochalasin D (Cyt D, 
2.5 μM) or latrunculin B (Lat B, 1 μM) for 1 hour before imaging. Cells were imaged using a 
100x Plan Achromat 1.4 NA oil immersion objective on a Zeiss LSM 780 confocal microscope 
with a GaAsP spectral detector, and groups were compared by Mann-Whitney U test 
(GraphPad Prism 6.0). Each spot represents one bleached region. *P<0.05, **P<0.001, 
***P<0.0001. 
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4.3 DISCUSSION 
 
The lateral organisation of membrane components into specific domains is essential for the 
correct functioning of many cellular processes. That the membrane of eukaryotic cells is best 
viewed as a ‘mosaic’ of microdomains of varying size, composition and dynamics  is now well 
established (Singer and Nicolson 1972, Maxfield 2002), but the content of these domains 
and the behaviour of the proteins within them is still to be explored. To understand the 
behaviour of CD81 in the membrane of HepG2 cells, FRAP was used to establish its diffusion 
under a number of conditions.  
Initially the variation in CD81 diffusion across the cell surface was investigated, and the 
regions of the cell identified for study represent areas we believe to play a role in HCV entry. 
The two areas of the membrane likely to undergo initial contact with HCV are the basolateral 
membrane of polarised hepatocytes and associated filopodia. In vitro, these regions are 
analogous to the basolateral membrane in contact with the growth substrate and the 
filopodia in contact with the media. Additionally, HCV has been shown to transmit between 
cells (Timpe, Stamataki et al. 2008, Brimacombe, Grove et al. 2011) and so membranes 
involved in cell-cell contacts were included.  
The diffusion coefficient of CD81 is lower at the filopodia than at the PM, but exhibits a 
slightly higher mobile fraction. Examination of the filopodial cytoskeleton using electron 
microscopy has shown it to be composed of tightly packed actin filaments, with a dense 
protein complex at the tip and a high expression of ERM (Lewis and Bridgman 1992), an 
adaptor protein which links CD81 and actin (Sala-Valdes, Ursa et al. 2006, Coffey, Rajapaksa 
et al. 2009). The link between CD81 and actin has been reported to be necessary for 
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Brownian diffusion of CD81 at the basolateral membrane but to have a minimal effect on the 
diffusion coefficient (Harris, Clerte et al. 2013). Actin activity is enhanced at the cell 
periphery (Chierico, Joseph et al. 2014), and the observation that a number of viruses use 
filopodia to ‘surf’ onto a target cell in an actin-dependent manner (Lehmann, Sherer et al. 
2005, Sherer, Lehmann et al. 2007, Schelhaas, Ewers et al. 2008, Oh, Akhtar et al. 2010) 
suggests that surface protein movement in these membrane structures is ordered and 
directional. Furthermore, filopodia have a high proportion of lipid domains (Goswami, 
Gowrishankar et al. 2008, Gowrishankar, Ghosh et al. 2012, Chierico, Joseph et al. 2014), in 
addition to being dependent on the presence of cholesterol microdomains for formation 
(Roux, Cuvelier et al. 2005). The high proportion of lipid and cholesterol in these membrane 
structures is likely to reduce membrane fluidity. These factors along with a high degree of 
actin linkage may provide a mechanism for the lower diffusion coefficient but increased 
mobile fraction.  
In the model used here, we distinguished between parts of the basolateral membrane in 
contact with other cells (‘cell contact’) and those in contact with the growth substrate 
(plasma membrane, ‘PM’). Many proteins are expressed on both the sinusoidal and lateral 
faces of the basolateral membrane of hepatocytes (reviewed in (Treyer and Musch 2013), 
but the interactions formed by CD81 in these two regions are likely to be different.  For 
example, interactions at the basal membrane may involve integrins, whereas those at cell 
contacts will be affected by the presence of adherens and tight junctions (Kojima, Yamamoto 
et al. 2003, Nelson 2003, Theard, Steiner et al. 2007). Junction structures are highly ordered 
and in polarised epithelial cells are tethered to the actin cytoskeleton, an association which 
may reduce CD81 mobility compared to the PM (Harris, Clerte et al. 2013). As a junctional 
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protein, claudin-1 is expressed in these structures. The extracellular loops of claudin-1 can 
form interactions both within and between cells (Krause, Winkler et al. 2008, Piontek, 
Winkler et al. 2008), likely reducing the movement of the protein. As the presence of 
claudin-1 has been shown to reduce CD81 diffusion (Harris, Davis et al. 2010), its high 
expression and relative confinement may partially account for the reduced diffusion 
coefficient observed at cell contact locations.  
In all locations the variation in diffusion coefficient and mobile fraction are similar, 
suggesting that similar factors affect CD81 diffusion both within and between membrane 
structures. Notably however, median CD81 diffusion coefficient at the cell contacts are 
skewed towards the lower values, suggesting that there is a subset of CD81 at the cell 
contact that is diffusing at a higher rate. As the diffusion rates of this set of proteins are 
similar to those observed at the PM, they may represent an overlap in bleached regions 
between the cell contact and PM. Another possible explanation may be found in the 
behaviour of actin at cell junctions, where two distinct pools of actin have been observed – 
dynamic and stable populations (Yamada, Pokutta et al. 2005, Kovacs, Verma et al. 2011, 
Mangold, Wu et al. 2011). If CD81 is linked to actin in these regions, these different pools of 
actin may be dictating CD81 diffusion.   
These data highlight the novel observation that there is a large variation in CD81 diffusion 
parameters between cell membrane structures, thus supporting the fluid mosaic model and 
highlighting the need to study and compare defined regions of the cell in experimental 
studies.  As there have been no reported instances of HCV contacting filopodia, the 
basolateral membrane in contact with the growth substrate was chosen for further study to 
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model the initial interactions between HCV and hepatocytes. This is consistent with other 
studies employing live imaging to study protein dynamics (Harris, Clerte et al. 2013). 
Hepatic polarity is complex, and involves the formation of distinct basolateral and apical 
membranes and integral tight junctions, developments which can be measurably quantified 
(Mee, Grove et al. 2008, Mee, Harris et al. 2009). Data presented here show that following 
five days in culture 53% of HepG2.AcGFP-CD81 cells share a bile canaliculus, and 81% of 
these have functional tight junctions, consistent with published data (Theard, Steiner et al. 
2007).  Additionally, it confirms published work showing that hepatocyte polarisation limits 
the permissivity of cells to HCV infection (Mee, Grove et al. 2008, Mee, Harris et al. 2009).  
The specialisation of membrane regions is central to the correct functioning of the polarised 
hepatocyte, and inherent in this is the arrangement of membrane lipids and proteins into 
microdomains, and apical and basal membranes in polarised cells. Between these domains 
there are likely to be differences in lipid composition and this will affect their fluidity 
(Espenel, Margeat et al. 2008, Danglot, Chaineau et al. 2010).  
CD81 diffusion coefficient is lower in polarised cells compared to non-polarised cells, 
however the mobile fraction is comparable. This is consistent with published single particle 
tracking data showing that in polarised cells CD81 undergoes slower diffusion with more 
mixed trajectories (Harris, Clerte et al. 2013, Potel, Rassam et al. 2013). A proportion of 
these areas of confinement overlap with TEMs (Harris, Clerte et al. 2013, Potel, Rassam et al. 
2013), as previously reported for CD9 (Espenel, Margeat et al. 2008).  
In a polarised HepG2 cell lipid diffusion is less than half that observed in a non-polarised cell, 
(Harris, Clerte et al. 2013) and therefore the reduced diffusion of both CD81 and claudin-1 is 
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likely to be affected by this to some degree. It is unlikely to be related to an increase in the 
formation of the coreceptor complex as the FRET values between CD81 and claudin-1 have 
been reported to be very similar between polarised and non-polarised cells (Mee, Harris et 
al. 2009). The observed reduction in the fraction of mobile claudin-1 is likely to be due to an 
increase in confinement to membrane domains with limited diffusion potential, possibly due 
to an increase in association with other proteins. In polarised HepG2 cells the 
phosphorylated CD81 adaptor protein ERM relocalises from the basolateral membrane to 
the apical membrane as with polarised airway cells, with a decreased incidence of CD81-
ERM associations at the basal membrane (Berryman, Franck et al. 1993, Berbari, O'Connor et 
al. 2009, Harris, Clerte et al. 2013). ERM links CD81 to the actin cytoskeleton, and actin 
polymerisation is necessary for the Brownian diffusion of CD81(Harris, Clerte et al. 2013). 
Thus, a reduction in CD81-ERM linkage may contribute to the observed lower diffusion 
coefficient (Harris, Clerte et al. 2013). 
The data presented here show that polarity is a central determinant of CD81 diffusion, and 
demonstrate a role for polarisation-dependent CD81 lateral diffusion in regulating HCV 
infection as previously reported (Harris, Clerte et al. 2013). However in vivo, hepatocytes do 
not exhibit a ‘non-polarised’ phenotype. Instead, they may become depolarised in response 
to inflammatory cytokines (Khakoo, Soni et al. 1997), and this often occurs in chronic 
hepatitis (Guidotti and Chisari 2006).  
Recent data has shown that TNF-α is the central cytokine involved in the inflammation-
driven depolarisation of hepatocytes (Fletcher, Sutaria et al. 2014), and therefore the effect 
of TNF-α on CD81 diffusion was examined. TNF-α reduces tight junctional integrity via NFκB-
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dependent activation of MLCK and MLC phosphorylation, and affects occludin localisation 
(Ye, Ma et al. 2006, Fletcher, Sutaria et al. 2014). However, TNF-α has no reported effect on 
the establishment of cellular polarity (Ye, Ma et al. 2006, Mee, Harris et al. 2009, Petecchia, 
Sabatini et al. 2012), an aspect distinct from tight junctional integrity, although 
administration of TNF-α and VEGF have been shown to increase permissivity to HCV 
infection (Mee, Harris et al. 2009, Mee, Farquhar et al. 2010, Fletcher, Sutaria et al. 2014). 
Data presented here supports a decrease in tight junction integrity and increase in infection 
levels but also shows a decrease in polarity following addition of TNFα. This discrepancy with 
published data is likely due to differences in the treatment times used, as data from our lab 
(not shown) has highlighted the transitional activation of the TNF-α signalling pathway in 
hepatocytes, with a treatment time longer than 4 hours losing any effect on polarity. The 
experiments presented here used a treatment time of only an hour whereas others used a 
much longer treatment time of 24  or 48 hours (Mee, Farquhar et al. 2010, Petecchia, 
Sabatini et al. 2012).    
The TNF-α-dependent depolarisation of HepG2.AcGFP-CD81 cells modulates CD81 diffusion 
alongside permissivity to HCV infection, and this supports recent data demonstrating that 
lateral diffusion of CD81 is a key determinant of HCV entry (Harris, Clerte et al. 2013),. Whilst 
the increase in diffusion coefficient represents a reversal of the impact of polarisation, the 
concomitant increase in mobile fraction suggests that there are additional processes 
affecting CD81 diffusion in depolarised cells. Given the short treatment time, this is likely to 
be related to the widespread structural changes occurring during depolarisation, which will 
affect not only membrane architecture relating to specialised regions but also the significant 
changes occurring in the cytoskeleton (reviewed in (Delorme-Axford and Coyne 2011). 
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Whilst this unstable environment would not model the long term inflammatory environment 
observed in HCV infection, it may well be representative of a liver during allograft transplant. 
As the focus of this study is to examine the interaction of HCV with CD81 in a normal liver, 
the basolateral membrane of a polarised cell was chosen for further study. 
To this point, the diffusion of CD81 has varied in a manner which implicates large scale 
cellular organisation in determining its diffusion. There have been numerous reports 
illustrating the limiting effects of F-actin on the diffusion of membrane proteins (Kusumi, 
Sako et al. 1993, Sako, Nagafuchi et al. 1998, Treanor, Depoil et al. 2011), and the 
reorganisation of the actin cytoskeleton is central to the establishment of polarity.  As CD81 
links to the cytoskeleton via its C-terminal association with phosphorylated ezrin in a Syk-
dependent manner (Sala-Valdes, Ursa et al. 2006, Coffey, Rajapaksa et al. 2009), we were 
interested to examine the importance of the actin cytoskeleton in modulating CD81 
diffusion.  
Phalloidin staining showed that addition of cytochalasin D has little effect on the localisation 
of CD81, but causes a deformation of bile canaliculi and the membrane, with a loss of 
filopodia. The deformation of the tight junction was supported by CMFDA data showing a 
loss of integrity, but there was no significant change in polarity index. In contrast, latrunculin 
B causes a loss of cytoskeletal organisation, with no visible bile canaliculus or membrane 
structures. CMFDA and MRP2 assays supported a significant loss of polarity and TJ integrity. 
CD81 localisation in these cells was completely cytoplasmic, supporting previous data that 
the actin cytoskeleton defines CD81 localisation (Brazzoli, Bianchi et al. 2008). That the 
integrity of the actin cytoskeleton is key to maintaining tight junctional integrity and polarity 
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has been previously observed (Harris, Clerte et al. 2013), and is in part due to the interaction 
between tight junction proteins such as occludin and the ZO family of proteins (Fanning, 
Jameson et al. 1998, Wittchen, Haskins et al. 1999, Wittchen, Haskins et al. 2000, Fanning, 
Ma et al. 2002). 
CD81 diffusion was significantly reduced by the addition of both cytochalasin D and 
latrunculin B, with latrunculin B having the largest effect. As the structure of the 
cytoskeleton is less disrupted with cytochalasin D, this suggests that the diffusion of CD81 is 
dependent on the integrity of the actin cytoskeleton, in support of published data using SPT 
(Harris, Clerte et al. 2013). The use of both drugs increased the fraction of mobile CD81, with 
latrunculin B again having a greater effect. This implies that whilst the cytoskeleton is 
necessary for CD81 diffusion, it is also responsible for confining it. This again supports more 
recent data using latrunculin B  showing that its addition decreased the number of confined 
trajectories observed and increased the amount of mixed and Brownian paths (Harris, Clerte 
et al. 2013). The dependence of these results on the actin cytoskeleton has since been 
demonstrated by Harris and colleagues who examined the effect of these drugs following 
deletion of the CD81 C-terminal domain, through which CD81 is linked to the cytoskeleton. 
The resulting data showed that these effects were ablated when the CD81 molecule could 
no longer connect to actin (Harris, Clerte et al. 2013). The observation that the actin 
cytoskeleton limits diffusion is not specific to CD81, with a number of other membrane 
proteins exhibiting limited mobility as a result of their linkage (Kusumi, Sako et al. 1993, 
Sako, Nagafuchi et al. 1998, Treanor, Depoil et al. 2011). For example, L1CAM diffusion is 
confined by linkage to the actin cytoskeleton through ankyrin, but promoted through linkage 
via ERM (Sakurai, Gil et al. 2008, Brachet, Leterrier et al. 2010).  
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The data presented here offers an insight into the organisation of the hepatic membrane 
and show that CD81 diffusion is dictated not only by the level of hepatic polarity, but also by 
its location within the cell.  We additionally show that the integrity of the actin cytoskeleton 
plays a key role in maintaining and confining CD81 Brownian diffusion. Furthermore, the 
values described here are similar to those previously observed for CD81 using FRAP and also 
fit within a similar order of magnitude to that described for other tetraspanins (Table 4.5). 
Therefore, these data support the current model in which a more mobile and faster diffusing 
CD81 has a higher capability of supporting infection. We hypothesise that this may allow it 
to form transient interactions with partner proteins such as claudin-1 and EGFR more 
frequently, and enhance their ability to move to sites of clathrin-mediated endocytosis.  
 
 
Table 4.5:  Diffusion parameters for CD81 and other tetraspanins 
 
  
Protein 
Diffusion 
Coefficient 
(μm2/s) 
Mobile 
Fraction (%) 
Reference 
CD9 0.23 ± 0.15 77 (Espenel, Margeat et al. 2008) 
CD45 0.45 - (Douglass and Vale 2005) 
CD46 0.13 ± 0.08 87 (Espenel, Margeat et al. 2008) 
CD50 
0.19, 
0.46 ± 0.05 
- 
(Suzuki, Fujiwara et al. 2007, 
Wieser, Moertelmaier et al. 
2007) 
CD55 0.24 ± 0.37 82 (Espenel, Margeat et al. 2008) 
CD81 (FRAP 
defined) 
0.07 ± 0.13 66 ± 10 (Harris, Clerte et al. 2013) 
CD81 (SPT 
defined) 
0.11 ± 0.11 70 ± 7 (Harris, Clerte et al. 2013) 
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5 THE EFFECT OF CORECEPTOR COMPLEX FORMATION ON THE RESPONSE 
TO EGF-INDUCED EGFR STIMULATION 
5.1 INTRODUCTION 
 
Epidermal growth factor receptor (EGFR) has been shown to play a role in the uptake of 
numerous viruses including human cytomegalovirus and influenza A virus (Chan, Nogalski et 
al. 2009, Eierhoff, Hrincius et al. 2010, Karlas, Machuy et al. 2010), and recent publications 
demonstrate its role in increasing the rate of HCV entry (Lupberger, Zeisel et al. 2011, Diao, 
Pantua et al. 2012, Zona, Tawar et al. 2014).  
A functional RNAi kinase screen has demonstrated that inhibiting EGFR signalling limits HCVcc 
infection and the entry of diverse HCVpp genotypes (Lupberger, Zeisel et al. 2011). Further 
investigation using Förster resonance energy transfer (FRET), demonstrated that following 
EGF stimulation an increased frequency of CD81-claudin-1 complexes was observed in Huh-
7.5.1 cells (Zona, Lupberger et al. 2013). Following stimulation with EGFR, it was shown that 
activated HRas moves to the plasma membrane where it associates with CD81. Detergent 
extraction and proteomic analysis of polarised HepG2 cells expressing CD81 demonstrated 
that CD81-HRas interactions occur in regions which contain claudin-1, tetraspanins, and 
tetraspanin-associated proteins such as integrins.  Thus these regions were classified as TEMs 
(Jensen, Kuhn et al. 2009, Lupberger, Zeisel et al. 2011, Zona, Lupberger et al. 2013).  
Therefore, in the current model HRas provides a possible physical link between the EGFR 
signalling pathway and the formation of the CD81-claudin-1 complex (Figure 5.1).   
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EGF has been reported to stimulate EGFR signalling in a number of hepatic cell types 
(Lupberger, Zeisel et al. 2011, Diao, Pantua et al. 2012) and Diao and colleagues have shown 
that recombinant forms of HCV-E2 and anti-CD81 ligation of CD81 can stimulate EGFR 
phosphorylation in Huh-7.5. They suggest that HCV particles can activate EGFR signalling, thus 
stimulating entry (Diao, Pantua et al. 2012).   
EGFR is a receptor tyrosine kinase (RTK) and a member of the ErbB family of signalling 
receptors. RTKs are transmembrane proteins with an extracellular ligand binding domain and 
an intracellular tyrosine kinase domain. Ligand binding promotes EGFR homo- or hetero-
dimerisation and autophosphorylation of tyrosine residues in the intracytoplasmic kinase 
domain (Schlessinger 2002). Following this, downstream signalling is mediated by proteins 
that interact with these phosphorylated tyrosines through their Src homology 2 (SH2) 
domains, such as the Src homology domain containing transforming protein 1 (Shc1) and 
growth factor receptor bound protein 2 (Grb2) (Kolch 2005). Signalling pathways activated 
downstream of EGFR phosphorylation include mitogen-activated protein kinase (MAPK), 
phosphoinositide 3-kinase (PI3K)/Akt and c-Jun N-terminal kinases (JNK) (Oda, Matsuoka et al. 
2005) (Figure 5.2).   
There are 8 ligands that have been shown to bind the ErbB receptor family (Henriksen, 
Grandal et al. 2013) (Harris, Chung et al. 2003, Wilson, Mill et al. 2012) but the best studied 
are EGF and transforming growth factor α (TGFα). The affinity of EGF for EGFR on 
hepatocytes is 20-fold higher than that of TGFα (Thoresen, Guren et al. 1998), and EGF 
stimulation in hepatocytes activates the Ras/MAPK signalling pathway with minimal 
evidence for JNK or PI3K/Akt activation (Zona, Lupberger et al. 2013). 
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 Figure 5.1: Proposed model of effect of EGF stimulation on HCV entry. (Zona, Tawar et al. 
2014) 
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Figure 5.2: Signalling pathways downstream of EGF stimulation of hepatocytes. Also shown 
are the targets of inhibitors of early stages of the pathway for which results have been 
demonstrated. Adapted from (Zona, Tawar et al. 2014) 
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EGFR signalling is reported to play a role in a number of cellular processes, including cell 
proliferation, survival, migration and adhesion (Schneider and Wolf 2009) and as such is 
frequently upregulated in various cancers.  Endocytosis of ErbB family receptors has long been 
accepted as an essential mechanism to control their signalling and the binding of different 
ligands results in distinct methods of internalisation and diverse downstream effects (Wilson, 
Mill et al. 2012, Henriksen, Grandal et al. 2013).  For example, the binding of EGF to EGFR 
promotes clathrin-dependent internalisation of the receptor followed by its degradation. This 
occurs as a result of c-Cbl recruitment by Grb2, leading to the subsequent ubiquitination and 
lysosomal degradation of EGFR (Ravid, Heidinger et al. 2004, Roepstorff, Grandal et al. 2009). 
This is in contrast to the outcome of TGF-α-induced signalling, in which the receptor is recycled 
to the membrane due to the rapid intracellular dissociation of TGF-α from the receptor. This 
may be due to the low pH of the endosome (Alwan, van Zoelen et al. 2003, Roepstorff, Grandal 
et al. 2009), and leads to the de-ubiquitination of the receptor and its recycling to the 
membrane (Roepstorff, Grandal et al. 2009).  
Zona and colleagues (Zona, Lupberger et al. 2013) demonstrated an increased interaction 
between CD81 and claudin-1 following EGF stimulation which was to some extent dependent 
on HRas,  but the underlying mechanism for this is not understood. The formation of the EGF-
induced CD81-HRas complex may be dependent upon an association between CD81 and 
claudin-1, or may precede the formation of this coreceptor complex.   
To investigate whether EGF regulates CD81 diffusion in a polarised cell type and whether this 
is dependent on CD81 association with claudin-1, a panel of CD81 mutants previously shown 
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to have varying associations with claudin-1 were employed (Davis, Harris et al. 2012) (Figure 
5.6).  
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5.2 RESULTS 
5.2.1 Effects of EGF and anti-CD81 mAbs on EGFR phosphorylation. 
 
A number of papers have demonstrated that addition of EGF to hepatic cell lines boosts 
levels of HCV infection. This has been shown in derivatives of the Huh-7 cell line, PHH and in 
polarised HepG2 cells expressing CD81 (Lupberger, Zeisel et al. 2011, Diao, Pantua et al. 
2012, Zona, Lupberger et al. 2013). Prior to confirming that HepG2 cells expressing AcGFP-
CD81 respond in the same way, we initially tested the timeframe of EGFR phosphorylation in 
these cells.  
Given the recent report demonstrating that addition of α-CD81 antibodies can promote 
EGFR phosphorylation (Diao, Pantua et al. 2012), we were interested to screen our panel of 
α-CD81 mAbs alongside EGF for their phosphorylation potential. Polarised HepG2 cells were 
incubated with EGF or anti-CD81 mAbs and at defined times the cells were lysed and probed 
for EGFR phosphorylation by Western Blot. Grb2 binds to EGFR at the pY1068 residue 
following EGF stimulation (Batzer, Rotin et al. 1994, Tan, Wang et al. 2007), and therefore 
this residue was selected for study. The timeframe was chosen for its relevance to FRAP 
experiments (Figure 5.3).   
EGF or members of the anti-CD81 antibody panel presented in chapter 3were added at 
concentrations of 1 μg/ml and 30 μg/ml respectively following a serum starvation period of 
30 minutes, sufficient to prevent any phosphorylation of EGFR (Figure 5.3a). 2s155 is shown 
as a representative antibody. EGF promoted EGFR phosphorylation at all time points tested. 
In contrast, anti-CD81 mAbs had no detectable effect (Figure 5.3a). Normalising the pY1068 
band intensity to the respective β-actin band showed EGFR phosphorylation at Y1068 from 
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15 minutes to 60 minutes (Figure 5.3b), and therefore this time period was chosen for later 
experiments.  CD81 mAbs were from this point discounted as a method to stimulate EGFR in 
polarised HepG2.AcGFP-CD81 cells.  
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(b) 
Figure 5.3: Addition of EGF but not CD81 mAbs leads to phosphorylation of EGFR. 
Following a serum starvation of 30 minutes, EGF was added at 1 μg/ml and the CD81 
mAbs 2s155 at 30 μg/ml for the stated timepoints. EGFR phosphorylation at Y1068 
was examined by Western Blot in relation to β actin (a) and quantified (b). 
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5.2.2 Effect of EGF stimulation on HCV entry into hepatic cell lines 
 
To ascertain whether cells expressing AcGFP-CD81 were capable of supporting infection in 
an EGF manner dependent, 5 day polarised HepG2.AcGFP-CD81 cells were serum starved for 
30 minutes before a 30 minute EGF treatment and the addition of H77 pseudoparticles. Huh-
7.5 and wild type HepG2 cells were tested for comparison (Figure 5.4). The results showed 
that, whilst addition of EGF prior to infection had no effect on CD81-negative HepG2 cells, 
the level of infection was increased from 5.4 x 104 RLU to 11 x 104 RLU  in polarised cells 
expressing HepG2.AcGFP-CD81 and from 1.9 x 106 RLU to 3.4 x 106 in Huh-7.5 cells (Figure 
5.4). These data indicate that AcGFP-CD81 is capable of acting as a receptor for HCV and that 
pre-treatment of cells expressing this protein leads to a boost in infection similar to that 
seen with Huh-7.5.  We were interested to understand the protein diffusion events 
underlying this effect. 
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Figure 5.4 EGF stimulation increases the HCV infection levels in polarised and non-
polarised hepatic cell lines. HepG2.AcGFP-CD81 cells were allowed to polarise for 5 
days prior to infection, whereas Huh-7.5 cells were plated the day before. Cells were 
serum starved for 30 minutes prior to the addition of 1 μg/ml for 30 minutes prior to 
infection. H77-HCVpp was then added and incubated for 72 hours at 37˚C before lysis 
and quantification. Groups were compared by Mann-Whitney U test (GraphPad Prism 
6.0) *P<0.05, **P<0.001, ***P<0.0001. 
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5.2.3 Effect of EGF on CD81 and claudin-1 diffusion 
 
Initial experiments were performed to verify recent work presented by Zona (Zona, 
Lupberger et al. 2013), who demonstrated that inhibition of EGFR signalling  increases CD81 
diffusion and decreases the association with claudin-1 in the Huh-7.5.1 cell type (Zona, 
Lupberger et al. 2013). However, no data on the effect of EGFR signalling on CD81 diffusion 
has been reported for polarised cell lines, nor has the effect of EGFR signalling on the 
diffusion of the coreceptor claudin-1 been assessed. The effect of EGFR signalling on CD81 
and on claudin-1 diffusion was examined in polarised HepG2 cells using the reversible RTK 
inhibitor Erlotinib. Erlotinib is an EGFR-specific RTK inhibitor which binds reversibly to the 
ATP binding site of the receptor and prevents tyrosine phosphorylation (Raymond, Faivre et 
al. 2000) (Figure 5.5).  
Cells expressing either AcGFP-CD81 or AcGFP-claudin-1 were allowed to polarise for 5 days 
prior to imaging. Cells were serum starved for 30 minutes prior to imaging (untreated 
sample, UT) or prior to the addition of 10µM Erlotinib for 1 hour prior to imaging. In all 
cases, cells were imaged within the following 30 minutes.  
Inhibition of EGFR signalling with Erlotinib significantly decreased the diffusion coefficient of 
CD81, from 0.070 μm2/s to 0.028 μm2/s, (Figure 5.5a, table 5.2). At the same time, the 
mobile fraction of CD81 increased from 83% to 87% following addition of Erlotinib (Figure 
5.5b, table 5.2).  
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Figure 5.5: Effect of EGFR signalling stimulation on CD81 and claudin-1 diffusion. Following 
a serum starvation of 30 minutes, cells were imaged with no stimulation (UT), following a 30 
minute stimulation with at 1 μg/ml  EGF (EGF) , or following an EGF stimulation with a 60 
minute erlotinib pre-treatment  (10 μM) (Erl  then EGF). This was carried out in HepG2.AcgFP-
CD81 (a,b) or HepG2.CD81.AcGFP-claudin-1 (c,d) following a 5 day polarisation period. Cells 
were imaged using a 100x Plan Achromat 1.4 NA oil immersion objective on a Zeiss LSM 780 
confocal microscope with a GaAsP spectral detector, and groups were compared by Mann-
Whitney U test (GraphPad Prism 6.0). *P<0.05, **P<0.001, ***P<0.0001.  
  
0.028 µm2/s 
83% 87% 
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As EGFR signalling has been reported to influence claudin-1 interactions, we studied the 
effect of inhibition of EGFR signalling on claudin-1 diffusion in polarised HepG2 cells. 
Inhibition of EGFR signalling led to a reduction in diffusion coefficient, from 0.040 μm2/s to 
0.022 μm2/s relative to the untreated sample (Figure 5.5c, table 5.2), whereas the mobile 
fraction was increased from 78% to 84% (Figure 5.5d, table 5.2).  
These data show that in a polarised cell line, inhibition of EGFR signalling affects both CD81 
and claudin-1 diffusion coefficients and mobile fractions similarly, and results in both 
proteins exhibiting a higher mobility but a lower rate of diffusion.  
No study has yet examined the changes in protein diffusion which accompany EGF 
stimulation. We therefore examined this effect and whether any changes were modulated 
via the CD81-claudin-1 complex or through the proteins are individually. We studied a series 
of CD81 mutants that have previously been characterised to no longer interact with claudin-
1 (Davis, Harris et al. 2012). CD81 was chosen for study as it has been shown to interact 
directly with HRas in polarised HepG2 cells (Zona, Lupberger et al. 2013).  
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Table 5.1 – Quantification of figure 5.5 a, b 
Table 5.2 – Quantification of figure 5.5 c, d 
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5.2.4 Effect of CD81-LEL mutations on CD81 and EGFR localisation 
 
The key residues in the CD81-LEL which are involved in the claudin-1 interaction have been 
previously identified (Figure 5.6). These are K148A, T149A, E152A and T153A. We had 
available engineered CD81 proteins expressing these mutants, in addition to the double 
mutants K148A/T149A and E152A/T153A, the former of which has a similar receptor activity 
to WT CD81 (Davis, Harris et al. 2012) (Table 5.4). HepG2 cells expressing the mutant 
proteins show varying abilities to support HCVpp infection (Davis, Harris et al. 2012) (Table 
5.4) and we assessed whether they had any effect on the localisation of either CD81 or EGFR. 
Cells were transduced to express fluorescent forms of these proteins and allowed to polarise 
for 5 days before costaining with antibodies specific for EGFR (Figure 5.7) to investigate how 
these proteins are localised. 
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Figure 5.6: Structural modelling of CD81-Claudin-1 association. Ribbon model of the 
predicted structure of the LEL domain of native claudin-1 (alpha helices in red, beta turn in 
white) with CD81 in green, key interacting residues are labelled (Davis et al., 2012). 
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AcGFP-CD81 displayed a classic ‘chicken-wire’-like pattern, consistent with cell membrane 
localisation as previously described (Mee, Harris et al. 2009), with EGFR also predominantly 
expressed in the same regions. The staining patterns of CD81 and EGFR in cells expressing 
mutant CD81 proteins were in all cases similar to those seen in the WT cells (Figure 5.7). 
As the proteins localised normally in polarised HepG2 cells, we examined the response of 
cells expressing these proteins to EGF stimulation. As a preliminary step prior to examining 
the effect of the CD81-claudin-1 complex on EGF-induced CD81 diffusion, the basal levels of 
diffusion of these mutant proteins were examined by FRAP in the absence of any EGFR 
signalling.  
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F 
Figure 5.7: Effect of CD81 mutant proteins on CD81 and EGFR expression. Cells expressing 
the mutant forms of CD81 were allowed to polarise for 5 days before fixing and costaining 
with EGFR-633. Cells were imaged using a 100x Plan Achromat 1.4 NA oil immersion 
objective on a Zeiss LSM 780 confocal microscope with a GaAsP spectral detector. 
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5.2.5 Mutations in the CD81-LEL affect protein diffusion 
 
The AcGFP-CD81 protein was shown to diffuse at 0.070 μm2/s, and the K148A and T149A 
variants displayed similar diffusion coefficients of 0.077 μm2/s and 0.062 μm2/s respectively. 
The double mutant K148A/T149A diffused at a higher rate of 0.088 μm2/s. In contrast, the 
other three mutant forms of CD81 diffused at much lower rates, with E152A, T153A and 
E152A/T153A diffusing at 0.039 μm2/s, 0.026 μm2/s and 0.046 μm2/s respectively (Figure 
5.8, table 5.3). Conversely, the mobile fractions show no significant alterations, with a 
variation of only 6%, between 85% and 79% respectively (data not shown).  
These results show that the mutations which ablate the interaction between CD81 and 
claudin-1 have diverse effects on the rate of diffusion, but have little effect on the mobility 
of CD81. There appear to be two groups of CD81 mutants – K148A, T149A and K148A/T149A 
which diffuse at a similar rate to WT CD81, and E152A, T153A and E152A/T153A – which 
diffuse at around half that rate (Figure 5.8 table 5.3). 
These data suggest that claudin-1 association can alter CD81 diffusion. However, this is not 
seen with every mutant, suggesting that there may be more than one contact site between 
CD81 and claudin-1, including the residues E152A and T153A, or that there may be 
additional, as yet unidentified, binding partners. The observed reduction in diffusion 
coefficient suggests an indirect mechanism contributing to the reduction in association with 
claudin-1. 
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Figure 5.8: Effect of CD81 EC2 mutations on protein diffusion. Cells expressing mutant forms 
of CD81 were allowed to polarise for 5 days. Cells were imaged using a 100x Plan Achromat 
1.4 NA oil immersion objective on a Zeiss LSM 780 confocal microscope with a GaAsP spectral 
detector, and groups were compared by Mann-Whitney U test (GraphPad Prism 6.0). 
*P<0.05, **P<0.001, ***P<0.0001. 
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Table 5.3: Effect of EGFR signalling stimulation and stimulation on protein diffusion. 
Quantification of figure 5.8. 
 
5.2.6 CD81-LEL mutations have varying effects on EGFR phosphorylation 
 
The diffusion speeds recorded for E152A, T153A and E152/T153A are similar to those 
observed for CD81 in the absence of any EGFR signalling. To determine whether these lower 
diffusion coefficients are related to an altered sensitivity to EGFR signalling, the effect of EGF 
stimulation on EGFR phosphorylation was examined in cells containing the mutant proteins. 
Polarised HepG2 cells expressing WT AcGFP-CD81 and mutant forms of CD81 were treated 
with EGF and the level of total EGFR and EGFR-pY1068 measured. Monitoring the cell’s 
response to this treatment showed that all mutants responded to EGFR phosphorylation to 
some degree (Figure 5.9a), however analysis demonstrated that the levels of pY1068 
differed significantly between the cell lines (Figure 5.9b). Cells expressing AcGFP-CD81, 
E152A or T153A exhibited similar high levels of EGFR phosphorylation.  The levels of 
178 
 
phosphorylation observed following stimulation of cells expressing K148A, T149A or 
K148A/T149A were significantly lower.  In cells expressing E152A/T153A, the levels of 
pEGFR, although depressed, were not significantly lower than seen in WT AcGFP-CD81 (after 
correction of the statistical tests for multiple comparisons). These data lead us to conclude 
that mutations in the LEL which modulate the association of CD81 and claudin-1 alter EGFR 
phosphorylation in response to EGF stimulation.  
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(a)  
 
Figure 5.9: Effect of CD81 mutant proteins on cellular response to EGF stimulation. 
Cells expressing the mutant forms of CD81 were allowed to polarise for 5 days. 
Following a 30 minute serum starvation period, cells were treated with 1 μg/ml EGF 
for 60 minutes. Cells were lysed and stained for total EGFR, EGFR-pY1068 and β-actin 
(a). Levels of pY1068 were compared to total EGFR (b). Groups were compared by 
Mann-Whitney U test (GraphPad Prism 6.0). *P<0.05, **P<0.001, ***P<0.0001. 
+E
G
F 
p
Y1
0
6
8
 
Β
-a
ct
in
 
To
ta
l 
 E
G
FR
 
gC
D
8
1
 
K
1
4
8
A
 
T1
4
9
A
 
K
1
4
8
A
/ 
T1
4
9
A
 
E1
5
2
A
 
T1
5
3
A
 
E1
5
2
A
/ 
T1
5
3
A
 
180 
 
Since EGF priming of EGFR phosphorylation predominantly leads to degradation of the 
receptor (Ravid, Heidinger et al. 2004, Roepstorff, Grandal et al. 2009), levels of total EGFR 
were compared in HepG2 cells expressing mutant CD81 proteins before and after EGF 
stimulation to examine the effect of the altered EGF signalling on downstream events. In 
cells expressing K148A and E152/T153A, total EGFR is reduced to around a third of pre-
exposure levels following EGF addition (Figure 5.10). This reduction is slightly less in T149A 
and K148A/T149A and suggests that in these cells, mutations in the LEL of CD81 which affect 
the interaction with claudin-1 have little effect on the levels of EGFR in comparison to 
AcGFP- CD81. In contrast, in cells expressing E152A and T153A there was a smaller reduction 
in total EGFR observed following EGF addition (Figure 5.10), with E152A showing a reduction 
of about half, and T153A around a quarter. Therefore, total EGFR levels are considerably 
influenced by mutations governing the interaction between CD81 and claudin-1, and this 
may be as a result of altered trafficking. When these findings are compared with published 
data (table 1), there appeared to be no direct correlation between the levels of EGFR-
pY1068 and CD81:claudin-1 association, which suggests that the mutations studied are 
having affects outside of those directly related to the interaction between CD81 and claudin-
1, and that these relate to EGFR signalling.  
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Figure 5.10: Effect of CD81 mutant proteins on cellular response to EGF stimulation. 
Cells expressing the mutant forms of CD81 were allowed to polarise for 5 days. 
Following a 30 minute serum starvation, cells were either left untreated or treated 
with 1 μg/ml for 60 minutes. Cells were then lysed and lysates were stained for total 
EGFR, EGFR-pY1068 and β-actin. Levels of total EGFR were compared between UT and 
EGF treated samples. 
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5.2.7 CD81 proteins bearing mutations in the LEL display varying reactions to EGF 
stimulation 
 
Having demonstrated that polarised HepG2.AcGFP-CD81 cells show an increase in infection 
levels following administration of EGF (Figure 5.4), we examined this further by studying the 
response of receptor diffusion to EGFR signalling and its dependence on the CD81-claudin-1 
complex. As pY1068 was visible from 15 minutes to 60 minutes post-EGF stimulation (Figure 
5.3), the period between 30 minutes and 60 minutes was chosen as the optimal time to 
observe EGF stimulation of EGFR phosphorylation in imaging experiments. 
WT AcGFP-CD81 and a number of the mutant proteins did not show any change in diffusion 
coefficient following the stimulation of EGFR. However, following EGF addition the 
K148A/T149A mutant became less mobile and diffused more slowly, with mobile fractions 
and diffusion coefficients of 85% and 70% and 0.088 μm2/s and 0.061 μm2/s respectively 
(Figure 11 a, b. Table 5.4). K148A also showed a significant reduction in diffusion, from 0.077 
μm2/s to 0.046 μm2/s, following EGF addition but showed no change in mobility (Figure 11 a, 
b. Table 5.4). In contrast, the T153A protein mobile fraction increased from 79% to 85% after 
the addition of EGF and the diffusion coefficient increased from 0.026 μm2/s to 0.080 μm2/s 
(Figure 11 a, b. Table 5.4).   
These data suggest that mutations in the CD81-LEL have additional effects beyond their role 
in defining the association between CD81 and claudin-1. This may be as a result of altered 
quaternary interactions formed by CD81 and claudin-1 which are dependent on the prior 
interaction between the two.  
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Figure 5.11: Effect of EGFR signalling on CD81 protein diffusion. Cells expressing mutant 
forms of CD81 were allowed to polarise for 5 days.  Following a 30 minute period of serum 
starvation, cells were either left untreated (UT) or treated with 1 μg/ml EGF for 30 minutes 
(EGF). Diffusion coefficient (a) and mobile fraction (b) are shown. Cells were imaged using 
a 100x Plan Achromat 1.4 NA oil immersion objective on a Zeiss LSM 780 confocal 
microscope with a GaAsP spectral detector, and groups were compared by Mann-Whitney 
U test (GraphPad Prism 6.0). *P<0.05, **P<0.001, ***P<0.0001. 
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Table 5.4: Summary table of receptor activity and FRET with CLDN-1 for each mutant 
and WT CD81. Significant changes in FRET between CD81 mutants and CLDN-1 are shown 
alongside their associated receptor activities, both of which are previously published by Dr. 
Christopher Davis (Davis, Harris et al. 2012). Cell lines which exhibit significant changes in 
diffusion following stimulation are highlighted in light grey, and the values which exhibit 
the significant change are in bold font. Groups were compared by Mann-Whitney U test 
(GraphPad Prism 6.0). * Represents those mutants with a diffusion coefficient which 
differs from WT CD81 with a P≤0.05, ** P≤0.001, *** P≤0.0001  
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5.3 DISCUSSION 
 
A recent publication has shown that EGF-induced EGFR stimulation and signalling increases 
HCV entry into non-polarized Huh-7.5.1 cells (Zona, Lupberger et al. 2013). Based on inhibition 
and siRNA data in this cell line, the authors hypothesized that stimulation with EGF reduced 
CD81 lateral diffusion, inducing an interaction with claudin-1 to form the coreceptor complex 
(Lupberger, Zeisel et al. 2011, Zona, Lupberger et al. 2013).  
In brief, the current model for this process is as follows: EGFR phosphorylation at pY1068 
allows Grb2 to bind, and the subsequent downstream signalling leads to the activation of HRas 
and its relocation to the cell membrane. Here, HRas binds CD81 and modulates an increase in 
the association with claudin-1. However, the underlying mechanism for this increase in CD81-
claudin-1 association has not yet been studied. It remains unclear whether HRas binds to the 
CD81 homodimer or to CD81 as part of the heteromeric coreceptor complex, as both CD81 
and claudin-1 have been demonstrated to be present in membrane domains in polarised 
HepG2 cells which have not been stimulated with EGF (Zona, Lupberger et al. 2013). In order 
to further our understanding of this process, we examined the dependence of the effects of 
EGF stimulation on the CD81-claudin-1 coreceptor complex.  
Initial experiments determined the correct timeframe of EGF stimulation for imaging and 
infection experiments. Phosphorylation of  EGFR in hepatocytes has been shown to occur for 
up to 60 minutes following stimulation with EGF or TGFα (Lupberger, Zeisel et al. 2011) or with 
HCV-E2 and CD81-specific mAbs (Diao, Pantua et al. 2012). Whilst we confirmed that EGF is 
capable of stimulating EGFR for up to 60 minutes in polarised HepG2.AcGFP-CD81 cells, this 
effect was not replicated with CD81 mAbs even when used at very high concentrations. No 
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stimulation of EGFR phosphorylation was observed following the addition of the panel of 
antibodies described in Chapter 3, therefore a possible explanation for this difference is the 
cell types used - the published work used the non-polarised Huh-7.5 cell type (Diao, Pantua et 
al. 2012), whereas this study used polarised HepG2 cells. Although JS-81 was not tested, this 
discrepancy is unlikely to be related to the antibodies used as JS-81, 2s155 and other members 
of the antibody panel all recognise the L162 residue (Farquhar et al., in preparation, appendix 
table 2) (Diao, Pantua et al. 2012). It may be interesting to examine the ability of our antibody 
panel to stimulate signalling pathways in this cell type, as previous work has shown that some 
pathways which are known to be stimulated downstream of EGF stimulation are not active 
following EGF administration in either Huh-7.5.1 or PHH cells (Zona, Lupberger et al. 2013), 
suggesting that cell type may have an impact on signal transmission following receptor 
stimulation.  
After showing that our cells responded to EGF stimulation, we examined their response to this 
stimulus during infection. The data presented here confirm that polarised HepG2 cells 
expressing AcGFP-CD81 are capable of supporting infection with HCV (Harris, Farquhar et al. 
2008) and also that there is a boost in infection of these cells following EGF stimulation of a 
similar magnitude to that seen in Huh-7.5 cells. These results are novel and support a number 
of published studies in other hepatic cell lines which show an increase in infection following 
EGF stimulation (Lupberger, Zeisel et al. 2011, Diao, Pantua et al. 2012, Zona, Lupberger et al. 
2013). As numerous studies speculate that there is a relationship between CD81 diffusion and 
HCV infection (Harris, Clerte et al. 2013, Potel, Rassam et al. 2013, Zona, Lupberger et al. 2013, 
Fletcher, Sutaria et al. 2014), we examined the effect of EGFR signalling on the diffusion of 
both CD81 and claudin-1. 
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Inhibition of the EGFR pathway with Erlotinib led to a decrease in the diffusion coefficients of 
both CD81 and claudin-1 alongside an increase the mobile fraction of both proteins. This 
increase in the mobile fraction of CD81 and claudin-1 following Erlotinib treatment is 
consistent with previous work in which the authors have hypothesised that signalling through 
EGFR leads to a recruitment of CD81 and claudin-1 to TEM domains (Zona, Lupberger et al. 
2013). A possible mechanism for the observed lower diffusion is that, following EGF 
stimulation, the mobile CD81 and claudin-1 proteins form new interactions or diffuse as part 
of a larger complex. This suggestion is supported by the observation that the diffusion 
coefficient of protein or complex is dependent upon its molecular weight (Saffman and 
Delbruck 1975, Gambin, Lopez-Esparza et al. 2006), and CD81 has been demonstrated to 
diffuse at a slower speed when it is part of a larger complex with EWI-2wint (Potel, Rassam et 
al. 2013).  
To assess whether EGFR signalling mediates its effect on infection and diffusion through the 
CD81-claudin-1 complex or on either protein independently, a panel of previously described 
CD81 proteins bearing mutations in the CD81-LEL which affect coreceptor complex formation 
were studied (Table 5.1) (Davis, Harris et al. 2012). The localisation of both CD81 and EGFR 
were examined in these cells using fluorescence microscopy.  
The mutant CD81 proteins were not differentially localised in comparison to WT AcGFP-CD81, 
in agreement with previously published data (Davis, Harris et al. 2012), and EGFR was similarly 
localised in all of the cells expressing the mutant forms of CD81. However, there was no 
evidence of CD81-EGFR colocalisation. These data suggest that any differences in CD81 
diffusion are unlikely to be related to abnormal localisation or an interaction with EGFR. 
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Examining the basal diffusion parameters of the mutant proteins demonstrated that, whilst 
they did not differ significantly from the WT AcGFP-CD81 protein in terms of their mobility, 
there was a subset of the mutant proteins which did display a significantly lower diffusion 
coefficient from the WT protein. Whilst the diffusion coefficients of K148A, T149A and 
K148A/T149A were similar to that observed for AcGFP-CD81, this value was much lower for 
E152A, T153A and E152A/T153A. These proteins also exhibited the lowest reported FRET with 
claudin-1, with E152A, T153A and E152A/T153A exhibiting values of 8%, 10% and 8% 
respectively (Davis, Harris et al. 2012). It is therefore likely that these specific mutant proteins 
form distinct interactions in the absence of claudin-1 from those formed by K148A, T149A and 
K148A/T149A. In the case of these proteins therefore, diffusion speed and receptor activity 
are related, and their low diffusion speed may contribute to the poor FRET with claudin-1 by 
reducing the number of interactions that form over a given time period.  
As E152A, T153A and E152A/T153A all show a similar diffusion coefficient to WT CD81 when 
treated with Erlotinib, we were interested to examine whether their altered interactions with 
CD81 may reflect an altered response to EGF stimulation.  
The effects of the CD81-claudin-1 complex on EGFR signalling, levels of phosphorylation and 
total EGFR were examined in cells expressing mutant forms of CD81. The level of Y1068 
phosphorylation varied widely between polarised cells expressing these mutant CD81 
proteins. Both E152A and T153A exhibited a high level of EGFR phosphorylation which was 
not significantly different to that observed in AcGFP-CD81. However these two mutants 
display very low levels of CD81-claudin-1 FRET – 10% and 8% respectively in comparison to 
35% for AcGFP-CD81. In contrast, the mutations which exhibited higher levels of FRET with 
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claudin-1 (Davis, Harris et al. 2012) - K148A and K148A/T149A - displayed significantly reduced 
levels of EGFR phosphorylation. However, the level of EGFR phosphorylation was very similar 
in cells expressing E152A/T153A or K148A. These results show that, whilst EGFR 
phosphorylation is influenced by the interaction between CD81 and claudin-1, it is not a direct 
product of the interaction itself. 
The effect of the coreceptor complex on pEGFR levels may be mediated by interactions formed 
by either CD81 or claudin-1 which impact on the recruitment or action of downstream EGFR 
signalling proteins. A possible candidate protein for this is ITGβ1. It has been demonstrated 
that ITGβ1, a protein which interacts with both CD81 and HRas, is involved in HCV entry (Zona, 
Lupberger et al. 2013), and it is known that ITGβ1 controls EGFR phosphorylation (Morello, 
Cabodi et al. 2011). That CD81 could be forming altered interactions with ITGβ1 following EGF 
stimulation is supported by preliminary data (not shown) demonstrating an altered interaction 
between CD81 and α-integrins following EGF stimulation. If this is the case, a possible 
candidate for the observed altered interaction is the α3 integrin, which ITGβ1 has been shown 
to bind.  
The mutant CD81 proteins also influenced the level of total EGFR in EGF-stimulated cells. In 
untreated samples the level of EGFR was not significantly different between the majority of 
mutant proteins, however the level of total EGFR in the untreated E152A/T153A sample was 
considerably lower than that in AcGFP-CD81 or the other mutant cell lines. Following EGF 
stimulation AcGFP-CD81 and all of the mutants, with the exception of E152A and T153A, 
showed a reduction in total EGFR levels to around a third. In contrast, E152A and T153A 
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showed a reduction of a half and quarter respectively, showing that these proteins do indeed 
have an altered response to EGFR signalling.  
As the mutant proteins are all capable of responding to EGF stimulation to some degree, we 
used these proteins to probe the dependence of the EGF response on the interaction between 
CD81 and claudin-1. As numerous studies have demonstrated that addition of EGF to polarised 
HepG2 cells stimulates HCV entry (Lupberger, Zeisel et al. 2011, Diao, Pantua et al. 2012), we 
studied EGF stimulation of the EGFR signalling pathway. The effect of the mutant CD81 
proteins on viral infection of polarised HepG2 cells was investigated, but the levels of infection 
observed were too low to draw significant conclusions. This is consistent with many previous 
reports showing that HepG2 cells support low levels of infection (Lindenbach, Evans et al. 
2005, Flint, von Hahn et al. 2006, Narbus, Israelow et al. 2011).  
Stimulation of WT AcGFP-CD81 with EGF had no effect on the diffusion coefficient or mobile 
fraction of CD81. This is unexpected given the effect of Erlotinib, but is consistent with a 
published observation that adding EGF to Huh-7.5.1 had no effect on the interaction between 
CD81 and claudin-1 (Zona, Lupberger et al. 2013). However, as stimulation with EGF increases 
the level of HCV entry, it is clear that in this case the diffusion speed of proteins is not 
mediating the increase in HCV entry levels. Instead, stimulation with EGF may induce a 
rearrangement of membrane domains in a manner which promotes HCV entry in cells 
expressing WT AcGFP-CD81. The data presented here suggest that this rearrangement may 
involve proteins activated by and involved in downstream EGFR signalling. 
In contrast to the WT protein, a number of the mutant CD81 proteins did demonstrate 
changes in diffusion following EGF stimulation. The diffusion coefficient of the K148A mutant 
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was decreased following EGF stimulation, whilst K148A/T149A displayed a decrease both in 
diffusion coefficient and mobile fraction. Conversely, T153A showed an increase in diffusion 
coefficient and mobile fraction. Therefore, these CD81 variants form EGF-dependent 
interactions in their mobile fractions which differ from those formed by WT AcGFP-CD81. 
Furthermore T153A and K148A/T153A are differentially localised following stimulation. If 
these changes are caused by HRas, as has been suggested in the Huh-7.5.1 cell line (Zona, 
Lupberger et al. 2013), then these data show that HRas is capable of binding CD81 when it is 
not interacting with claudin-1. 
The CD81 residues K148, K148/T149 and T153 appear to be central to EGF-dependent 
diffusion, as mutation of these residues causes the protein to behave significantly differently 
to the WT protein. Interestingly, the pattern of diffusion of K148A/T149A and T153A following 
appear to be opposites of one another. Therefore, it is likely that CD81 forms distinct 
interactions through these residues as a result of EGF stimulation, and that these interactions 
have directly contrasting effects on diffusion despite the relatively close proximity of 
K148A/T149A and E152A in the CD81 molecule. Our model that the two protein variants form 
different interactions is supported by the variation in diffusion and the level of total and 
phosphorylated EGFR between the two.  
The effect of the T153A mutation partially recapitulates the effect of Tipifarnib, whereas 
K148A/T149A mimics the effect of Erlotinib. Therefore, T153A may be responsible for forming 
the interaction with HRas. In contrast, the diffusion of K148A/T149A following EGF 
administration recapitulates the effect of Erlotinib on WT AcGFP-CD81, suggesting an 
interaction with another EGFR-related protein.  
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There are a number of possible interpretations of the diffusion and the EGFR signalling data: 
 The CD81 mutant proteins which have the highest receptor activity and which FRET 
with claudin-1 respond in a similar manner to EGF stimulation (K148A and 
K148A/T149A) and exhibit a decrease in diffusion coefficient following EGF 
stimulation. This implies that some level of interaction between CD81 and claudin-1 
may be necessary for the observed decrease in CD81 diffusion coefficient and mobile 
fraction in response to EGF signalling. These residues may be involved in recruitment 
of the coreceptor complex to a larger complex with other proteins following EGF 
stimulation.  The dominant residue is K148, which causes a decrease in diffusion rates 
following EGF stimulation. However, the further mutation of residue 149 for T to A 
causes an additive effect, demonstrating that both residues are involved in this 
process. 
 The mutant T153A exhibits a considerably different pattern of diffusion following EGF 
stimulation from the other proteins – an increase in both diffusion coefficient and 
mobile fraction following EGF stimulation. Cells expressing this protein show defective 
EGFR trafficking, and the unusual pattern of diffusion in response to EGF may reflect 
this, possibly as a result of a higher amount of EGFR being retained at the membrane. 
The mutation at T153A is similar to the pattern of diffusion observed following 
Tipifarnib treatment (Zona, Lupberger et al. 2013), suggesting that this residue may be 
involved in the association of CD81 with HRas and this may provide a mechanism for 
the poor receptor activity of this protein (Davis, Harris et al. 2012).  
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In conclusion, the data presented here highlight the complex relationship between the CD81-
claudin-1 complex and EGFR signalling. We identified three residues or groups of residues 
which appear to play an important role in the diffusion response of CD81 to EGF stimulation 
and suggest that T153 may be key the residue involved in the interaction with HRas. 
These data expand the simplistic observation that CD81 diffusion defines HCV entry (Harris, 
Clerte et al. 2013) as we show that, whilst the diffusion speeds of the mutant proteins in their 
basal state mirrors their receptor activity, the boost in infection normally seen following EGF 
stimulation is not correlated with WT AcGFP-CD81 diffusion speed and the mobile fraction. 
Instead, the boost observed in HCV entry may be due to a reorganisation of putative TEM 
domains to promote entry. Studying EGF signal transduction suggests that this reorganisation 
may involve proteins or complexes which affect EGFR phosphorylation and trafficking, as EGFR 
signalling appears to be affected by the interactions formed by CD81. A possible candidate for 
mediating these effects is the α3 integrin and ITGβ1.   
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6 GENERAL DISCUSSION AND CONCLUDING REMARKS 
 
6.1 A COMPARATIVE ANALYSIS OF CD81 PRESENTATION BETWEEN CELL TYPES 
 
CD81 is expressed ubiquitously on all cell types with the exception of platelets and 
neutrophils and is an essential receptor in HCV entry. Residues in the CD81-LEL interact with 
HCV-E2, and several studies have demonstrated that inhibiting this association both in vivo 
and in vitro reduces infection (Chapel, Christie et al. 2001, Bertaux and Dragic 2006, Pestka, 
Zeisel et al. 2007, Keck, Machida et al. 2008, Meuleman, Hesselgesser et al. 2008, Farquhar, 
Hu et al. 2012). Antibody disruption of the CD81-HCV-E2 interaction therefore provides a 
promising target for therapeutic intervention. However, antibody ligation of CD81 can 
induce a variety of biological effects including activation of T, B and NK cells alongside 
stimulation of various signalling pathways.  
Tetraspanin conformation has been shown to be altered by partner proteins in a manner 
which can be detected with antibody probes (Rubinstein, Le Naour et al. 1996, Serru, Le 
Naour et al. 1999, Sincock, Fitter et al. 1999). CD81 forms cell-type specific interactions on 
hepatocytes and T and B cells (Rubinstein, Le Naour et al. 1996, Todd, Lipps et al. 1996, 
Rocha-Perugini, Montpellier et al. 2008, Fournier, Peyrou et al. 2010, Montpellier, Tews et al. 
2011) and using a panel of anti-CD81 mAbs I sought to identify hepatocyte-specific epitopes 
in the CD81-LEL that could be of therapeutic value.  
Due to the lack of proper optimisation of antibody staining in the experiments presented 
here, initial steps for continuation of this work would require this to be carried out. 
Optimisation would require the titration of antibodies on all cell types used to determine the 
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optimal staining concentration, followed by a consideration of appropriate staining 
conditions and fixation. If, as a result, the repetition of these experiments identify 
differences in antibody binding, it would be interesting to carry out a number of further 
experiments.  
It would be ideal to confirm initial flow cytometry binding data to binding affinity data 
captured by surface plasmon resonance (SPR). Instead of looking at antibody binding at a 
single point in time as with flow cytometry, SPR data allows the researcher to understand 
the association and dissociation rates and affinity of an antibody for the antigen. This would 
provide information as to the number and strength of interactions formed between the 
antibody and antigen, and experiments could be extended to look at epitope mapping.  
Ideally, SPR would be carried out in situ on the cell surface.  In a recent paper, van Spriel et 
al., reported using an ultrasound pulse to generate flat ‘membrane sheets’ in which the 
spatial localisation of membrane proteins is not affected and the cytoskeleton is at least 
partially intact (Zuidscherwoude, Gottfert et al. 2015). By using these sheets, it may be 
theoretically possible to look at the binding of these antibodies to CD81 in a more relevant 
background than following detergent extraction. However, this would involve a number of 
practical issues involving the size the membrane, adhesion to the chip, and the level of signal 
generated from a mixed population of proteins. 
It would also be informative to confirm the dependence of the binding of antibodies of 
interest on the conformation of the protein by examining their binding by western blot 
under reducing and non-reducing conditions. If these results were to show a dependence on 
conformation, I could then look at this in more detail by looking at the effect of mutating the 
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essential CD81 cysteine residues to determine their impact on the presentation of these 
epitopes.  
Using immunoprecipitation it would be possible to use these antibodies to carry out pull-
downs to examine any differences in binding partners such as integrins and other 
tetraspanin-associated proteins between different cell types or between antibodies with 
different binding patterns. In a similar manner, further wok for this project could include 
examining the propensity of these antibodies to stimulate common or published signalling 
pathways as this may help in establishing interacting partners and therapeutic use.  
 
6.2 EFFECT OF HEPATIC POLARITY ON CD81 DIFFUSION 
 
In recent years our understanding of protein dynamics has increased, and the relationship 
between receptor diffusion and viral entry has become a topic of research interest. In terms 
of CD81, studies have demonstrated that situations in which CD81 diffusion is limited 
coincides with a restriction of HCV entry (Harris, Clerte et al. 2013, Potel, Rassam et al. 2013, 
Fletcher, Sutaria et al. 2014).  
I used the HepG2 cell line to examine the importance of polarity and cell membrane 
organisation on CD81 diffusion properties. In addition to providing further support to the 
observation that CD81 diffusion speed is reduced upon polarisation, I found that TNF-α 
depolarised cells and reversed the effects on diffusion coefficient and infection that are 
caused by polarisation. The mobile fraction of CD81 also increased following TNF-α 
treatment, providing an additional mechanism for the increased level of infection observed 
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in inflammatory environments (Fletcher, Sutaria et al. 2014). This observation may be 
pertinent to our understanding of how re-infection occurs during allograft transplant. 
Both the data I present and previous publications (Harris, Clerte et al. 2013) highlight the 
importance of studying physiologically relevant models when assessing receptor diffusion 
and related effects. I extended previous work by showing that cell membrane structures 
dictate protein diffusion parameters in a manner which is likely to be actin-dependent. 
Studying relevant membrane features has led to breakthroughs in our understanding of MLV 
infection mechanisms (Sherer, Lehmann et al. 2007), and given data presented here I would 
encourage that this is considered in the design of future studies looking at the diffusion of 
either viruses or proteins. 
I also provide evidence to demonstrate that the diffusion of the CD81 coreceptor protein, 
claudin-1, may play a role in defining HCV entry, as the diffusion parameters of this protein 
are also mediated by polarisation. Notably, there is a large variation seen across the 
diffusion parameters of both CD81 and claudin-1. This variation suggests that both proteins 
may be forming multiple interactions, and provides an explanation for the lack of an obvious 
pattern in binding of the CD81 antibodies tested in chapter 3.  
Therefore, I present a model in which the diffusion parameters and receptor activity of CD81 
is regulated by the polarised status of the cell, cellular structures, and the local environment 
including the proteins with which it forms interactions. I speculate that this is related to the 
actin linkage of the protein.  
There are a number of possible future directions for this work. In order to confirm the 
mechanism of CD81 and claudin-1 restriction, it would be necessary to establish the 
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localisation of both proteins to TEM or lipid domains, and this could be established by 
detergent extraction or colocalisation of the proteins with known members of TEMs such as 
other tetraspanins and integrins, or using high resolution imaging of these regions. It would 
also be interesting to look at the ERM association of these proteins, as this has previously 
been shown to affect CD81 diffusion (Harris, Clerte et al. 2013).  
In order to further investigate the effect of cellular structures on CD81 diffusion, it would be 
useful to examine the actin dynamics in these regions along with cholesterol or lipid staining 
in these areas. This is an area in which SPT would be very useful, as it may be possible to see 
direction flow of receptors on filopodia as has been observed with MLV virions (Sherer, 
Lehmann et al. 2007). 
6.3 THE EFFECT OF CORECEPTOR COMPLEX FORMATION ON THE RESPONSE TO EGF-INDUCED 
EGFR STIMULATION 
 
Recent work has demonstrated that EGF increases the level of HCV infection and that this is 
related to an increase in the formation of CD81-claudin-1 coreceptor complexes (Lupberger, 
Zeisel et al. 2011, Diao, Pantua et al. 2012, Zona, Lupberger et al. 2013). Although supported 
by FRAP data in a non-polarised cell type, I examined this effect further to address CD81 
diffusion and its dependence on coreceptor complexes. To do this, I used a panel of 
previously characterised CD81 mutants where claudin-1 interactions were disrupted.  
I present novel data showing that the interaction between CD81 and claudin-1 influences the 
level and transmission of EGFR signalling, although this is not directly related to the 
interaction between the two proteins. Additionally, in contrast to previous instances where 
an increase in infection occurs concomitantly with an increase in CD81 diffusion speed, there 
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is no effect on CD81 diffusion following EGFR stimulation despite the increase in infection 
observed. As CD81 is increasingly confined in polarised cells (Harris, Farquhar et al. 2008, 
Harris, Clerte et al. 2013), I suggest a model in which stimulation of the EGFR signalling 
pathway induces a reorganisation of TEM or domains of restricted diffusion in a manner 
which promotes virus entry rather than a recruitment of new proteins to these regions. 
Preliminary data looking at the associations formed by CD81 following EGF stimulation 
suggests that this rearrangement may involve the integrin ITGB1 and specifically the α3 
integrin. ITGB1 has previously been shown to affect EGFR signal transduction, strengthening 
this hypothesis (Morello, Cabodi et al. 2011) and providing a possible mechanism for the 
effect observed on EGFR signalling. I further hypothesise that three residues or groups of 
residues in the CD81-claudin-1 interacting region are key to this reorganisation and to 
dictating CD81 diffusion following EGF stimulation – K148, K148/T149 and T153. However, 
their involvement in this process is complex and requires more investigation. 
Further work is needed to substantiate these models. In order to ascertain whether ITGB1 
regulates the interaction between CD81 and claudin-1 and stimulation of the EGFR pathway, 
it would be necessary to repeat immunoprecipitation experiments with a probe specific to 
ITGB1. It would also be interesting to examine the recruitment of c-Cbl and the 
phosphorylation status of other members of the EGFR signalling pathway in stimulated cells. 
It would be necessary to do this with and without mutant CD81 proteins to examine where 
and if the pathway is affected by the formation of the CD81-claudin-1 complex.  
In this thesis I have studied the presentation and behaviour of CD81 on hepatocytes. I have 
shown that functionally important epitopes in the LEL of CD81 differ between hepatocytes 
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and T and B cells, and postulate that this may contribute to the hepatic specificity of the 
virus. Additionally, I have shown significant changes in the conformation and level of 
expression of CD81 between  primary cells and immortalised cell lines, demonstrating a 
possible side-effect of transformation. This may have significant impacts on the use of such 
cells for testing administration of antibodies for blocking virus-receptor interactions.   
Using live imaging studies I have shown that receptor diffusion is dependent not only on the 
state of polarity of the cell, but also on the presence of specific membrane structures and 
inflammatory mediators. With live imaging studies using both SPT and FRAP becoming a 
rapidly growing area of research, these data demonstrate a number of crucial factors which 
must be taken into account when designing and interpreting such data.  
Additionally, I have demonstrated that claudin-1 diffusion is affected in situations in which 
HCV entry is enhanced, suggesting that the diffusion of claudin-1 may be influencing the 
entry of HCV to same extent as CD81. Indeed, the diffusion speed of claudin-1 but not CD81 
is increased following EGF stimulation. However, I demonstrate that CD81 diffusion rates do 
not always define entry.  
Finally, I demonstrate a complex relationship between stimulation of the EGFR signalling 
pathway and the formation of the coreceptor complex, and hypothesise that the presence of 
the receptor complex may be necessary for the formation of larger, EGF-induced complexes 
which promote the rate of HCV entry in a manner distinct from the rate of receptor 
diffusion. I suggest that the K148, K148/T149 and T153 residues in the CD81-LEL play a 
central role in this reorganisation. 
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7 APPENDICES 
 
 
Clone ID 
 
Reactivity with1 
 CD81FL CD81LEL 
   
 1s73 0.25 0.76 
 1s135 1.90 1.79 
 1s201 2.67 2.15 
 1s262 0.33 0.89 
 1s337 1.72 1.89 
 2s20 1.33 1.77 
 2s24 1.90 0.45 
 2s48 2.33 2.10 
 2s63 1.53 2.01 
 2s66 1.76 1.72 
 2s131 2.01 1.94 
 2s139 1.57 1.99 
 2s141 2.13 2.02 
 2s155 2.70 2.06 
 
Appendix table 1: Assessing antibody interaction with CD81 by EIA.  mAb (1 µg/mL) EIA 
reactivity for CD81-FL and CD81-LEL where the data is expressed at optical density at 450nm. 
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Appendix table 2: mAb (5 µg/mL) reactivity with wild type (WT) and mutant MBP-CD81-LEL 
proteins where:   denotes a 25 – 75% reduction in binding;   - a 75 – 90% reduction and 
 >90% reduction in binding. Farquhar et al., in preaparation. 
 
1 mAb (5 µg/mL) reactivity for overlapping LEL peptides, reactivity was only observed with 
peptide 1144 representing amino acids 173-192 
3 JS81 was obtained from BD Biosciences 
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